Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS
Health Economics, Outcomes & Epidemiology
PUBLISHED RESEARCH AND PRESENTATIONS

A COMpendium of our research

Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoconomics in place for ready use across their customers and therapeutic areas.

For nearly three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through May 2017.

For more information on our research activities and health care consulting practice, please visit our website, www.analysisgroup.com.
## CONTENTS

<table>
<thead>
<tr>
<th>Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune/Inflammatory</td>
<td>4</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>17</td>
</tr>
<tr>
<td>Dermatology</td>
<td>35</td>
</tr>
<tr>
<td>Endocrine/Metabolic/Diabetes</td>
<td>57</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>70</td>
</tr>
<tr>
<td>Hematology</td>
<td>84</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>104</td>
</tr>
<tr>
<td>Neurology</td>
<td>109</td>
</tr>
<tr>
<td>Oncology</td>
<td>142</td>
</tr>
<tr>
<td>Renal</td>
<td>188</td>
</tr>
<tr>
<td>Respiratory</td>
<td>195</td>
</tr>
<tr>
<td>Substance Abuse</td>
<td>206</td>
</tr>
<tr>
<td>Other Diseases &amp; Conditions</td>
<td>210</td>
</tr>
<tr>
<td>Other (Health Policy, Market Access, and other topics)</td>
<td>218</td>
</tr>
</tbody>
</table>
Autoimmune/Inflammatory

Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
*Publication:* Clinical Therapeutics 2017 03. e-pub ahead of print 2017/04/02; doi: 10.1016/j.clinthera.2017.03.005.
*Authors:* Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M.

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
*Publication:* Clinical and Experimental Rheumatology 2017 03. e-pub ahead of print 2017/03/25.
*Authors:* Yang M, Galebach PJ, Signorovitch JE, Garg V.

Drug Cost per Responder for the Treatment of Moderate-to-Severe Psoriasis and Active Psoriatic Arthritis.
*Authors:* Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M, A G.

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.
*Authors:* Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
*Authors:* Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.

Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
*Authors:* Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.

Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: A matching-adjusted indirect comparison.
*Authors:* Betts KA, Mittal M, Song J, Skup M, Joshi A.

Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.
*Authors:* Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia and Mexico.
ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.


*Authors:* van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, Bao Y.

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.


An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis.


*Authors:* Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.

The economic burden of dermatomyositis and polymyositis in the us.


Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP, United States Nov 11-16, 2016.

*Authors:* Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.


*Authors:* Husni ME, Griffith J, Betts K, Song Y, Ganguli A.

Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.

*Abstract:* American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP, United States Oct 11-16, 2016.

*Authors:* Keystone EC, Betts KA, Schlacher CA, Song Y, Ganguli A, Griffith J.

Prediction of flaring in rheumatoid arthritis patients upon biologics dose tapering: a chart review study in Taiwan.


Real-world Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study.


Effects of Adalimumab on Health-related Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Value of Reducing PASI Scores and Systemic Inflammation.


Authors: Okun M, Yang M, Koo V, Sundaram M, Signorovitch J.

Evaluation of timely versus delayed use of tumor necrosis factor inhibitors in the treatment of psoriatic arthritis: Economic and clinical results from a modeling study.


Authors: Strand V, Husni ME, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor, Interleukin, and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.


Authors: Strand V HM, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.


Authors: Betts K, Mittal M, Joshi A, Song J, Bao Y.

Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.


Authors: Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.


Authors: Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.

Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.


Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.


Authors: Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R.

Comorbidity burden and medication use among patients with psoriatic arthritis in the US.


Authors: Merola J, Han S, Xie J, Song H, Herrera V, Wei J, Wu EQ, Palmer JB.
Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfected with HIV: A matching-adjusted indirect comparison.


Economic Burden and Treatment Patterns of Cycling between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) among Patients with Rheumatoid Arthritis (RA).

Authors: Li N, Betts KA, Griffith J, Ristovska L, Douglas K, Ganguli A.


Authors: Strand V, Husni ME, Reichmann W, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.

Authors: Betts KA, Mittal M, Joshi A, Song J, Bao Y.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.


Impact of Taiwan health policy for dose tapering and withdrawing biologics in rheumatoid arthritis patients: A real-world chart review study.


Projected economic impact of increased use of biologic treatments for rheumatoid arthritis in Argentina, Colombia, and Mexico over 10 years.

Abstract: ISPOR 5th Latin America Conference, Santiago, Chile Sep 6-8, 2015.
Authors: Rojas Serrano J, de Abreu M, Tundia N, Skup M, Sorg R, Macaulay D, Bao Y, Chaves L, Chao J.

Short-term clinical outcomes and healthcare resource utilization in patients with rheumatoid arthritis tapering anti-TNF agents in Taiwan.

Abstract: 17th Asia Pacific League of Associations for Rheumatology Congress (APLAR), Chennai, India Sep 6-9, 2015.

Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy.

Authors: Deodhar A, Mittal M, Joshi A, Signorovitch JE, Yang M, Bao Y.
Economic evaluation of timely versus delayed use of anti-tumor necrosis factor (TNF) biologics in the treatment of psoriatic arthritis (PSA) in the US.

Authors: Zhou Z, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A.

Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.

Authors: Betts K, Reichmann W, Guo J.

Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.

Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.

Authors: Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

Economic implications of flares among patients with early rheumatoid arthritis (ra).

Authors: Signorovitch J, Betts K, Garg V, Bao Y.

Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.

Authors: Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS.

Economic implications of flares among patients with early rheumatoid arthritis (ra).

Authors: Signorovitch J, Betts K, Garg V, Bao Y.

An indirect comparison and cost per responder analysis of adalimumab, methotrexate (MTX) and apremilast in the treatment of MTX-naive psoriatic arthritis (PSA) patients.

Authors: Strand V, Griffith J, Betts K, Friedman A, Signorovitch J, Ganguli A.

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.

Authors: Sweet D, Song J, Zhong Y, Signorovitch J.

ASAS40 and ASDAS responses are associated with improved physical function, HRQOL, and work productivity in patients with non-radiographic axial spondyloarthritis.

Authors: Van Der Heijde D, Joshi A, Mittal M, Pangan A, Chen N, Betts K, Qi C, Bao Y.

Claims database analysis of adherence to adalimumab therapy and health care costs for patients with rheumatoid arthritis.

Authors: Liu Y, Tundia N, Skup M, Ayyagari R, Du EX, Chao J, Mulani P, Bao Y.
A prediction model that identifies patients most likely to benefit from first-line therapy with adalimumab plus methotrexate in early rheumatoid arthritis.


Authors: Van Vollenhoven RF, Betts K, Signorovitch J, Bao C, Shaw JW, Ganguli A.

Real-world risk of fall-related injuries among rheumatoid arthritis (RA) patients treated with tumor necrosis factor inhibitors (anti-TNFs) or methotrexate (MTX).


Authors: Bao Y, Ganguli A, De G, Kelkar S, Curtis JR.

Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection.


Authors: Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J.

Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.


Authors: Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.


Authors: Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema JK, Cifaldi MA.

Real-world treatment patterns during and after an emergency room or acute care facility visit for gout.


Authors: Krishnan E, Cloutier M, Guérin A, Héroux J.

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.


Authors: Sweet D, Song J, Zhong Y, Signorovitch J.

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.


Authors: Zhang HF, Gauthier G, Hiscock R, Curtis JR.

Cost-per-responder analysis of biological agents for the treatment of active ankylosing spondylitis in Germany.


Authors: Betts KA, Joshi AD, Yan SY, Zhou Z, Rao S, Wolff M, Cifaldi M.

Indirect comparison of joint damage prevention with adalimumab v. Abatacept, each in combination with methotrexate, in early rheumatoid arthritis.


Authors: Wu EQ, Cifaldi M, Diener M, Kaltenboeck A, Ganguli A, Bergman M.

Assessment of wage and salary growth in patients with rheumatoid arthritis (RA).


Authors: Bergman MJ, De G, Ganguli A, Signorovitch J, Bao Y.
Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany.


*Authors:* Wolff M, Zhou ZY, Signorovitch J, Shaw JW, Ganguli A.

The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.


*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema J, Cifaldi MA.

Spondyloarthritis epidemiology and burden phase 2 [speed 2] study: Disease progression in axial spondyloarthropathy (SpA).


*Authors:* Ruderman E, Strand V, Joshi A, Bao Y, Betts K, Chopra P, McGuire MB, Rao SA.

Clinical outcomes and healthcare utilization following early versus late diagnosis of systemic lupus.


*Authors:* Korves C, Laliberte F, Suthoff E, Wei R, Oglesby A, Dennis G, Duh MS.

Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: Results from the ability-2 clinical trial.


*Authors:* Mease PJ, Rao S, Betts KA, Lu M, Fan L, Pangan AL, Van Der Heijde D, Cifaldi MA.

The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.


*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: Is USPA a proxy for non-radiographic axial SPA?


Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use.


*Authors:* Signorovitch J, Bao Y, Samuelson T, Mulani PM.

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on oral disease-modifying anti-rheumatic drugs (DMARDs).


*Authors:* Zhang F, Guerin A, Gauthier G, Curtis J.
Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.


Authors: Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

Health care resource utilization (HRU) and costs associated with disease activity in systemic lupus erythematosus (SLE): A retrospective observational cohort analysis.


Authors: Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio AE, Jhingran PM, Narayanan S, Molta C.

Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.


Authors: Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.


Authors: Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C.

Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.


Authors: Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.

Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.


Authors: Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.


Authors: Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.


Authors: Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M.

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).


Authors: Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells.


Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.


Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsch B, Lefebvre P.
Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.

Authors: Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M.

Authors: Bergman MJ, Shaw JW, Cifaldi MA, Guerin A, Chopra P, Signorovitch J.

Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs etanercept.
Authors: Xie J, Ganguli A, Yang H, Parikh K, Wu EQ, Cifaldi M.

Health care costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying anti-rheumatic drug (DMARDs) or methotrexate (MTX).
Authors: Zhang F, Hiscock R, Curtis J.

Healthcare costs in psoriatic arthritis patients newly initiated on a biologic disease-modifying anti-rheumatic drug or methotrexate.
Authors: Zhang F, Hiscock R, Curtis J.

Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis.
Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012 Washington, DC United States Nov 9-14 2012.

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on non-biologic disease modifying anti-rheumatic drugs (DMARDS).
Authors: Curtis J, Gauthier G, Hiscock R, Zhang F.

Treatment patterns in psoriatic arthritis patients newly initiated on non-biologic disease-modifying anti-rheumatic drugs.
Authors: Curtis J, Gauthier G, Hiscock R, Zhang F.

Use of anti-tumor necrosis factor therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.
Authors: Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.
**Adherence to subcutaneous vs. Oral disease-modifying antirheumatic drugs in rheumatoid arthritis.**


*Authors:* Bergman M, Bao Y, Ayyagari R, Mulani PM.

**Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials.**


*Authors:* Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Impact of early versus late systemic lupus erythematosus (SLE) diagnosis on clinical and economic outcomes.**


*Authors:* Oglesby AK, Dennis GL, Korves C, Laliberte F, Suthoff ED, Wei R, Duh MS.

**Variation in the use of biologics in the management of rheumatoid arthritis across the United kingdom.**


*Authors:* Choy E, McAuliffe S, Roberts K, Sargeant I.

**Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.**


**Economic burden of psoriatic arthritis and obesity in patients with psoriatic arthritis in the United States.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 Chicago, IL United States. Nov 4-9, 2011.

*Authors:* Zhang F, Guerin A, Latremouille-Viau D, Day RR, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriatic arthritis in the united states.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 Chicago, IL United States. Nov 4-9, 2011.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 SUPPL, Chicago, IL United States. Nov 4-9, 2011.


**Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2011 SUPPL, Chicago, IL United States. Nov 4-9, 2011.


**Economic model of workplace impacts of anti-TNF therapy for rheumatoid arthritis in Brazil.**

*Abstract:* ISPOR 3rd Latin America Conference Mexico City Mexico. Sep 8-10, 2011.

*Authors:* Teich V, Chaves L, Birnbaum H, Pike C, Waryas C, Cifaldi M.
Indirect comparison of adalimumab versus etanercept for the treatment of psoriatic arthritis.
Authors: Kirson NR; S.; Birnbaum, H. G.; Kantor, E.; Wei, R.; Cifaldi, M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Abstract: 30th Annual Scientific Meeting of the American Pain Society Conference Austin, TX United States. May 19-21, 2011.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.
Authors: Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors.
Authors: Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwislik SH.

Refractory gout brings economic pain.
Publication: PharmacoEconomics & Outcomes News 2011 03; 623: 5.
Authors: Wu E.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
Authors: Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

Societal cost of rheumatoid arthritis patients in the US.
Authors: Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

Direct and indirect costs of spondlyoarthritis patients pre-and post-diagnosi.
Authors: Kirson N, Birnbaum H, Rao S, Swallow E, Waldman T, Dayoub E, Cifaldi M.

Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.
Authors: Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoel-Streefland M, Jiang W, Zimetbaum PJ.

Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis.
Authors: Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M.
Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.

Authors: Kimball A, Signorovitch J, Mulani P, Bao Y.

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
Authors: Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.
Authors: White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG.

Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.
Authors: Birnbaum H, Pike C, Kaufman R, Cifaldi M.

Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
Authors: Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E.

Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.
Authors: Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M.

Changes in health care utilization and costs for employed patients with rheumatoid arthritis from 19972006.
Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09 Atlanta, GA United States Nov 6-11, 2010.
Authors: Birnbaum H, Pike C, Banerjee R, Waldman T, Cifaldi M.

The costs of treatment failure gout: A claims-based analysis.
Authors: Wu EQ, Yu AP, Guerin A, Latremouille-Viau D, Tsaneva M, Forsythe A.

Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.
Authors: Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

Impact of adalimumab treatment in the workplace in patients with rheumatoid arthritis.
Authors: Cifaldi MA, Birnbaum H, Pike C, Kaufman R, Schiller M, Shi L, Sun P, Ray S.

Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.
Authors: Mease P, Signorovitch J, Mulani P, Gupta S.
The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.


*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.


*Authors:* White AG, Birnbaum HG, Janagap C, Buteau S, Schein J.

Disease-related and all-cause health care costs of elderly patients with gout.

*Publication:* Journal of Managed Care Pharmacy 2008 03; 14(2): 164-175.

*Authors:* Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.


*Authors:* White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.

*Publication:* Current Medical Research and Opinion 2008 08; 24(8): 2229-2240. doi: 10.1185/0300799080229548.

*Authors:* Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Mapping MOS Sleep Scale scores to SF-6D utility index.


*Authors:* Yang M, Dubois D, Kosinski M, Sun X, Gajria K.

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.


*Authors:* Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.


*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.


*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP.

Book Section: Linking administrative claims data with archival productivity measures to inform employer decision making.

*In:* Kessler R, Stang P (eds).


*Authors:* Greenberg PE, Birnbaum HG.

Linking Administrative Claim Data with Archival Productivity Measures to Inform Employer Decision-Making.


*Authors:* Greenberg P, Birnbaum H.
Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.


Tighter control of serum uric acid in gout is associated with lower morbidity and health care costs.

**Publication:** Journal of Rheumatology 2004 08; 31(8): 1621-1629.

**Authors:** Wu EQ, Mody RR, Krishnan E, Yu AP, Cahill KE, Tang J, Patel PA.

Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.

**Publication:** Journal of Rheumatology 2004 08; 31(8): 1621-1629.

**Authors:** Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F.

Economic cost and epidemiological characteristics of patients with fibromyalgia claims.

**Publication:** Journal of Rheumatology 2004 08; 31(8): 1621-1629.

**Authors:** Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ.

Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients.


**Authors:** Duh MS, Walker AM, Lindmark B, Laties AM.

Direct and indirect costs of rheumatoid arthritis to an employer.

**Publication:** Journal of Occupational Environmental Medicine 2000 06; 42(6): 588-596.

**Authors:** Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC.

Calculating the workplace cost of chronic disease.

**Publication:** Business and Health 1995 09; 13(9): 27-28, 30.

**Authors:** Greenberg PE, Finkelstein SN, Berndt ER.

**Cardiovascular**

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.


**Authors:** Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

Real-world costs of ischemic stroke by discharge status.


**Authors:** Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ.

Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.


**Authors:** Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.
Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.


**Authors:** Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.


**Authors:** Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson ED.

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.


**Authors:** Agus DB, Gaudette E, Goldman DP, Messali A.

Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.


**Authors:** McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

Cost impact of switching from metoprolol to nebivolol for hypertension.


**Authors:** Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E.

Impact of a Telehealth and Care Management Program on All-Cause Mortality and Healthcare Utilization in Patients with Heart Failure.


**Authors:** Kao DP, Lindenfeld J, Macaulay D, Birnbaum HG, Jarvis JL, Desai US, Page RL, 2nd.

Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.


**Authors:** Deitelzweig S, Laliberte F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

**Abstract:** ISPOR 19th Annual European Congress, Austria Oct 29 - Nov 2, 2016.

**Authors:** Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ.

Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

**Abstract:** ISPOR 19th Annual European Congress, Austria Oct 29 - Nov 2, 2016.

**Authors:** Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ.

Cardiac resynchronization therapy and adherence to heart failure management regimens.

**Abstract:** 20th Annual Scientific Meeting of the Heart Failure Society of America United States, Sep 17-20, 2016.

**Authors:** Der Sarkissian M, Xiao Y, Shen Y, May D, Tsintzos SI, Lefebvre P, Duh MS.

Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

**Abstract:** ISPOR 7th Asia-Pacific Conference, Singapore Sep 3-6, 2016.

**Authors:** Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang P, Liu L, Lu J, Song H, Du E, Wu EQ.
Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: an analysis of electronic medical record data.


Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.

Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD, Germany Sep 12-16, 2016.
Authors: Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Healthcare costs among patients diagnosed with deep vein thrombosis in the outpatient setting and treated with Rivaroxaban versus low-molecular-weight Heparin and Warfarin.

Authors: Laliberte F, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Real-world costs of ischemic stroke by discharge status.

Authors: Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.

Publication: Menopause 2016 06; 23(6): 600-610. doi: http://dx.doi.org/10.1097/GME.0000000000000590.
Authors: Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.


The Relationship between Local Economic Conditions and Acute Myocardial Infarction Hospital Utilization by Adults and Seniors in the United States, 1995-2011.
Authors: Carls GS, Henke RM, Karaca Z, Marder WD, Wong HS.

Response to comment on "is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database”.

Publication: Journal of Cardiac Failure 2015 05; 21(5): 435. doi: 10.1016/j.cardfail.2015.03.003.
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Duh MS, Ong SH.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.


Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.

*Authors:* Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.

The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.

*Authors:* Penn MS, Yenikomshian MA, Cummings AK, Klemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG.

Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis.

*Authors:* Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E.

Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.

*Authors:* Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.

*Authors:* Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.


Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.

*Authors:* Merli GJ, Hollander JE, Lefebvre P, Laliberte F, Raut MK, Olson WH, Pollack CV, Jr.

Development of a shared decision-making tool to assist patients and clinicians with assessing the individualized risks and benefits of oral anticoagulation therapy for atrial fibrillation.

*Abstract:* ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA August 22-26, 2015.

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.

*Abstract:* SHMs Annual Meeting, Mar 29 - Apr 1, 2015.
*Authors:* Merli; GJ, Hollander; JE, Lefebvre; P, Laliberté; F, Raut; MK, Olson; WH, Bookhart; B, Pollack; CV.

Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.

*Authors:* Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberte F, Dea K, Germain G, Lynch SM.
Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.


**Authors:** Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE.


**Authors:** Gradman AH, Vekeman F, Eldar-Lissai A, Khairy P, Therrien J, Mackie AS, Marelli A.

Specialized adult congenital heart disease care: the impact of policy on mortality.

**Publication:** Circulation 2014 05; 129(18): 1804-1812. doi: 10.1161/CIRCULATIONAHA.113.005817.

**Authors:** Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

**Publication:** Pharmacoepidemiology and Drug Safety 2014 03; 23(3): 268-277.

**Authors:** Chawla AJ, Mytelka DS, McBride SD, Nellessen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.

**Publication:** Pharmacoeconomics 2014 03; 32(3): 305-313. doi: 10.1007/s40273-014-0131-4.

**Authors:** Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

A cost-analysis model for anticoagulant treatment in the hospital setting.


**Authors:** Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

**Publication:** Current Medical Research and Opinion 2014 07; 30(7): 1317-1325. doi: 10.1185/03007995.2014.907140.

**Authors:** Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.


**Authors:** Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.

Risk factors associated with myocardial infarction in venous thromboembolism patients.


**Authors:** Laliberte F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S.

Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.


**Authors:** Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

Pulse pressure and stroke risk: development and validation of a new stroke risk model.


**Authors:** Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.


*Authors:* Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?


*Authors:* Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.


*Authors:* Laliberte F, Coleman Cl, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.

Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension.


*Authors:* Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ.

Effects of rivaroxaban vs warfarin on hospitalization days, healthcare resource utilization, and costs in nonvalvular atrial fibrillation patients using rivaroxaban.


Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.


*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers.


*Authors:* Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ.

Pulse pressure and stroke risk: Development and validation of a new stroke risk model.


*Authors:* Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.


*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Anticoagulant options and inpatient costs for patients with non-valvular atrial fibrillation.


*Authors:* Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension.


*Authors:* Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ.
Costs of venous thromboembolism (VTE) among hospitalized patients in China.
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.
Authors: Penn MS, Yenikomshian MA, Cummings AKG, Damron JM, Purvis S, Birnbaum HG.

Effect of prasugrel vs clopidogrel on hospital readmission among acute coronary syndrome patients treated with prasugrel.

Hospital length of stay: Does rivaroxaban reduce impatient stay compared to warfarin among patients with non-valvular atrial fibrillation.
Authors: Laliberté F, Pilon D, Raut M, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Real-World Comparative Effectiveness and Safety of Rivaroxaban and Warfarin in Nonvalvular Atrial Fibrillation Patients.
Montreal, QC, Canada May 31 - June 4, 2014.
Authors: Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, P. L.

Gastrointestinal comorbidities associated with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.
Authors: Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy.
Authors: Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS.

Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives.
Authors: Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ.

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.
Authors: Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.

All-cause and disease-related health care costs associated with recurrent venous thromboembolism.
Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S.
Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?


*Authors:* Laliberte F, Pilon D, Raut M, Nelson WW, Duh MS, Schein JR, Lefebvre P.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.


*Authors:* Laliberte F, Cloutier M, Nelson WW, Coleman CI, Sheng Duh M, Pilon D, Damaraju CV, Schein JR, Lefebvre P.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.


*Authors:* Lefebvre P, Coleman CI, Bookhart B, Wang ST, Mody SH, Tran K, Zhuo D, Huynh L, Nutescu EA.

Pulse pressure and stroke risk: Development and validation of a stroke risk equation.


*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.


*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

All-cause and disease-related costs associated with recurrent venous thromboembolism.


*Authors:* Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori JC, Bookhart B, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Association of patient characteristics with the initiation of dabigatran versus warfarin among anticoagulant naive patients with non-valvular atrial fibrillation.


*Authors:* Walker DR, Ivanova J, Betts KA, Rao S, Wu EQ.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.


*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart B, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the united states.


*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Lacomte P, Ong SH, Duh MS.

Improved clinical outcomes associated with dual-goal (HBA1C and LDL-C) achievement in newly diagnosed type 2 diabetes mellitus.


*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Kang AL, Fonseca VA.
An economic model of improved acute stroke care in the management of acute ischemic stroke from a state medicaid perspective.


Authors: Zhou ZY, Fan L, Chen E, Xie J, Wu EQ.

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

Publication: Current Medical Research and Opinion 2013 30(4): 645-653.

Authors: Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.


Authors: Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.

Publication: Journal of Managed Care Pharmacy 2012 06; 18(5): 363-374.

Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.


Authors: Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.


Authors: Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S.

Integrated telehealth and care management program reduces all cause mortality in medicare beneficiaries with heart failure.


Authors: Page RL, Kao DP, Macaulay D, Bimbaum HG, Jarvis J, Desai U, Lindenfeld J.

Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide.


Authors: Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J.

Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide.


Authors: Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, Wu EQ.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.


Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.
Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review.


Authors: Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S.

Are vasodilators of value in the care of patients hospitalized for acute heart failure?


Authors: Duh MS, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Gradman AH.

Chronic heart failure in the elderly: Clinical characteristics and resource utilization following initial hospitalization.


Authors: Korves C, Eldar-Lissai A, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

Acute heart failure patients with and without renal impairment: A study of heart failure-related resource utilization and costs in the United States.


Authors: Eldar-lissai A, Eapen S, Ong SH, Rodermund D, Duh MS.

All-cause and disease-specific health care utilization and costs associated with venous thromboembolism in commercial, medicare and medicaid beneficiaries.


Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, Lamori JC, Bookhart B, Olson W, Dea K, Schein J, Kaatz S.

Are vasodilators of value in the care of patients hospitalized for acute heart failure?


Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

Chronic heart failure in the elderly: Costs and resource utilization following initial hospitalization.


Authors: Eldar-lissai A, Korves C, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.


Authors: Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment.


Authors: Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

Impact of once-daily vs. Twice-daily dosing frequency on adherence in chronic medications among patients with non-valvular atrial fibrillation.


Authors: Laliberte F, Nelson WW, Schein JR, Rondeau-Leclerc J, Lefebvre P, Duh MS.
Risk of cardiovascular events associated with hypertension among Chinese and Caucasian stroke patients in the US.


Authors: Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

Are vasodilators of any value in the care of hospitalized acute heart failure patients?


Authors: Gradman A, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh M.

Gastrointestinal conditions among patients with atrial fibrillation.


Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.


Authors: Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.


Authors: Kirven C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng Duh M.

A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery.

Publication: Current Orthopaedic Practice 2012 23(3): 221-228.

Authors: Balcom WB, Mishol DN, Eapen S, Bookhart BK, Nutescu EA, Schein JR, Duh MS.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.


Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.


Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.


Authors: Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February).


Authors: Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P.
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.


Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.

*Autors:* Signorovitch J, Brainsky A, Grotzinger KM.

Comparison of bleeding rates between statin and statin-free patients on warfarin: A claims database approach.

*Autors:* Guerin A, Hylek EM, Frois C, Ponce De Leon Barido D, Marrone C, Bae JP, Zhao Z.

Factors associated with failing to achieve low density lipoprotein cholesterol goal with existing statin therapy: A chart extraction-based approach.

*Autors:* Zhao Z, Ivanova J, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Frois C.

Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.

*Autors:* Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

Risk of gastrointestinal conditions among patients with atrial fibrillation.

*Autors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism:

*Autors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the US.

*Autors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Antithrombotic treatment patterns, hospitalizations, and associated costs in acute coronary syndrome (ACS) patients.


Clinical characteristics, blood pressure (BP) control, and antihypertensive treatment (TRX) patterns among elderly patients (PTS) with hypertension (HTN).

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism:
Estradiol transdermal system versus oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Hospitalization due to heart failure is associated with significant medical resource utilization and costs.
Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: A matched cohort study.
Authors: Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

Impact of initial combination therapy vs monotherapy on major cardiovascular (CV) events: A matched cohort study.
Authors: Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.
Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.
Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

A single-center experience with low-dose warfarin in patients undergoing total hip or total knee replacement surgery.
Authors: Balcom WB, Bookhart BK, Mishol DN, Eapen S, Nutescu EA, Schein JR, Duh MS.

Treatment persistence among atrial fibrillation/flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting.
Authors: Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy.
Authors: Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.
**Long-term consequences and costs associated with venous thromboembolism.**
*Abstract:* 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP 2011 Minneapolis, MN United States. Apr 27-29, 2011.
*Authors:* Mody S, Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

**Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy.**
*Abstract:* 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP 2011 Minneapolis, MN United States. Apr 27-29, 2011.
*Authors:* Guerin A, Lin J, Jhaveri M, Wu E, Alpert J.

**Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.**
*Authors:* Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ.

**Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.**
*Authors:* Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP.

**Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy.**
*Authors:* Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

**Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.**
*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.**
*Authors:* Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J.

**Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.**
*Authors:* Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

**Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives.**
*Authors:* Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG.

**Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease.**
*Authors:* Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM.
Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.
Authors: Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.

Persistence with nebivolol compared to other beta-blockers in the treatment of hypertension: A retrospective claims analysis.
Authors: Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ.

The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure.
Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

Alikiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis.
Authors: Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ.

Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in South Central region.
Authors: Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.

Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis.
Authors: Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP.

Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBS) in patients with hypertension.
Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH.
Incidence rate of venous thromboembolism and hemorrhage in patients undergoing total hip or knee arthroplasty: A managed care perspective.

Abstract: 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP, San Diego, CA United States. Apr 7-10, 2010.

Authors: Lefebvre P, Vekeman F, Nutescu E, Duh M, Bookhart B, Schein J, Dea K.


Authors: Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH.

Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.


Authors: Simpson RJ Jr., Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.


Authors: Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.


Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.


Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Economic impact of switching from valsartan to other angiotensin II receptor blockers for nonmedical reasons in patients with hypertension.


Authors: Wu EQ, Signorovitch J, Yu AP, Latremouille-Viau D, Dastani HB, Kahler K.

Healthcare costs and resource utilization of patients receiving combination treatments of angiotensin receptor blocker with chlorthalidone or with hydrochlorothiazide.


Authors: Sun S, Yu A, Chen K, Mattson M, Xu Y, Dabbous O.

The association of aspirin use on risk of hospitalization in CHF patients taking ace inhibitors: A retrospective analysis of a national cohort of veterans.


Authors: Parikh NM, Shah DH, Deswal A, Ashton CM, Agarwal SJ, Chen H, Johnson M.

Cost trend associated with cardiovascular (CV) events in patients (pts) with hypertension (HTN) in us managed care settings.


Authors: Jayawant SS, Fulcher N, Ramamurthy P, Moyneur E, Ong SH, Duh MS.


*Authors:* Shaya FT, Gu A, Yan X.

An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).

*Publication:* Journal of Clinical Hypertension (Greenwich, Conn.) 2008 06; 10(6): 436-442.

*Authors:* Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, Investigators TS.

Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences.


*Authors:* Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR.

Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.


Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence.


*Authors:* Yu AP, Yu YF, Nichol MB, Gwadry-Sridhar F.

Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?


*Authors:* Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG.

The value of antihypertensive drugs: a perspective on medical innovation.


Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.


*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.


*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay.

*Abstract:* American Society of Nuclear Cardiology (ASNC), San Diego, CA Sep 6-9, 2007.

*Authors:* Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ.

Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA.


*Authors:* Long G, Cutler DM, Berndt ER.
The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS).

*Publication:* Healthc Q 2007 05; 10(2): 38-46.
*Authors:* Cremieux PY, Fortin P, Meilleur MC, Montague T, Royer J.

Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands.

*Authors:* Boersma C, Ivanova J, Koopmanschap MA, Voors AA, Postma MJ.

Health-Related Quality Of Life Of Stroke Survivors in the U.S.

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific.
*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Mensah GA, Labarthe D.

Assessing the economic impact of chronic conditions in postmenopausal women.

*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

Economic burden and co-morbidities of atrial fibrillation in a privately insured population.

*Authors:* Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Luftkin E, Mallet D.

Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.

*Authors:* Radeva JI, Reed SD, Kalo Z, Kauf TL, Cantu E, Castor AR, Jackman W, Cretin N, Schulman KA.

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).

*Authors:* Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Valiant-Investigators.

Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP.

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
*Authors:* Wu EQ, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J.


*Authors:* Patel MR, Meine TJ, Radeva J, Curtis L, Rao SV, Schulman KA, Jollis JG.
Cost and Comorbidities Associated with Atrial Fibrillation.
Authors: Wu EQ, Howard BG, Mareva MN.

PCV22 Cost and comorbidities associated with atrial fibrillation in different age groups.
Authors: Wu E, Birnbaum H, Milena M.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.
Authors: Birnbaum H, Leong S, Kabra A.

Clinical and Economic Value of Cardiovascular Nuclear Medicine.
Publication: Meniscus Health Care Communications 1996.
Authors: Mulhern C, Neels K.

Dermatology

Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.
Publication: Diabetic Medicine 2017 03; 34: 189. doi: http://dx.doi.org/10.1111/dme.13302.
Authors: Hassan SW, Hadjijanni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.

Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin:
Data from UK patients.
Publication: Diabetic Medicine 2017 03; 34: 189-190. doi: http://dx.doi.org/10.1111/dme.13302.
Authors: Hassan SW, Gulati K, Hadjijanni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with
Type 2 Diabetes: A Retrospective Observational Study.
Publication: Diabetes Therapy 2017 03. e-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.

Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective
Database Study Among People with Type 2 Diabetes Mellitus in Japan.
Authors: Hadjijanni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M.

Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a
United States database from 2010 to 2014.
Authors: Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

Health-related quality of life and work productivity associated with HiSCR and NRS30 response among
patients with moderate to severe hidradenitis suppurativa.
Authors: Kimball A, Yang M, Song Y, Valdecantos W, Ganguli.
High-Value Subpopulation for Skin Pain Improvement in Adalimumab-Treated Patients with Moderate to Severe Hidradenitis Suppurativa.

**Abstract:** American Academy of Dermatology 75th Annual Meeting, Orlando, FL  Mar 3-7, 2017.

**Authors:** Qureshi A, Yang M, Song Y, Zhang A, Sundaram M, Ganguli A.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.


**Authors:** Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.


**Authors:** Wu JJ, Guerin A, Gauthier G, Sundaram M.

Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.


**Authors:** Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.


**Authors:** Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.

Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.


Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.


**Authors:** Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis.


**Authors:** Jemec GB, Guerin A, Kaminsky M, Okun M, Sundaram M.

Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.


**Authors:** Brown J, Su Y, Nelleson D, Shankar P, Mayo C.
Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.
Authors: Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.

A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.
Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sep 12-16, 2016.

Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US
Authors: Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.

The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.

Patients’ Willingness to Pay for a Subcutaneous Injection Device That Reduces Injection Site Pain in the Treatment of Psoriasis.
Authors: Cividino A, Mittal M, Yang M, Signorovitch JE, M. S.

Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.
Authors: Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.
Authors: Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Adalimumab Is Associated With Reduced Risk of Joint-related Signs and Symptoms Compared with Methotrexate in Patients with Moderate to Severe Psoriasis.
Authors: Merola J, Sundaram M, Yang M, Li J, Galebach P, Okun M.
Cardiovascular (CV) event risk assessment in psoriasis (PS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) versus phototherapy.

*Authors:* Wu J, Cloutier M, Gauthier-Loiselle M, Guerin A, Sundaram M.

Cardiovascular Event Risk Assessment in Patients with Psoriasis Treated with Tumor Necrosis Factor-alpha Inhibitors versus Phototherapy.

*Authors:* Cloutier M, Gauthier-Loiselle M, Guerin A.

Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons in psoriatic disease patients.

*Authors:* Lewwohl M, Skup M, Sundaram M, Yang H, Faust E, Kageleiry A, Chao J, Wolf D.

Comparison of Outcomes between Psoriasis Patients who Switched from Etanercept to Adalimumab versus to Ustekinumab.


How is the severity of hidradenitis suppurativa measured in clinical practice?

*Authors:* Sundaram M, Lin P, Thomason D, Signorovitch J.

Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis.

*Authors:* Armstrong A, Betts K, Li J, Sundaram M, Wu E, Signorovitch J.

Predicting PASI90 Response Among Adalimumab-Treated Patients With Moderate to Severe Psoriasis.

*Authors:* Ryan C, Sundaram M, Yang M, Goyal R, Zhou Z, Signorovitch J.

Progression from a Milder to a More Severe Form of Hidradenitis Suppurativa is Associated with a Substantial Economic Burden.

*Authors:* Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

Progression from mild hidradenitis suppurativa (HS) to moderate-to-severe (m<sup>2</sup>s) HS is associated with a substantial economic burden.

*Authors:* Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

Psoriasis Plaque Resolution by Body Region and Plaque Signs with Adalimumab and Etanercept: an Indirect Comparison.

*Authors:* Papp K, Sundaram M, Yang M, Jarvis J, Signorovitch J.

Relative efficacy and costs per responder for adalimumab versus secukinumab in the treatment of moderate to severe psoriasis.

*Authors:* Armstrong A, Betts K, Sundaram M, Li J, Wu E.
Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.


**Authors:** Betts K, Mittal M, Joshi A, Song J, Bao Y.

Risk and economic burden of antibiotic failure in patients with moderate to severe hidradenitis suppurativa.

**Abstract:** 74th Annual Meeting of the American Academy of Dermatology Washington, DC Mar 4-8, 2016.

**Authors:** Kimball A, Sundaram M, Gauthier G, Pivneva I, Nitulescu R, Guerin A.

Treatment patterns and key factors associated with high treatment costs among commercially insured patients with advanced basal cell carcinoma.

**Abstract:** 74th Annual Meeting of the American Academy of Dermatology Washington, DC Mar 4-8, 2016.

**Authors:** Migden M, Wei J, Tang W, Herrera V, Xie J, Palmer J.

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.

**Publication:** BMJ Open 2016 02; 6(2): e009421. e-pub ahead of print 2016/02/18; doi: 10.1136/bmjopen-2015-009421.


Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.


**Authors:** Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

Psoriasis Treatment Patterns: Phototherapy, Oral Nonbiologic, and Biologic Therapies.

**Publication:** American Journal of Pharmacy Benefits 2015 05.

**Authors:** Kimball AB GG, Hiscock R, Zhang HF.

Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.


**Authors:** Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.


**Authors:** Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.


**Authors:** Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.


**Authors:** Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.
Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.

Authors: Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornick M, Margolis DJ, Parsons NB.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.


Cost per Responder Associated with Biologic Therapies for Psoriasis.

Authors: Liu Y, Reichmann W, Macaulay D.

Indirect Treatment Comparison of Adalimumab, Etanercept, Certolizumab, Golimumab, and Infliximab for the Treatment of Ankylosing Spondylitis.

San Diego, CA Apr 7-10, 2015.
Authors: Betts KA, K. H.

Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.

Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

Comparative efficacy of methotrexate versus apremilast for methotrexatenaive psoriasis patients: An indirect comparison.

Authors: Armstrong AW, Betts K, Sundaram M, Thomason D, Signorovitch J.

Health care resource utilization, health care costs, and dose escalation in biologic-naive psoriasis patients initiated on ustekinumab versus adalimumab.

Authors: Guerin A, Sundaram M, Gauthier G.

Long-term Effect of Achieving PASI90 Compared with PASI75 Response on Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis.

Authors: Ryan C, Sundaram M, Yang M, Goyal R, Signorovitch J.

A practical model for early identification of response with methotrexate for moderate to severe psoriasis.

Authors: Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.

Authors: Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.
Starting-dose trends over time in biologic-naive and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab.

Authors: Guerin A, Sundaram M, Gauthier G.

Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.

Burden of venous leg ulcers in the United States.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.
Authors: Chawla AJ, Mytelka DS, McBride SD, Nellessen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
Authors: Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus.
Publication: American Journal of Managed Care 2014 01; 20(1).
Authors: Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M.

Quality measure attainment in patients with type 2 diabetes mellitus.
Publication: American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15.
Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Authors: Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.

Early identification of response with methotrexate for moderate-to-severe psoriasis.
Authors: Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

Health care costs in psoriasis patients newly initiated on a biologic therapy or methotrexate.
Authors: Zhang F, Hiscock R.

Authors: Sundaram M, Guérin A, Styles A, M K.
Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alfa inhibitors versus methotrexate.
Authors: Wu JJ, Guerin A, Dea K, Wang K, Sundaram M, Mulani P.

Higher health care costs and dose escalation rates in psoriasis patients treated with ustekinumab compared to adalimumab.
Authors: Guerin A, Wang K, Sundaram M.

Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.
Authors: Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

Nail psoriasis significantly impairs health-related quality of life among patients with chronic plaque psoriasis.
Authors: Okun M, Kageleiry A, Signorovitch J, Yang M, Sundaram M.

Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis.
Authors: Langley RG, Signorovitch J, Wang K, KA B, Sundaram M, Mulani P, Yan S.

Patient preferences and willingness to pay for enhancements to subcutaneous injection devices used to treat psoriasis.
Authors: Cividino A, Signorovitch JE, Skup M, Tundia N, Mulani P, Arulmani U, Bao Y.

Economic and comorbidity burden of moderate-to-severe psoriasis.
Authors: Feldman S, Zhao Y, Tran MH, Shi L.

Burden of diabetic foot ulcers for medicare and private insurers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.

Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes.
Authors: Virdi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R.

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.
Authors: Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.
Authors: Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.
Authors: Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

Authors: Betts KA, Sundaram M, Mughal F, Yan SY, Signorovitch J, Wang K, Wu EQ.

Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).
Authors: Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

Economic Outcomes Associated With Hba1c And Ldl-C Goal Achievement In Patients With Type 2 Diabetes Mellitus.
Authors: Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

Medical, drug, and work-loss costs of diabetic foot ulcers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Medical, drug, and work-loss costs of venous leg ulcers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Trend in economic burden of diabetes in urban china from 2009 to 2011.
Authors: Wu E, Xie J, Du E, Liu M, Liu G.

Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.
Authors: Kimball AB, Signorovitch JE, Sundaram M, Samuelson T.

Authors: Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

Economic burden of hidradenitis suppurativa after a single surgical intervention: Assessment of unmet needs using a retrospective claims-based analysis.
Authors: Jemec G, Guerin A, Okun M, Kaminsky M, Sundaram M.
Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.


Authors: Sundaram M, Styles A, Guerin A, Aberki C, Okun M, Hayes O, Mulani P.

Validation of the hidradenitis suppurativa clinical response as a clinical endpoint for hidradenitis suppurativa treatment evaluation.


Authors: Okun M, Yang M, Sundaram M, Gu Y.

Validation of the physician’s global assessment of psoriasis of the hands and/or feet as a clinical endpoint.


Authors: Goldblum O, Sundaram M, Yang M, Thomason D.

Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.


Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.


Risks of developing psychiatric disorders in pediatric patients with psoriasis.


Authors: Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).


Authors: Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.


Authors: Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.


Authors: Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIb trial.


Authors: Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM.
Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in Germany.
Authors: Betts K, Yan Y, Sundaram M, Hengst N, Wolff M, Bensimon AG.

Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.
Authors: Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.
Authors: Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P.

Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.
Authors: Kimball AB, Sundaram M, Samuelson TM, Signorovitch JE.

Economic burden of hidradenitis suppurativa following a single surgical intervention: Assessment of unmet need using a retrospective claims-based analysis.
Authors: Jemec G, Guérin A, Sundaram M, Kaminsky MS, Okun MM.

Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event-free response versus etanercept.
Authors: Reich K, Signorovitch JE, Sundaram M, Mulani PM.

Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate.
Authors: Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM.

PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).
Authors: Bron M, Chen K, Cheng D, Bensimon A, Wu E.

Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.
Authors: Sundaram M, Okun MM, Guérin A, Styles A, Hayes OA, Aberki C, Mulani PM.
Psoriasis is significantly associated with lower rates of pregnancy and live births.
*Authors:* Cather JC, Horn EJ, Sundaram M, Latremouille-Viau D, Guérin A.

Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.
*Authors:* Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

Treatment Patterns in Psoriasis Patients Newly Initiated on an Oral Conventional Systemic Therapy or on Phototherapy.
*Authors:* Zhang F, Guérin A, Hiscock R, Kimball A.

Economic burden associated with workplace productivity losses (WPL) in patients with psoriasis in a population in the United States.
*Authors:* Zhang F, A G, Gauthier G, Day R, Khan Z.

Economic burden of psoriasis (PSO) and obesity in patients with psoriasis in the United States.
*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.
*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Quality-of-life effects of psoriasis skin symptoms affecting different body regions.
*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Mulani PM.

Sex differences in health-related quality of life in patients with moderate to severe psoriasis.
*Authors:* Cather JC, Horn EJ, Sundaram M, Yang M, Farooqui S, Mulani PM.

*Authors:* Zhang F, Guerin A, Latremouille-Viau D, Day R, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.
*Authors:* Guerin A, Zhang F, Gauthier G, Day R, Khan Z.
Psoriasis is significantly associated with lower rates of pregnancy and live births.


Authors: Cather JC, Latremouille-Viau D, Horn EJ, Bao Y.

Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.


Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity.


Authors: Li K, Li L, Yang M, Liu H, Liu D, Yang H, Boden G, Yang G.

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.


Authors: Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.


Authors: Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Economic burden of comorbidities in patients with psoriasis is substantial.


Authors: Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.


Authors: Wu EQ, Guérin A, Latremouille-Viau D, Day R, Khan Z, Zhang F.

Treatment patterns of psoriasis patients and trends over time.

Abstract: ISPOR 14th Annual European Congress Madrid Spain Nov 5-8, 2011.

Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z.

Economic Burden of Psoriasis and Diabetes in a Population of Patients with Psoriasis in the United States.


Authors: Wu EQ, Guérin A, Latremouille-Viau D, Gauthier G, Day R, Khan Z, Zhang F.

Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.


Authors: Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.
Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).
Authors: Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

ABT-874 versus methotrexate in moderate to severe psoriasis: Effects on health-related quality-of-life outcomes.
Authors: Reich K, Tsaneva M, Sundaram M, Bao Y.

Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with ABT-874.
Authors: Papp K, Yu A, Sundaram M, Bao Y.

Adalimumab provides health-related quality of life benefits for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.
Authors: Duffin K, Menter A, Yang H, Gupta S.

Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept.
Authors: Papp K, Signorovitch J, Mulani P, Bao Y.

Effects of ABT-874 treatment on health-related quality of life and Work Productivity and Activity Impairment in patients with psoriasis.
Authors: Papp K, Signorovitch J, Sundaram M, Bao Y.

Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis.
Authors: Papp K, Wu E, Goldblum O, Gupta S.

Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis.
Authors: Papp K, Latremouille-Viau D, Mulani P, Gupta S.

Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo.
Authors: Crowley J, Yang H, Sundaram M, Mulani P.
Health-related quality of life outcomes in patients with moderate to severe psoriasis treated with ABT-874 versus etanercept or placebo.

*Authors:* Menter A, Signorovitch J, Sundaram M, Bao Y.

Persistent impairment of work productivity and activity in patients with longer disease duration of psoriasis with hand/foot involvement.

*Authors:* Kimball A, Mulani P, Gupta S, Signorovitch J.

Resource utilization and costs associated with adalimumab or etanercept for moderate to severe psoriasis in a real-world setting.

*Authors:* Papp K, Guerin A, Gupta S, Bao Y.

Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis.

*Authors:* Papp K, Guerin A, Mulani P, Gupta S.

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

*Authors:* Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

*Authors:* Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.

*Authors:* Cremieux PY, Eapen S, Trask SW, Ghosh A.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.

*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.

*Authors:* Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Authors: Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.
Authors: Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes—an application of marginal structural models.
Authors: Yu AP, Yu YF, Nichol MB.

PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large us managed care cohort.
Abstract: International Society for Pharmacoeconomics and Outcomes Research, Sep 5-7, 2010.
Authors: Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life.

Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.

Adalimumab provides health-related quality-of life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy.
Authors: Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM.

Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).
Authors: Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.
Effects of ABT-874 versus etanercept or placebo on health-related quality of life in patients with moderate to severe psoriasis.
Authors: Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P.

Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity.
Authors: Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment.

Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting.
Authors: Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM.

Burden of illness in patients with hidradenitis suppurativa.
Authors: Guerin A, Mulani P, Gupta S.

Adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy: Effects on patient-reported outcomes in patients with psoriasis.
Authors: Thaçi D, Xie J, Gupta S, Mulani P.

Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder.
Authors: Wu EQ, Signorovitch JE, Bao Y, Mulani PM.

Comorbidity prevalence in psoriasis patients: A meta-analysis.
Authors: Mrowietz U, Guerin A, Mulani P, Gupta S.

Comorbidity risks increase over time in patients with psoriasis.
Authors: Kimball A, Yu A, Mulani P, Bao Y.
Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety, and cost per responder.

Authors: Wu E, Signorovitch J, Mulani P, Bao Y.

Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis.

Authors: Papp K, Signorovitch J, Mulani P, Bao Y.

Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis.

Authors: Signorovitch J, Kantor E, Mulani P, Bao Y.

Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparison of adalimumab with etanercept, infliximab, and ustekinumab.

Authors: Signorovitch J, Mulani P, Gupta S, Bao Y.

Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis.

Authors: Signorovitch J, Gupta SR, Bao Y, Mulan PM.

Direct and indirect economic burden of employees with moderate to severe psoriasis.

Authors: Reich K, Wu E, Mulani P, Gupta S.

Economic burden of comorbidities in patients with psoriasis.

Authors: Kimball A, Wu E, Mulani P, Bao Y.

Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy on patient-reported outcomes in psoriasis patients.

Authors: Thaci D, Xie J, Mulani P, Gupta S.

Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol on patient-reported outcomes in patients with palmoplantar, nail, or scalp psoriasis.

Authors: Thaci D, Xie J, Mulani P, Gupta S.
Increased cancer risks among patients with psoriasis.
Authors: Kimball A, Guerin A, Mulani P, Bao Y.

Increased economic burden associated with moderate to severe psoriasis compared with mild psoriasis.
Authors: Kimball A, Yu A, Mulani P, Bao Y.

Increased risk of psychiatric disorders in a pediatric population with psoriasis.
Authors: Kimball A, Yu A, Mulani P, Gupta S.

Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.
Authors: Kimball A, Signorovitch J, Mulani P, Bao Y.

Potential drug-drug interactions of oral systemic therapies for psoriasis have adverse outcomes in a real-world setting.
Authors: Saurat JH, Guerin A, Mulani P, Gupta S.

Psoriasis is associated with increased mortality risk.
Authors: Kimball A, Guerin A, Mulani P, Bao Y.

Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept.
Authors: Wu EQ GA, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y.

Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis.
Authors: Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y.

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.
Authors: Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM.

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.
Publication: Dermatology 2010 02; 220(2): 128-137. doi: 10.1159/000275198.
Authors: Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM.
Economic burden of psoriasis compared to the general population and stratified by disease severity.

**Publication:** Current Medical Research and Opinion 2009 10; 25(10): 2429-2438. doi: 10.1185/03007990903185557.

**Authors:** Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective

**Publication:** Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.

**Authors:** Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial.


**Authors:** Reich K, Signorovitch J, Ramakrishnan K, Gupta S, Mulani P.

Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.


**Authors:** Menter A, Signorovitch J, Mulani P, Gupta S.

Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.


**Authors:** Mease P, Signorovitch J, Mulani P, Gupta S.

Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis.


**Authors:** Papp K, Signorovitch J, Mulani P, Gupta S.

Adalimumab’s benefits for patient-reported outcomes in psoriasis patients are consistent across subgroups with different disease histories.


**Authors:** Kimball AB, Wu EQ, Mulani P, Gupta S.

The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities.


**Authors:** Kimball A, Chen L, Mulani P, Gupta S.

Comorbidities of psoriasis have an independent effect on impairing patient health-related quality of life and work productivity.


**Authors:** Strober B, Guerin A, Mulani P, Gupta S.
Discontinuation of adalimumab treatment for psoriasis following sustained response: Effects on health-related quality of life.
Authors: Menter A, Wu EQ, Mulani P.

The effect of adalimumab on improving work productivity among moderate to severe psoriasis patients.
Authors: Kimball AB, Yu AP, Mulani P, Gupta S.

The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.
Authors: Mease P, Signorovitch J, Mulani P, Gupta S.

Health-related quality of life and work productivity among psoriasis patients by disease severity.
Authors: Kimball A, Chen L, Mulani P, Gupta S.

The risk of coronary heart disease and stroke among psoriasis patients.
Authors: Kimball A, Guerin A, Mulani P, Gupta S.

Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial.
Authors: Reich K, Yu AP, Mulani P, Gupta S.

The impact of psoriasis on health care costs and patient work loss.
Authors: Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

Direct and indirect costs among employees with diabetic retinopathy in the United States.
Authors: Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Bimbaum HG.

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.
Authors: Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.
Publication: Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.
Authors: Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.  
**Publication:** Current Medical Research and Opinion 2007 09; 23(9): 2157-2169. doi: 10.1185/0300799007X219544.  
**Authors:** Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.  
**Publication:** Managed Care Interface 2007 10; 20(10): 26-32.  
**Authors:** Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes.  
**Abstract:** American College of Gastroenterology (ACG), Philadelphia, PA Oct 12-17, 2007.  
**Authors:** Loftus EV, Wu EQ, Yu AP.

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs.  
**Authors:** Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS.

**Authors:** Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization.  
**Publication:** Cutis 2006 06; 77(6): 385-392.  
**Authors:** Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Emani S.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.  
**Publication:** Women’s Health Issues 2003 11; 13(6): 204-213.  
**Authors:** Birnbaum H, Leong S, Kabra A.

PDB6: Factors associated with high-risk diabetic patients in the california medicaid populations (medi-cal).  
**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, 2003.  
**Authors:** Chaikledkaew U, Wu E, Johnson K.

PDB10: A Methodology to identify high-risk patients with diabetes in the california medicaid population (MEDI-CAL).  
**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, 2003.  
**Authors:** Chaikledkaew U, Wu E, Johnson K.

Productivity and medical costs of diabetes in a large employer population.  
**Publication:** Diabetes Care 2002 01; 25(1): 23-29.  
**Authors:** Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.

Identification of Diabetes Patients Using Claims Data: An Economic Analysis.  
**Authors:** Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.
Endocrine/Metabolic/Diabetes

Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.
Publication: Diabetic Medicine 2017 03; 34: 189. doi: http://dx.doi.org/10.1111/dme.13302.
Authors: Hassan SW, Hadjiyianni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.

Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin: Data from UK patients.
Publication: Diabetic Medicine 2017 03; 34: 189-190. doi: http://dx.doi.org/10.1111/dme.13302.
Authors: Hassan SW, Gulati K, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.
Publication: Diabetes Therapy 2017 03. e-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.

Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.
Authors: Hadjiyianni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Enloe C, Birnbaum HG, Perez-Nieves M.

Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.
Authors: DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS.

Clinical and Economic Burden Associated with Chronic Hypoparathyroidism: A Retrospective Chart Review in the United States, Canada, United Kingdom, France, Germany, Italy, and Spain.
Authors: Chen K, Krasner A, Li N, Xiang CQ, Souroutzidis A, Xie J.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
Authors: Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

Authors: Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.

Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.
Authors: Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.
A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany. Sep 12-16, 2016.


Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.


*Authors:* Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.

*Abstract:* AMCP Nexus 2016 Conference, National Harbor, Maryland October 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

The Prevalence of Hyperkalemia in the United States.

*Abstract:* AMCP Nexus 2016 Conference, National Harbor, Maryland October 3-6, 2016.

*Authors:* Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhania A, Pham H, Hollenack K, Wu EQ.

Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.


The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.


Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

*Authors:* Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

Time to treatment intensification and its association with subsequent macrovascular outcomes among patients with type 2 diabetes.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

*Authors:* Kim J, Desai U, Kirson NY, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

*Authors:* Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.
Epidemiological assessment of real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.

Authors: Huynh L, Herring M, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

Economic model to examine the cost benefit associated with resolution or improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide T in patients with neuroendocrine tumors based on data from a retrospective chart review study at three large tertiary oncology centers in the United States.

Authors: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

Maintenance of weight loss or stable weight in subjects with obesity: A retrospective longitudinal analysis of electronic medical record data.

Authors: Der Sarkissian M, Bhak R, Huang J, Buchs S, Vekeman F, Ganguly R, Duh MS.


Authors: Lefebvre P, Chow W, Pilon D, Emond B, Lafeuille M, Pfeifer M, Rupnow MF, Duh MS.

Patterns of Weight Loss, Maintenance, and Gain in Patients with Obesity.

Authors: Huang; J, Buchs; S, DerSarkissian; M, Bhak; R, Vekeman; F, Ganguly; R, Duh; MS.

Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.

Authors: Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.


Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.


Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.

Authors: Muram D, Kaltenboeck A, Boytsov N, Hayes-Larson E, Ivanova J, Birnbaum HG, Swindle R.

Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.

Authors: Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.
Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.

Authors: Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.


Authors: Chawla A, Carls G, Deng E, Tuttle E.

For a Step Change to Curb the Obesity Epidemic.

Authors: Frois C, Cremieux PY.

Policy Makers’ Views of Obesity-Related Challenges Around the World: An interview between Pierre Cremieux (of Analysis Group, Inc., and Guest Editor of this Special Issue) and policy makers from Brazil (Patricia Constance Jaime), Canada (Kimberly Elmslie), China (Bin Wang), France (Francois Cremieux), and the USA (Mark McClellan).

Authors: Cremieux P.

Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.

Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.

Authors: Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons NB.

Real-world evaluation of weight loss in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA) - an electronic health-record (EHR)-based study.

Abstract: Obesity Week, Los Angeles, CA Nov 2-6, 2015.
Authors: P; L, W; C, D; P, B; E, MH; L, M; P, MFT; R, MS; D.


Abstract: 16th World Conference on Lung Cancer (WCLC), Denver, CO Sep 6-9, 2015.


Authors: Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

Economic outcomes among medicare patients receiving skin substitutes for treatment of diabetic foot ulcers.

Authors: Rice JB, Desai U, Ristovska L, Cummings AG, Birnbaum HG, Skornicki M, Margolis D, Parsons N.
Glycated hemoglobin (Hba1c) control in patients with Type 2 Diabetes Mellitus (T2DM) treated with canagliflozin in a real world setting.


Authors: Lefebvre P, Pilon D, Robitaille M, Lafeuille M, Chow W, Pfeifer M, Duh MS.

Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.


Costs after initiating saxagliptin, sulfonylurea, or sitagliptin in patients with T2DM.


Authors: Kaltenboeck A, Ivanova J, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.

Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.


Authors: Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.


Authors: Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease.


Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus.

Publication: American Journal of Managed Care 2014 01; 20(1).

Authors: Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M.

Quality measure attainment in patients with type 2 diabetes mellitus.

Publication: American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15.

Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P.

Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities.


Authors: Truong HL, Nellesen D, Ludlam WH, Neary MP.

Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.


Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data.

**Abstract:** ISPOR 17th Annual European Congress Amsterdam Netherlands. Nov 8-12, 2014.

**Authors:** Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L.

Aove standard dose of octreotide-lar in patients with neuroendocrine tumors (NET) for control of carcinoid syndrome symptoms: A multi-center retrospective chart review study.


**Authors:** Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

The burden of “serial non-adherence” in type 2 diabetic patients.


**Authors:** Frois C, Dea K, Ling D, Dunn J, Baron M.

Systematic Review of real-world evidence on treatment of Acromegaly.


**Authors:** Guérin A, Xu Y, Hiscock R, Begelman SM, Mu Y, Alaghband R, Wu EQ.

Units and costs per day per claim of comparable insulins supplied to medicaid patients.

**Abstract:** ISPOR 19th Annual International Meeting , Montreal, QC Canada May 31-Jun 4, 2014.

**Authors:** Ivanova JI, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R.

Burden of diabetic foot ulcers for medicare and private insurers.


**Authors:** Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.

Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes.

**Publication:** J Diabetes Sci Technol 2013 09; 7(5): 1229-1242.

**Authors:** Virdi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R.

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.


**Authors:** Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.


**Authors:** Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.


**Authors:** Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis.


**Authors:** Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E.
Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis.

Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in patients with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).
Authors: Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).
Authors: Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

Clinical characteristics, quality measure attainment, and diabetes-related health care costs in elderly versus overall people living with type-2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).
Authors: Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Economic Outcomes Associated With Hba1c And Ldl-C Goal Achievement In Patients With Type 2 Diabetes Mellitus.
Authors: Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin.
Authors: Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep FA, Birnbaum H.

Medical, drug, and work-loss costs of diabetic foot ulcers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Medical, drug, and work-loss costs of venous leg ulcers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Trend in economic burden of diabetes in urban china from 2009 to 2011.
Authors: Wu E, Xie J, Du E, Liu M, Liu G.

Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.

The direct and indirect costs among U.S. privately insured employees with hypogonadism.
Authors: Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.
Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.


*Authors:* Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.


*Authors:* Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus.

*Abstract:* 1st American Diabetes Association Middle East Congress, Dubai, UAE Dec 4-6, 2012.

*Authors:* Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB.

Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens versus vials.


*Authors:* Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Hba1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM).


*Authors:* Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ.

Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients.


*Authors:* Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus.


*Authors:* Chen K, Wu E, Cheng D, Bensimon A, Bron M.

Glycemic control and quality of life for patients with type 2 diabetes mellitus in China.

*Abstract:* ISPOR 5th Asia-Pacific Conference Taipei Taiwan (Republic of China) Sep 2-4, 2012.

*Authors:* Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ.

PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research Sep 2-4, 2012.

*Authors:* Bron M, Chen K, Cheng D, Bensimon A, Wu E.

Predictors of reaching Hba1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis.


*Authors:* Chen K, Bron M, Cheng D, Sharma H, Wu EQ.
Economic burden of type 2 diabetes mellitus in China.


Effect of diabetes patient characteristics on the willingness-topay for a new basal insulin—a discrete choice experiment.

Authors: Yang M, Lin P, Wintfeld N, Frois C.

Health utility for patients with type 2 diabetes mellitus in China.

Authors: Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ.

Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.

Authors: Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Authors: Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity.
Authors: Li K, Li L, Yang M, Liu H, Liu D, Yang H, Boden G, Yang G.

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.
Authors: Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

Prevalence rates and costs of metabolic syndrome and associated risk factors using employees’ integrated laboratory data and health care claims.
Authors: Birnbaum HG, Mattson ME, Kashima S, Williamson TE.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Authors: Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.
Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.

*Abstract:* IDF World Diabetes Congress, Dubai, United Arab Emirates Dec 4-8, 2011.

*Authors:* Bron M, Yang HY, Yu AP, Marynchenko M, Fan L

Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM).

*Abstract:* ISPOR 14th Annual European Congress Madrid Spain Nov 05-08, 2011.

*Authors:* Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ.

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.

*Abstract:* ACR/ARHP Annual Scientific Meeting, Chicago, IL Nov 4-9, 2011.

*Authors:* Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population.


*Authors:* Yang H, Marynchenko M, Bron M, Wu E, Yu AP.

Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population.


*Authors:* Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP.

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation.


Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.


*Authors:* Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.

Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus.


*Authors:* Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP.

Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization.


*Authors:* Wu E, Zhou S, AP Y, Lu M, Graf TR.

Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence.


*Authors:* Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP.
Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs.

Authors: Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ.

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization.

Authors: Wu E, Zhou S, Yu AP, Lu M, Graf TR.

Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes.

Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients.

Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

The direct and indirect costs associated with hypogonadism among privately-insured employees in the United States.

Authors: Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R.

Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET).

Authors: Lefebvre P, Sarda SP, Laliberte F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS.

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

Authors: Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.

Authors: Cremieux PY, Eapen S, Trask SW, Ghosh A.

The impact of bariatric surgery on comorbidities and medication use among obese patients.

Authors: Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M.

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.

Authors: Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.
Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models.

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research, Dec 2010.

*Authors:* Yu AP, Yu YF, Nichol MB.

**PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large us managed care cohort.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research, Sep 5-7, 2010.

*Authors:* Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

**Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes.**


*Authors:* Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T.

**Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients.**


*Authors:* Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O.

**Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs.**

*Abstract:* 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP, San Diego, CA United States Apr 7-10, 2010.

*Authors:* Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ.

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.**


*Authors:* Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

**Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbA1c<7.0.**


*Authors:* Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S.

**Anti-hypertensive drug use and risk of dementia in patients with diabetes mellitus (DM).**

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL United States May 16-20, 2009.

*Authors:* Johnson ML, Parikh NM, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Morgan R.

**Risk factors for dementia in elderly patients with diabetes mellitus.**

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL United States May 16-20, 2009.

*Authors:* Parikh NM, Morgan R, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Johnson M.

**A study on the economic impact of bariatric surgery.**

*Publication:* American Journal of Managed Care 2008 09; 14(9): 589-596.

*Authors:* Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M.

**Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.**

*Publication:* Bariatric Times 2008 11.

*Authors:* Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.
Direct and indirect costs among employees with diabetic retinopathy in the United States.
Authors: Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.

Achieving Glycemic Goal with Initial Combination Therapy Versus Sequential Augmentation Therapy using Metformin and Pioglitazone.
Abstract: 44th EASD meeting, Rome, Italy Sep 7-11, 2008.
Authors: Pandya BJ, Yu A, Wu EQ, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW.

Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies.
Authors: Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.
Publication: Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.
Authors: Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
Publication: Current Medical Research and Opinion 2007 09; 23(9): 2157-2169. doi: 10.1185/030079907X219544.
Authors: Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Authors: Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

Prevalence of diabetic peripheral neuropathy and associated pain in French adults.
Abstract: JOURNAL OF NEUROLOGY.

Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients.

Authors: Wu E, Xie J, Crémieux P, Sullivan P.

Obesity’s Impact on Diabetes Patients’ Health-Related Quality Of Life In The U.S.
Authors: Cremieux P, Xie J, Greenberg P, Wu EQ, Castor A.
**POB7 Obesity and quality of life in the united states: 2000-2002.**
*Abstract:* International Society for Pharmacoeconomics and Outcomes Research, 2006.
*Authors:* Wu E, Xie J, Sullivan P.

**Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes.**
*Abstract:* American Diabetes Association (ADA), 2006.

**Employment and Income Associated with Obesity and Overweight in the US.**
*Abstract:* North American Association for the Study of Obesity (NAASO).
*Authors:* Wu EQ, Xie J, Sullivan PW.

**Employment and Income Associated with Obesity and Overweight in the US.**
*Abstract:* Academy of Managed Care Pharmacy (AMCP).

**Quality of Life of Obese Adults in the US.**
*Abstract:* International Society for Quality of Life Research (ISOQOL).
*Authors:* Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW.

**Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Prospective.**
*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
*Authors:* Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**
*Authors:* Birnbaum H, Leong S, Kabra A.

**PDB6: Factors associated with high-risk diabetic patients in the california medicaid populations (medi-cal).**
*Authors:* Chaikledkaew U, Wu E, Johnson K.

**PDB10: A Methodology to identify high-risk patients with diabetes in the california medicaid population (MEDI-CAL).**
*Authors:* Chaikledkaew U, Wu E, Johnson K.

**Productivity and medical costs of diabetes in a large employer population.**
*Authors:* Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.

**Identification of Diabetes Patients Using Claims Data: An Economic Analysis.**
*Authors:* Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.

**Gastrointestinal**

**Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.**
*Authors:* Hassan SW, Hadjilianni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.
Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin: Data from UK patients.
Publication: Diabetic Medicine 2017 03; 34: 189-190. doi: http://dx.doi.org/10.1111/dme.13302.
Authors: Hassan SW, Gulati K, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.
Publication: Diabetes Therapy 2017 03. e-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.

Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.
Authors: Hadjiyianni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M.

Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.
Authors: DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS.

Clinical and Economic Burden Associated with Chronic Hypoparathyroidism: A Retrospective Chart Review in the United States, Canada, United Kingdom, France, Germany, Italy, and Spain.
Authors: Chen K, Krasner A, Li N, Xiang CQ, Souroutzidis A, Xie J.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.
Authors: Thomas MC, Paldanis PM, Ayyagari R, Ong SH, Groop PH.

Authors: Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.

Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.
Authors: Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.

A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.


**Authors:** Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.

**Abstract:** AMCP Nexus 2016 Conference, National Harbor, Maryland October 3-6, 2016.

**Authors:** Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

The Prevalence of Hyperkalemia in the United States.

**Abstract:** AMCP Nexus 2016 Conference, National Harbor, Maryland October 3-6, 2016.

**Authors:** Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhania A, Pham H, Hollenack K, Wu EQ.

Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

**Authors:** Zhou Z, Yang H, Fang A, Zhao J, Wu E, Chaudhari P, Seifeldin R.

The healthcare costs and utilization associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

**Authors:** Yang H, Zhou Z, Zhao J, Fang A, Wu E, Chaudhari P, Seifeldin R.

Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sep 12-16, 2016.

**Authors:** Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

Time to treatment intensification and its association with subsequent macrovascular outcomes among patients with type 2 diabetes.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sep 12-16, 2016.

**Authors:** Kim J, Desai U, Kirson NY, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sep 12-16, 2016.

**Authors:** Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Epidemiological assessment of real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.


**Authors:** Huynh L, Herring M, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.
Economic model to examine the cost benefit associated with resolution or improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide in patients with neuroendocrine tumors based on data from a retrospective chart review study at three large tertiary oncology centers in the United States.


**Authors:** Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

---

**Maintenance of weight loss or stable weight in subjects with obesity: A retrospective longitudinal analysis of electronic medical record data.**


**Authors:** Der Sarkissian M, Bhak R, Huang J, Buchs S, Vekeman F, Ganguly R, Duh MS.

---

**Real-world evaluation of weight loss in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health record-based study.**

**Abstract:** ISPOR 21st Annual International Meeting Research, Washington, DC. May 21-25, 2016.

**Authors:** Lefebvre P, Chow W, Pilon D, Emond B, Lafeuille M, Pfeifer M, Rupnow MF, Duh MS.

**Patterns of Weight Loss, Maintenance, and Gain in Patients with Obesity.**

**Abstract:** ENDO, Boston, MA Apr 1-4, 2016.

**Authors:** Huang; J, Buchs; S, DerSarkissian; M, Bhak; R, Vekeman; F, Ganguly; R, Duh; MS.

---

**Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.**


**Authors:** Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

---

**Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.**

**Publication:** BMJ Open 2016 02; 6(2): e009421. e-pub ahead of print 2016/02/18; doi: 10.1136/bmjopen-2015-009421.


---

**Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.**


**Authors:** Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

---

**Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.**


**Authors:** Muram D, Kaltenboeck A, Boytsov N, Hayes-Larson E, Ivanova J, Birnbaum HG, Swindle R.

---

**Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.**


**Authors:** Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.

---

**Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.**


**Authors:** Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.
Authors: Chawla A, Carls G, Deng E, Tuttle E.

For a Step Change to Curb the Obesity Epidemic.
Authors: Frois C, Cremieux PY.

Policy Makers’ Views of Obesity-Related Challenges Around the World: An interview between Pierre Cremieux (of Analysis Group, Inc., and Guest Editor of this Special Issue) and policy makers from Brazil (Patricia Constante Jaime), Canada (Kimberly Elmslie), China (Bin Wang), France (Francois Cremieux), and the USA (Mark McClellan).
Authors: Cremieux P.

Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.
Authors: Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons NB.

Real-world evaluation of weight loss in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA) - an electronic health-record (EHR)-based study.
Abstract: Obesity Week, Los Angeles, CA Nov 2-6, 2015.
Authors: P, L; W; C; D; P; B; E; MH; L; M; P; MFT; R; MS; D.

Abstract: 16th World Conference on Lung Cancer (WCLC), Denver, CO Sep 6-9, 2015.

Authors: Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

Economic outcomes among medicare patients receiving skin substitutes for treatment of diabetic foot ulcers.
Authors: Rice JB, Desai U, Ristovska L, Cummings AG, Birnbaum HG, Skornicki M, Margolis D, Parsons N.

Glycated hemoglobin (Hba1c) control in patients with Type 2 Diabetes Mellitus (T2DM) treated with canagliflozin in a realworld setting.
Authors: Lefebvre P, Pilon D, Robitaille M, Lefeuille M, Chow W, Pfeifer M, Duh MS.
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.


Costs after initiating saxagliptin, sulfonylurea, or sitagliptin in patients with T2DM.

Authors: Kaltenboeck A, Ivanova J, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.

Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.

Authors: Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

Authors: Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towe A, Garrison LP.

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease.


Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus.

Publication: American Journal of Managed Care 2014 01; 20(1).
Authors: Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M.

Quality measure attainment in patients with type 2 diabetes mellitus.

Publication: American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15.
Authors: Lafuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P.

Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities.

Authors: Truong HL, Nellesen D, Ludlam WH, Neary MP.

Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.


Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data.

Authors: Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L.
Above standard dose of octreotide-lar in patients with neuroendocrine tumors (NET) for control of carcinoid syndrome symptoms: A multi-center retrospective chart review study.


Authors: Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

The burden of "serial non-adherence" in type 2 diabetic patients.


Authors: Frois C, Dea K, Ling D, Dunn J, Baron M.

Systematic Review of real-world evidence on treatment of Acromegaly.


Units and costs per day per claim of comparable insulins supplied to medicad patients.

Authors: Ivanova JJ, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R.

Burden of diabetic foot ulcers for medicare and private insurers.


Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.

Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes.


Authors: Virdi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R.

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.


Authors: Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.


Authors: Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.


Authors: Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis.


Authors: Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E.

Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis.


Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in patients with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).


Authors: Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).


Authors: Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

Clinical characteristics, quality measure attainment, and diabetes-related health care costs in elderly versus overall people living with type-2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).


Authors: Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Economic Outcomes Associated With Hba1c And Ldl-C Goal Achievement In Patients With Type 2 Diabetes Mellitus.


Authors: Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin.


Authors: Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep FA, Birnbaum H.

Medical, drug, and work-loss costs of diabetic foot ulcers.


Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Medical, drug, and work-loss costs of venous leg ulcers.


Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Trend in economic burden of diabetes in urban china from 2009 to 2011.


Authors: Wu E, Xie J, Du E, Liu M, Liu G.

Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.


The direct and indirect costs among U.S. privately insured employees with hypogonadism.


Authors: Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.

Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.


Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.

Authors: Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus.

Abstract: 1st American Diabetes Association Middle East Congress., Dubai, UAE Dec 4-6, 2012.
Authors: Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB.

Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens versus vials.

Authors: Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Hba1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM).

Authors: Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ.

Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients.

Authors: Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus.

Authors: Chen K, Wu E, Cheng D, Bensimon A, Bron M.

Glycemic control and quality of life for patients with type 2 diabetes mellitus in China.

Authors: Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ.

PDB17 Comparison of Clinical and Economic Outcomes Associated With Dpp4 Inhibitors (DPP4I) Versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).

Authors: Bron M, Chen K, Cheng D, Bensimon A, Wu E.

Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis.

Authors: Chen K, Bron M, Cheng D, Sharma H, Wu EQ.

Economic burden of type 2 diabetes mellitus in China.

Effect of diabetes patient characteristics on the willingness-to-pay for a new basal insulin—a discrete choice experiment.


*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

Health utility for patients with type 2 diabetes mellitus in China.


*Authors:* Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ.

Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.


*Authors:* Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.


*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.


*Authors:* Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity.


Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.


*Authors:* Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

Prevalence rates and costs of metabolic syndrome and associated risk factors using employees’ integrated laboratory data and health care claims.


*Authors:* Birnbaum HG, Mattson ME, Kashima S, Williamson TE.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.


*Authors:* Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.

*Abstract:* IDF World Diabetes Congress, Dubai, United Arab Emirates Dec 4-8, 2011.

*Authors:* Bron M, Yang HY, Yu AP, Marynchenko M, Fan L.
Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM).
*Abstract:* ISPOR 14th Annual European Congress Madrid Spain Nov 05-08, 2011.
*Authors:* Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ.

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.
*Abstract:* ACR/ARHP Annual Scientific Meeting Chicago, IL Nov 4-9, 2011.
*Authors:* Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population.
*Authors:* Yang H, Marynchenko M, Bron M, Wu E, Yu AP.

Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population.
*Authors:* Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP.

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation.

Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.
*Authors:* Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.

Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus.
*Authors:* Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP.

Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization.
*Authors:* Wu E, Zhou S, AP. Y, Lu M, Graf TR.

Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence.
*Authors:* Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP.

Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs.
*Authors:* Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ.
Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization.


Authors: Wu E, Zhou S, Yu AP, Lu M, Graf TR.

Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes.


Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients.


Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

The direct and indirect costs associated with hypogonadism among privately-insured employees in the United States.


Authors: Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R.

Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET).


Authors: Lefebvre P, Sarda SP, Laliberte F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS.

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.


Authors: Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.


Authors: Cremieux PY, Eapen S, Trask SW, Ghosh A.

The impact of bariatric surgery on comorbidities and medication use among obese patients.


Authors: Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M.

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.


Authors: Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.

Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models.


Authors: Yu AP, Yu YF, Nichol MB.
PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large US managed care cohort.

Abstract: International Society for Pharmacoeconomics and Outcomes Research, Sep 5-7, 2010.

Authors: Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes.


Authors: Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T.

Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients.


Authors: Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O.

Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs.

Abstract: 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP, San Diego, CA United States Apr 7-10, 2010.

Authors: Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Publication: Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.

Authors: Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbA1c<7.0.


Authors: Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S.

Anti-hypertensive drug use and risk of dementia in patients with diabetes mellitus (DM).


Authors: Johnson ML, Parikh NM, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Morgan R.

Risk factors for dementia in elderly patients with diabetes mellitus.


Authors: Parikh NM, Morgan R, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Johnson M.

A study on the economic impact of bariatric surgery.

Publication: American Journal of Managed Care 2008 09; 14(9): 589-596.

Authors: Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M.

Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.

Publication: Bariatric Times 2008 11.

Authors: Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.

Direct and indirect costs among employees with diabetic retinopathy in the United States.


Authors: Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.
Achieving Glycemic Goal with Initial Combination Therapy Versus Sequential Augmentation Therapy using Metformin and Pioglitazone.

**Abstract:** 44th EASD meeting, Rome, Italy  Sep 7-11, 2008.
**Authors:** Pandya BJ, Yu A, Wu EQ, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW.

Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies.

**Authors:** Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.

**Publication:** Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.
**Authors:** Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

**Publication:** Current Medical Research and Opinion 2007 09; 23(9): 2157-2169. doi: 10.1185/030079907X219544.
**Authors:** Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.

**Publication:** Obesity (Silver Spring) 2007 02; 15(2): 511-521. doi: 10.1038/oby.2007.580.
**Authors:** Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.

**Authors:** Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.


**Authors:** Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

Prevalence of diabetic peripheral neuropathy and associated pain in French adults.

**Abstract:** JOURNAL OF NEUROLOGY.
**Authors:** Wu E, Borton J, Kahn E, Said G, Le T, Garcia-Cebrian A, Monz B.

Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients.

**Abstract:** American Diabetes Association (ADA), 2006.
**Authors:** Yu AP, Wu EQ, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M.


**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, 2006.
**Authors:** Wu E, Xie J, Crémieux P, Sullivan P.

Obesity’s Impact on Diabetes Patients’ Health-Related Quality Of Life In The U.S.

**Abstract:** International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
**Authors:** Cremieux P, Xie J, Greenberg P, Wu EQ, Castor A.


**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, 2006.
**Authors:** Wu E, Xie J, Sullivan P.
Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes.

Employment and Income Associated with Obesity and Overweight in the US.
Authors: Wu EQ, Xie J, Sullivan PW.

Employment and Income Associated with Obesity and Overweight in the US.
Abstract: Academy of Managed Care Pharmacy (AMCP).

Quality of Life of Obese Adults in the US.
Abstract: International Society for Quality of Life Research (ISOQOL).
Authors: Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW.

Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Prospective.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.
Authors: Birnbaum H, Leong S, Kabra A.

PDB6: Factors associated with high-risk diabetic patients in the california medicaid populations (medi-cal).
Authors: Chaikledkaew U, Wu E, Johnson K.

PDB10: A Methodology to identify high-risk patients with diabetes in the california medicaid population (MEDI-CAL).
Authors: Chaikledkaew U, Wu E, Johnson K.

Productivity and medical costs of diabetes in a large employer population.
Authors: Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.

Identification of Diabetes Patients Using Claims Data: An Economic Analysis.
Authors: Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.

Hematology

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Authors: Latremouille-Vial D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.


*Authors:* Skarbnik AP, Ma E, Lafueille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.


*Authors:* Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.


*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency.


*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.


*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.


Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.


*Authors:* Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.


*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.


Economic burden of relapsed/refractory chronic lymphocytic leukemia.

Abstract: 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, NSW Australia Sep 6-9, 2015.

Authors: Guerin A, Ray S, Gauthier G, Hsu LI, Zhdanava M, Heroux J, Wu E.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.


Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.


Authors: Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispensieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Nicaulescu L, Quick M, Rajkumar SV.


Abstract: 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, Italy Nov 7-11, 2015.

Authors: Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G.

Epidemiologic and clinical characteristics of thalassemia (THAL) intermedia (TI) in the US.


Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).

Abstract: Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 (Date of Publication: May 2016), United States Jun 3-7, 2016.


Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Abstract: European Association for the Study of the Liver, (EASL) 50th Inernational Liver Congress, Vienna, Austria Apr 22-26, 2015.


Treatment patterns and healthcare costs in newly diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States: A retrospective claims database analysis.


Authors: Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon-Sanschagrin P, Chen L.
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.


Authors: Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.

Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.


Authors: Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.


Authors: Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.

Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII FC fusion protein and conventional recombinant factor VIII.


Authors: Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.


Authors: Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.

Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.


Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.

Publication: Clinical Therapeutics 2015 06. doi: 10.1016/j.clinthera.2015.05.503.

Authors: Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

Publication: J Manag Care Spec Pharm 2015 04; 21(4): 308-318.

Authors: Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

Epidemiologic and clinical characteristics of thalassemia intermedia in the United States.


Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from us payers’ perspective.


Authors: Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.
The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.

Abstract: 57th ASH Annual Meeting and Exposition, Dec 5-8, 2015.
Authors: Guerin A, Ray S, Gauthier G, Hsu L-I, Zhdanava M, Wu E.

Nilotinib vs Dasatinib as Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) based on Real-World Data.

Abstract: ASH annual meeting, Orlando, FL December 5-8, 2015.
Authors: Li N, Yang C, Fan L, Totev T, Guerin A, Chen L.

Patterns of prior treatment and bleeds among patients with severe hemophilia a: Impact on frequency of dosing with bay 81-8973 in the leopold i trial.

Authors: Church N, Ayyagari R, Pcoski J, Sajeeg K, Kelkar SS, Du EX, Mass-Enriquez M, Xie J.

Factor consumption for prophylaxis and treatment of bleeding: Recombinant factor IX FC fusion protein compared with conventional recombinant factor IX.

Authors: Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

Treatment patterns and best response in a contemporary cohort of patients with relapsed / refractory chronic lymphocytic leukemia with 17p deletion.

Abstract: (Lamanna, Hurst, Latremouille-Viau, Ionescu-Itu, Guerin, Yim, Reyes) Hematologic Malignancies Section/Herbert Irving Comprehensive Cancer Center, NY, USA; Genentech, Inc., South San Francisco, CA, USA; Analysis Group, Inc., Montreal, Canada, Sydney, NSW Australia Sep 6-9, 2015.
Authors: Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Itu, Guerin A, Yim YM, Reyes C.

Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products.

Authors: Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products.

Authors: Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

Real-world outcomes of patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion.

Authors: Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Itu R, Guerin A, Yim YM, Reyes C.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in medicaid patients with thalassemia.

Authors: Vekeman F, Sasane M, Cheng WY, Agnihotram RV, Fortier J, Duh MS, Paley C, Adams-Graves P.
Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.

Authors: Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis C genotype 3: A matching-adjusted indirect comparison.


A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV) and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.

Authors: Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) with the T315I mutation.


Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.

Authors: Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

Comparative Efficacy and Tolerability of Combination Treatment with Daclatasvir and Asunaprevir versus Peginterferon-Alpha/Ribavirin-Based Regimens for Patients Infected with Genotype 1b Hepatitis C Virus.

Authors: Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

Economic consequences of cytomegalovirus disease among stem cell transplant recipients.

Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snyderman DR.

One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.

Authors: Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chien L, DeAngelo DJ.

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Authors: Guerin A, Chen L, Ionescu-Ittu R, Marynychenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ.
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.

*Authors:* Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L.

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.

*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in medicaid patients with sickle cell disease.

*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Duh MS, Paley C, Adams-Graves P.

Associations between joint damage and quality of life among patients with severe hemophilia a in the 3-year spinart trial.

*Authors:* Pocoski J, Lin PL, Hong W, Kelkar SS, Jiao T, Du EX, Humphries TJ, Xie J.

A retrospective analysis of treatment patterns in elderly patients with chronic myeloid leukemia receiving dasatinib or nilotinib as second-line therapy after imatinib.


Subcutaneous (SQ) bortezomib (BTZ) in patients (PTS) with relapsed mantle cell lymphoma (MCL): Retrospective, observational study of treatment patterns and outcomes in us community oncology practices.

*Authors:* Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, Ng Y, Van De Velde H, Dow E, Niculescu L, Bonthapally V, Goy A.

Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP).

*Authors:* Guerin A, Revol C, Ramanakumar AV, Foster R, Wu EQ, Mhatre SK, Chen L.
Demographics and clinical characteristics associated with high healthcare resource utilization (hru) and costs among chronic hepatitis C (CHC) patients.
*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients With Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.
*Authors:* Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Associations between clinical outcomes, healthcare resources utilization, and quality of life among patients with severe hemophilia A.
*Authors:* Lin PL, Pocoski J, Du EX, Kelkar SS, Silberman C, Xie J.

Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C.
*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

High cost patients and cost patterns from pediatric to adult care in a medicaid population with sickle cell disease.
*Authors:* Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

High utilizers of health care resources: Results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy.

Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
*Authors:* Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

An indirect comparison of the efficacy of prophylactic use of rF VIII Fc and other rFVIII products and model of the effect of compliance.
*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness.
*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.
Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: Simulating the effect of compliance on real-world effectiveness.

Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis modeling the effect of compliance.

Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use.

Authors: Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R.

One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.

Authors: Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ.

Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis C infection.

Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ.

Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).

Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Comparison of Survival, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.


Comparison of Treatment Patterns of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.


Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.

Authors: Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.

Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.


**Authors:** Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.

Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM).


**Authors:** Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Dhanda R, Niculescu L, Ba-Mancini A, Ma E, Quick M, Rajkumar SV.

Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.

**Abstract:** HEP DART frontiers in drug development for viral hepatitis 2013, Hawaii Dec 8-12, 2013.

**Authors:** Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

Medical complications in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.


**Authors:** Vekeman F, Cheng WY, Sasane M, Huynh L, Kaminsky M, Duh MS, Paley C, Mesa RA.

Transition from pediatric to adult care of high cost patients in a medicaid population with sickle cell disease.


**Authors:** Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.


**Authors:** Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL.

Age-related emergency department reliance (EDR) and healthcare resource utilization in patients with sickle cell disease (SCD).


**Authors:** Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Final results from the multicenter compact study of complications in patients with sickle cell disease (SCD) and utilization of iron chelation therapy: A retrospective medical records review.


Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.


Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD).

Authors: Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Direct and indirect cost burden of chronic hepatitis C infection in privately-insured patients, stratified by liver disease severity.


Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.

Abstract: Digestive Disease Week (DDW) 2013, Orlando, FL May 18-21, 2013.

Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders.

Authors: Jordan L, Duh MS, Vekeman F, Matter S, Bieri C, Sasane M.

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors: Guerin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A.

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.

Authors: Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E.

Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.

Authors: Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS.


Publication: Current Medical Research and Opinion 2012 07; 28(7)
Authors: Wu E, Chen L.

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.

Publication: Current Medical Research and Opinion 2012 07; 28(7)
Authors: Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.

Authors: Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Authors: Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C.

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Age-related emergency department reliance and healthcare resource utilization in patients with sickle cell disease.
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.
Authors: Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.
Authors: Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Wu EQ.

Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib as second-line therapy.
Authors: Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

Dynamics of improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP) in EXTEND.
Authors: Grotzinger KM, Bussel JB, Saleh MN, Bieri C, Orlova Y, Brainsky A.

Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.

Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey.
Authors: Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guerin A, Liu N, Kaminsky M, Wu EQ.
Meta-analysis of the efficacy and safety of bortezomib retreatment in patients with multiple myeloma (MM).


*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP).


*Authors:* Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

Development and validation of a classification algorithm for prophylactic vs. on-demand factor VIII therapy in patients with hemophilia a.


Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.


Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.


Improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP): Results of extend from june 2006 to february 2011.


*Authors:* Grotzinger K, Bieri C, Olney H, Saleh M, Sheng Duh M, Brainsky A.

Interim results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.

*Abstract:* 17th Congress of the European Hematology Association Amsterdam Netherlands Jun 24-17, 2012.


Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML).


*Authors:* Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ.

Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.


*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.

Authors: Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.

Age-related blood transfusion patterns in patients with Sickle Cell Disease (SCD) and the association with sickle cell complications.

Authors: Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

Age-related iron chelation utilization and healthcare costs in patients with Sickle Cell Disease (SCD).

Authors: Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.

Authors: Guerin A, Bollu VK, Guo A, Stepner M, Griffin JD, Wu EQ.

Preoperative hemoglobin levels, characteristics, and resource utilization in total hip replacement patients with an anemia diagnosis versus without an anemia diagnosis: An electronic medical record analysis.

Authors: Forlenza JB, Ellis L, Parise H, Lafeuille MH, Lefebvre P.

Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting.

Authors: Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E.

Risk of venous thromboembolism complications.

Authors: Lefebvre P, Laliberte F, Nutescu E, Duh MS, Lamori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

The economics of the hematopoietic growth factors.

Authors: Eldar-Lissai A, Lyman GH.

Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.

Authors: Lefebvre P, Vekeman F, Cremieux PY.
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.

Authors: Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

Authors: Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Authors: Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.

Authors: Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.

Authors: Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ.

The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML).

Authors: Wu EQ, Guerin A, Bollu V, Williams D, Guo A, De Leon Barido DP, Yu AP, Quintas-Cardama A.

Monitoring and treatment of transfusional iron overload: Findings from an electronic medical records review study at the Moffitt cancer center and research institute.


Comparison of skeletal complications and treatment patterns associated with early versus delayed zoledronic acid therapy in multiple myeloma.

Authors: Yu AP, Bensimon AG, Marynchenko M, Wu EQ, Namjoshi M, Guo A, Ericson SG, Raje N.

Persistence and compliance of deferoxamine (DFO) versus deferasirox (DFX) in medicaid patients with sickle-cell disease (SCD).

Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.
Active dose re-escalation of nilotinib following dose reduction is associated with improved efficacy in patients with chronic phase chronic myeloid Leukemia (CML-CP) who fail imatinib.


Persistence and compliance of deferoxamine versus deferasirox in medicaid patients with sickle-cell disease (SCD).

Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.

Authors: Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.

Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.

Authors: Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

Comparison of healthcare utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia.

Authors: Wu EQ, Bollu VK, Guo A, Guerin A, Tsaneva M, Williams D, Griffin JD.

The cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.

Authors: Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): A sub-analysis of the ENACT (expanding nilotinib access in clinical trials) study.

Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): Sub-analyses of the ENACT (expanding nilotinib access in clinical trials) study.


Lower healthcare resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients - Evidence from a clinical practice setting study.


*Authors:* Guerin A, Bollu VK, Williams D.

Molecular response, efficacy and safety analysis of 168 adult french patients with chronic myeloid leukemia (CML) in chronic phase (CP) from the ENACT (expanding nilotinib access in clinical trials) study.


Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the enact (expanding nilotinib access in clinical trials) study.


Persistence and compliance of deferoxamine versus deferasirox in medicaid patients with sickle-cell disease.


*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia.

*Abstract:* ASCO Annual meeting, Orlando, FL May 29 - Jun 2, 2009.


Association of health-related quality of life (HRQoL), bleeding, and platelet levels in chronic idiopathic thrombocytopenic purpura (ITP): Results from RAISE and EXTEND.

*Abstract:* 14th Congress of the European Hematology Association Berlin Germany June 4-7, 2009.

*Authors:* Bussel J, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Brainsky A.

Improvement in fatigue and health-related quality of life (HRQoL) with long-term Eltrombopag therapy in chronic idiopathic thrombocytopenic purpura: results of phase 3, double-blind study (raise).


*Authors:* Provan D, Bussel JB, Cheng G, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.
Improvement in fatigue and health-related quality of life with long-term Eltrombopag treatment in adults with chronic idiopathic thrombocytopenic purpura: The EXTEND study.

**Abstract:** 14th Congress of the European Hematology Association Conference Berlin Germany. Jun 4-7, 2009.

**Authors:** Bussel J, Saleh M, Salama A, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

**Abstract:** ISPOR 14th Annual International Meeting, Orlando, FL United States. May 16-20, 2009.

**Authors:** Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: Data from multi-center clinical practices.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States. May 16-20, 2009.

**Authors:** Raptis A, Duh MS, Wang ST, Dial E, Fanourgaki I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib.

**Abstract:** ASCO Annual meeting, Orlando, FL May 29 - June 2, 2009.

**Authors:** Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD.


**Authors:** Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundie S.

Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.


**Authors:** Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.

Anaemia and the risk of injurious falls in a community-dwelling elderly population.

**Publication:** Drugs and Aging 2008 04; 25(4): 325-334.

**Authors:** Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT.


**Publication:** Pharmacoeconomics 2008 01; 26(2): 99-120.

**Authors:** Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE.

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.

**Publication:** American Journal of Health-System Pharmacy 2007 09; 64(18): 1943-1949. doi: 10.2146/ajhp060585.

**Authors:** Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer’s perspective.


**Authors:** Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?


**Authors:** Wu WK, Duh MS, Lefebvre P.

Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients.

**Abstract:** ASCO Annual Meeting, Chicago, IL Jun 1-5, 2007.

**Authors:** Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J.
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.
Authors: Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.
Authors: Cremieux P, Vekeman F, Lefebvre P.

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Authors: Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
Publication: Current Medical Research and Opinion 2006 10; 22(9): 1623-1631. doi: 10.1185/030079906X120968.
Authors: Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.
Authors: Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives.
Authors: Duh MS, Latypova A, Greenberg P.

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
Authors: Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Authors: Chu E, Einhorn LH, Lefebvre P.

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
Authors: Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.
Authors: Gosselin A, McKenzie R, Lifebvre P, Mody S, Piech C, Duh M.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Publication: Drugs and Aging 2006 12; 23(12): 969-976.
Authors: Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.
Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.


*Authors:* Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.

Health-Related Quality Of Life of Anemia Patients in the U.S.

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific.

*Authors:* Cremieux P, Xie J, Wu EQ, Castor A.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.


*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.


*Authors:* Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.


*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J.

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.


*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.


*Authors:* Duh MS, L Mark T.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis.


*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.

*Publication:* Journal of Managed Care Pharmacy 2004 11; 10(6): 531-537.

*Authors:* Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendick AM.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?

*Publication:* Critical Care Medicine 2004 03; 32(3): 666-674.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH, Group CS.

The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.


*Authors:* Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, Macintyre NR, Shabot MM, Duh MS, Shapiro MJ.
PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.

Authors: Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.
Authors: Gabriolove JL, Sarokhan B, Cremieux P.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
Authors: Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Anemia-related costs for cancer patients.
Authors: Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

Costs Associated with Anemia and Cancer.
Authors: Cremieux PY GM, Holland M, Slavin MB.

Publication: Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472.
Authors: Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

Infectious Diseases

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Authors: Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.

Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.
Authors: Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
Authors: Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

Daclatasvir +asunaprevir versus sofosbuvir/ledipasvir for the treatment of chronic hepatitis c genotype 1 in Japanese patients: A matching-adjusted indirect comparison.
Abstract: 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, Italy Nov 7-11, 2015.
Authors: Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Abstract: European Association for the Study of the Liver, (EASL) 50th International Liver Congress, Vienna, Austria Apr 22-26, 2015.

Indirect comparison of daclatasvir+asunaprevir vs sofosbuvir/ledipasvir for HCV in Japanese patients.
Authors: Swallow E, Kelley C, Signorovitch J, McPhee F, Wygant G.

Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.
Authors: Krishnarajah G, Duh MS, Korves C, Demissie K.

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Authors: Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
*Publication:* Clinical Therapeutics 2015 06. doi: 10.1016/j.clinthera.2015.05.503.
*Authors:* Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

The epidemiology of herpes zoster and its complications in Medicare cancer patients.
*Authors:* Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.
*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318.
*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfected with HIV: A matching-adjusted indirect comparison.

Association of Obesity with 30-day readmission rates among patients Hospitalized with Acute Bacterial Skin and Skin-Structure Infections (ABSSI).
*Authors:* Ayyagari R, Revol C, Tang W, Faust E, Tuttle EG.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.
*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabakar A.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.

Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection.

A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.
*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.
Comparative Efficacy and Tolerability of Combination Treatment with Daclatasvir and Asunaprevir versus Peginterferon-Alpha/Ribavirin-Based Regimens for Patients Infected with Genotype 1b Hepatitis C Virus.

Authors: Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

Economic consequences of cytomegalovirus disease among stem cell transplant recipients.

Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snydman DR.

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.

Authors: Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.

Publication: Journal of Medical Economics 2014 12; 17(12); 862-871. doi: 10.3111/13696998.2014.964720.
Authors: Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

Demographics and clinical characteristics associated with high healthcare resource utilization (hru) and costs among chronic hepatitis c (hcv) patients.

Authors: LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

The pharmacoeconomics review of 7-valent pneumococcal conjugate vaccination in Asian-pacific region.

Authors: Zhu L.

Cost burden of cytomegalovirus (CMV) disease among solid organ transplant recipients.


Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients With Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.

Authors: Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C.

Authors: Le TK, Kalsekar A, Yuan Y, Macalalad D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection.

Authors: Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J.

Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.

Authors: Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.
Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.
Authors: Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

Treatment patterns, health care resource utilization and costs in United States patients diagnosed with chronic hepatitis C infection.
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ.

Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.
Authors: Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.
Authors: Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
Authors: Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

The epidemiology of herpes zoster (HZ) and its complications in medicare cancer patients.
Authors: Yenikomshian MA, La Casce AS, AT S, Trahey A, Guignard A, Haguinet FF, Karner PE, Duh MS.

Budget impact analysis of liposomal amphotericin b and amphotericin b lipid complex for treating invasive fungal infections in hospitalized patients.
Authors: Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ.

Direct and indirect cost burden of chronic hepatitis C infection in privately-insured patients, stratified by liver disease severity.

Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.
Abstract: Digestive Disease Week (DDW) 2013, Orlando, FL May 18-21, 2013.

Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.
Authors: Xie J, Judy TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.
Direct and indirect cost burden is higher in HCV infection compared with a matched non-HCV infected cohort in a privately-insured population.


Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials.

Authors: Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States.

Authors: Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D.

The role of public-sector research in the discovery of drugs and vaccines.
Authors: Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML.

PIH14 Rates and Predictors of Chlamydia re-Screening among Privately insured Patients with Chlamydia in 2007-2009.
Abstract: International Society for Pharmacoeconomics and Outcomes Research, Nov 5-8, 2011.
Authors: Shi L, Liu J, Kissinger P, Khan M, Wu E.

Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.
Authors: Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

Abstract: ISPOR 14th Annual European Congress Madrid Spain Nov 5-8, 2011.
Authors: Shi L, Liu J, Kissinger P, Khan M, Wu EQ.

Lower respiratory tract infections: impact on the workplace.
Publication: Pharmacoeconomics 2003 06; 21(10): 749-759.
Authors: Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

Economic burden of respiratory infections in an employed population.
Publication: Chest 2002 08; 122(2): 603-611.
Authors: Birnbaum HG, Morley M, Greenberg PE, Colice GL.

Neurology
Corrigendum to “Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy” [Neuromuscular Disorders 26/9 (2016) 576-583].
Authors: Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, collaborative Trajectory Analysis P.
Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.

**Publication:** European Child and Adolescent Psychiatry 2017 03. e-pub ahead of print 2017/03/05; doi: 10.1007/s00787-017-0962-6.
**Authors:** Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.

**Authors:** Pilon D, Amos TB, Germain G, Lafuille MH, Lefebvre P, Benson CJ.

Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study.

**Abstract:** American Academy of Neurology 69th Annual Meeting, Boston, MA Apr 22-28, 2017.
**Authors:** Ye X, Kantor D, Barbato LM, Wakeford C, Yang M, Macaulay D, Marshall T.

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

**Authors:** Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.

Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

**Publication:** Am Health Drug Benefits 2016 10; 9(7): 399-410.
**Authors:** Lafeuille MH, Fros C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M.


**Authors:** Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.

**Publication:** Neuromuscular Disorders 2016 05. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016.
**Authors:** Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ.

Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population.

**Authors:** Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.
Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.
Authors: Joseph A, Cloutier M, Guerin A, Nitulescu R, Sikirica V.

Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.

Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.
Authors: Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R.

The economic burden of schizophrenia in the United States in 2013.
Publication: Journal of Clinical Psychiatry 2016 04. e-pub ahead of print 2016/05/03; doi: 10.4088/JCP.15m10278.

Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.
Authors: Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the first-HD and tetra-HD trials.
Authors: Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

Authors: Kantor D, Johnson K, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V.

Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare resource use and costs in veterans with schizophrenia with limited antipsychotic exposure in the prior 12 months.
Authors: Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak R, Kageleiry A, Duh MS, Shiner B, Young-Xu Y.

Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis.
Abstract: 20th International Congress of Parkinson’s Disease and Movement Disorders, Germany Jun 19-23, 2016.

Can indirect comparison methods mitigate evolving trial populations in adjunctive antiepileptic drug trials? A propensity score matched indirect comparison of brivaracetam and levetiracetam.
Authors: Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.
A life-course assessment of medication use and medical costs of lennox-gastaut syndrome (LGS).
Authors: Montouris G, Pina-Garza JE, Vekeman F, Cheng WY, Tuttle EG, Giguere-Duval P, Duh MS, Isojarvi J.

Association of Rescue Medication Use with Clinical Outcomes and Health Care Costs in Patients with Seizure Clusters.

Epilepsy treatment patterns among patients with tuberous sclerosis complex.

Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.
Authors: Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.
Authors: Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

Authors: Fox E, Johnson K, Lin F, Signorovitch J, Li N, Peeples M, Ristovska L, Souroutzidis A, Hong W, Herrera V.

Subependymal giant cell astrocytoma treatment patterns among patients with tuberous sclerosis complex.

Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Authors: Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
Abstract: International Society for Pharmacoeconomics and Outcomes Research, Sep 2015.
Authors: Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.

Patient and Caregiver Burden Associated With Fragile X Syndrome in the United States.
Authors: Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.
The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.
Authors: Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R.

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Authors: Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM.

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.

Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.
Authors: Xiao Y, Muser E, Lafeuille MH, Pesaj, Fastenau J, Duh MS, Lefebvre P.

Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Authors: Lafeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P.

Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Authors: Zhou ZY, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J.

Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Authors: Yermakov S, Davis M, Calnan M, Faye M, Cox-Buckley B, Sarda S, Duh MS, Iyer R.

Medical costs of Alzheimer’s disease misdiagnosis among US Medicare beneficiaries.
Authors: Hunter CA, Kirson NY, Desai U, Cummings AK, Faries DE, Birnbaum HG.

The Growing Economic Burden of Depression in the U.S.
Publication: Scientific American MIND Guest Blog 2015 02.
Authors: Greenberg P.

The economic burden of adults with major depressive disorder in the United States (2005 and 2010).
Authors: Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC.

Development of a classifier to identify patients with Lennox–Gastaut syndrome in health insurance claims databases via the random forest methodology.
A life-course assessment of treatment patterns and healthcare costs of Lennox-Gastaut syndrome.
Philadelphia, PA; Dec 4-8, 2015.
Authors: Montouris GD, Piña-Garza JE, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Isojarvi J.

Predicting factors for reaching stabilized maintenance with once-monthly paliperidone almitate in Medicaid patients with schizophrenia.
Authors: Muser E, Pilon D, Emond B, Xiao Y, Amos T, Lefebvre P, Benson C.

Treatment patterns in schizophrenia patients reaching stabilized maintenance therapy with once-monthly paliperidone palmitate.
Authors: Amos T, Pilon D, Muser E, Emond B, Xiao Y, Lefebvre P, Benson C.

Functional limitations and healthcare resource utilization for individuals with cognitive impairment without dementia: Findings from a U.S. population-based survey.

Development of a risk score to guide individualized treatment selection in attention-deficit/hyperactivity disorder.

Systematic literature review and mixed treatment comparison of guanfacine extended release (GXR) versus other pharmacotherapies in children and adolescents with attention deficit/hyperactivity disorder (ADHD).
Authors: Joseph A, Xie J, Bischof M, Zhanabekova Z, Cai S, Zhuo Y, Huss M, Sikirica V.

The burden of treatment switch in patients with major depression: A US retrospective administrative claims analysis.
Authors: Perez V, Gauthier G, Guerin A, Francois C, Merkle E.

Description of prophylactic drug utilization patterns in migraine patients.
Authors: Shei A, Woolley JM, Desai PR, Enloe CJ, Kirson NY, Birnbaum HG, Corey-Lisle PK, Sapra S.

Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: A retrospective chart review.
Authors: Vazquez B, Sidovar M, Squillacote D, Wu E, Macaulay D, Sorg R, Guo A.

Healthcare Utilization and costs among Adults with Major depressive Disorder treated with Vilazodone vs. Other selective Serotonin Reuptake Inhibitors.
Authors: Zhou Z, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE.
Predictors of receiving at least 5 claims for once monthly paliperidone palmitate among medicaid patients with schizophrenia.

Authors: Lafeuille MH, Xiao Y, Muser E, Pesa J, Fastenau J, Duh MS, Lefebvre P.

Real-world treatment outcomes in adults with attention deficit/hyperactivity disorder treated with lisdexamfetamine versus atomoxetine following methylphenidate treatment.

Authors: A. Joseph, M. Cloutier, A. Guérin, R. Nitulescu, V. Sikirica.

Relative efficacy and tolerability of vortioxetine versus approved antidepressants for major depressive disorder: A meta-regression of clinical trials.

Authors: Diamand F, Danchenko N, Brignone M, Rive B, Perez V, Ereshefsky L, Francois C, Merikle E.

Treatment patterns among chronic users of immediate-release oxycodone initiating treatment with extended-release opioids.

Authors: Pergolizzi JV, Kirson NY, Bell J, Jones C, Mantovanelli F, Cummings AG, Birnbaum HG, Ben-Jospeh R.

Comparison of medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.

Authors: Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Development of a claims-based classifier to identify Lennox-Gastaut Syndrome.

Authors: Pina-Garza EJ, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

A systematic review and network meta-analysis of eslicarbazepine acetate and other recently-approved anti-epileptic drugs for adjunctive treatment of partial-onset seizures in adults.

Authors: Betts K, Bollu V, De G, Blum D, Velez F.

Medical resource use and costs among pain patients with potential opioid-tolerability issues.

Authors: Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R, Michna E.

Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec.


Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.

Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Erder MH, Dammerman RS, Robertson B, Wu EQ.
Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec.


Implications of early treatment among Medicaid patients with Alzheimer's disease.

Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.

Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.

Authors: Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ.

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.

Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Burden of schizophrenia on selected comorbidity costs.

Authors: Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P.

Clinical characteristics and treatment pattern in cluster seizures: A preliminary chart review analysis.

Authors: Vazquez B, Wu E, Macaulay D, Sidovar M, Roberts H, Squillacote D, Rabinowicz AL, Guo A.

The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs.


Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: A longitudinal analysis.


Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.

Systematic literature review and mixed treatment comparison of GXR versus other treatments in children and adolescents with attention deficit hyperactivity disorder (ADHD).

**Abstract:** ISPOR 17th Annual European Congress Amsterdam Netherlands. Nov 8-12, 2014.
**Authors:** Joseph A, Ayyagari R, Bischof M, Cai S, Xie M, Zhanabekova Z, Sikirica V.

Comparison of re-hospitalization and emergency room visit patterns among patients with schizophrenia receiving paliperidone palmitate or oral atypical antipsychotics in an inpatient setting.

**Abstract:** 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Conference Taipei Taiwan (Republic of China). Oct 24-27, 2014.
**Authors:** Lafeuille MH, Grittner A, Muser E, Fastenau J, Duh MS, Lefebvre P.

Healthcare resource utilization preceding first diagnosis for fragile x syndrome (fxs).

**Authors:** Nazareth T, Marynchenko M, Chopra P, Li N, Zhou Z, Signorovitch J, Wu E, Marvel J, Ahmed S, Sasane R.

Medical specialists involved in caring for patients with fragile x syndrome (FXS): a Medicaid perspective.

**Authors:** Nazareth T, Marynchenko M, Li N, Chopra P, Zhou Z, Signorovitch J, Wu EQ, Ahmed S MJ, Sasane R.

Assessing the impact of time-dependent treatment with once-monthly paliperidone palmitate or oral atypical antipsychotics on healthcare resource utilization and Medicaid spending among patients with schizophrenia using marginal structural models.

**Authors:** Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pes J, Fastenau J, Duh MS.

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.

**Abstract:** 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA United States. Sept 9-13, 2014.

Comparison of healthcare resource utilization and Medicaid spending among patients with schizophrenia treated with once monthly paliperidone palmitate or oral atypical antipsychotics using the inverse probability of treatment weighting approach.

**Authors:** Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pes J, Fastenau J, Duh MS.

Impact of improved adherence to disease-modifying therapies on healthcare resource utilization and medical costs for patients with multiple sclerosis.

**Abstract:** 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA United States. Sep 10-13, 2014.
**Authors:** Yermakov S, Davis M, Calnan M, Fay M, Buckley B, Sarda S, Duh MS, Iyer R.

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.

**Abstract:** 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA United States. Sep 10-13, 2014.
**Authors:** Vollmer T, Signorovitch JE, Huynh L, Galebach P, Kelley C, Marvel J, Di Bernardo A, Sasane R.
Abstract: 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA United States. Sep 10-13, 2014.
Authors: Nazareth T, Marvel J, Sikirica S, Xie J, Reichmann W, Zhao C, Sasane R.

Assessing the economic burden of Alzheimer's disease patients treated by specialists within three months of preliminary diagnosis of cognitive decline.

Excess costs associated with possible misdiagnosis of Alzheimer's disease among patients with vascular dementia in a UK CPRD population.
Authors: Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Price D, Belger M, Hunter CA, Lenox-Smith AJ, Reed CC.

Medical resource use and costs among pain patients with potential opioid tolerability issues.
Authors: Birnbaum H, Kirson N, Shei A.

Comparison of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics in an inpatient setting.
Authors: Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

Effect of improving adherence to disease-modifying agents on health care resource utilization and medical costs in patients with multiple sclerosis.
Authors: Yermakov S, Davis M, Calnan M, Fay M, Duh M, Iyer R.

Factors associated with performance on the medicaid HEDIS measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia.
Authors: Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa JA, Clancy Z, Fastenau J, Durkin M.

Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective.
Authors: Signorovitch J, Wu E, Li N, Chopra P.

Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective.
Authors: Signorovitch J, Wu E, Li N, Chopra P.

Systematic review of long-acting injectables (LAI) versus oral atypical antipsychotics (OA) on hospitalization in schizophrenia.
Authors: Lafeuille MH, Cloutier M, Fortier J, Duh MS, Fastenau J, Dirani R, Lefebvre P.
Treatment patterns of patients receiving paliperidone palmitate in an inpatient setting.
*Authors:* Lafeuille MH, Fortier J, Grittner AM, Muser E, Fastenau J, Duh MS, Lefebvre P.

Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review.
*Authors:* Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J.

HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington’s Disease.
*Publication:* Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 223. doi: 10.7916/D8PN93NZ.

Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.
*Publication:* Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 224. doi: 10.7916/D8JW8BWS.

Costs of Parkinson’s disease in a privately insured population.
*Authors:* Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.


Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.

An economic model of Parkinson’s disease: implications for slowing progression in the United States.
*Authors:* Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD.
Authors’ reply to Alatorre et al.: “cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison”.
Authors: Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Authors: Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.
Authors: Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.

Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.
Authors: Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.
Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

Pre-diagnosis excess acute care costs in Alzheimer’s patients among a US Medicaid population.
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

Glioblastoma treatment patterns and outcomes and resource use in the united states.

Health care resource use and direct costs associated with fragile x syndrome (FXS) in the United States.
Authors: Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada.

Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.
Authors: Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.
Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010.

Authors: Betts KA, Sikirica V, Hodgkins P, Du E, Zhou Z, Erder HM, Wu EQ.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.

Authors: Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Dug MS.

Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec.


Excess costs associated with misdiagnosis of Alzheimer’s disease among U.S. Medicare beneficiaries with vascular dementia or Parkinson’s disease.

Authors: Kirson N, Hunter C, Desai U, Cummings A, San Roman A, Faries D, Hardwick C, Birnbaum H.

Therapy combination: a prevalent pattern among children and adolescents with attention deficit/hyperactivity disorder treated with stimulants in the Canadian province of Quebec.

Abstract: World Congress on ADHD, Milan, Italy June 6-9, 2013.

Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression.

Authors: Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R.

Burden of schizophrenia on selected comorbidities costs.

Authors: Lafeuille MH, Dean J, Fasteneau J, Panish JM, Olson WH, Markowitz M, Duh MS, Lefebvre P.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.

Authors: Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Dug MS.

Guanfacine immediate release vs. Guanfacine extended release: Comparative medication adherence, resource utilization, and healthcare costs among children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Authors: Sikirica V, Xie J, He TL, Erder MH, Hodgkins P, Yang H.

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.

Authors: Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fasteneau J, Duh MS.
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.
Authors: Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Authors: Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Publication: Journal of Managed Care Pharmacy 2012 11; 18(9): 676-689.
Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

Authors: Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Authors: Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ.

Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease.
Authors: Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
Authors: Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

Duloxetine use in chronic low back pain: treatment patterns and costs.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
Publication: Managed Care 2012 01; 21(1): 49-58.
Authors: Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Authors: Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Characteristics, clinical and economic outcomes in medicaid pediatric vagus nerve stimulation (VNS) therapy patients for the treatment of refractory epilepsy.

Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Economic value of screening for early Parkinson’s disease in a European setting.

Authors: Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

Economic value of slowing Parkinson’s disease in Germany: Modeling progression through Hoehn and Yahr stages.

Authors: Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.

Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers.

Authors: Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

Period prevalence of stimulant augmentation among pediatric attention deficit/hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population.

Authors: Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, EQ W.

Economic value of screening for early Parkinson’s disease in a European setting.

Authors: Johnson S, Siderowf AD.

Economic value of slowing Parkinson’s disease in Germany: Modelling progression through Hoehn and Yahr stages.

Authors: Johnson SJ, Birnbaum HG, Siderowf AD.

The impact of long-acting injectable vs oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.

Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.
Impact of long-acting injectable vs. oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.

Authors: Lafeuille MH, Laliberte-Augur F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis.

Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

Prevalence, comorbidity burden and treatment of Alzheimer’s disease among the elderly in the United States.


An application of group-based modeling approach for trajectory recognition: The developmental courses of hyperactivity and inattentive symptoms.

Authors: Cheng W, Goodwin R, Wu P, Vitaro F, Tremblay R.

Economic value of screening for early Parkinson’s disease.

Authors: Johnson S, Siderowf A.

Economic value of slowing Parkinson’s disease to payers and patients: Modeling progression through Hoehn and Yahr stages.

Authors: Johnson S, Diener M, Kaltenboeck A, Birnbaum H, Grubb E, Siderowf A.

The impact of long-acting injectable versus oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.

Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Impact of long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.

Authors: Lafeuille MH, Laliberte-Augur F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Incremental clinical and economic burden of uncontrolled partial-onset seizures in a privately-insured population.

Authors: Paradis PE, Parise H, Duh MS, Bowers BW, Faught E.
Model of rasagiline versus standard of care for parkinson's disease: Comparison of progression effects.


Authors: Johnson S, Wang ST, Birnbaum H, Grubb E.

Treatment patterns, resource utilization and costs associated with guanfacine immediate release versus guanfacine extended release among children and adolescents with attention deficit/hyperactivity disorder (ADHD).


Authors: DiBello J, Sikirica V, Samuelsom T, Xie J, He T, Erder MH.

Characteristics and use patterns of chronic hydrocodone users.


Authors: Rice J, Samuelson T, Birnbaum H, Katz N.

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.


Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

Urgent care utilization for adolescents treated with atypical antipsychotics or nonantipsychotics: A comparison of rates and reasons.


Authors: Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH.

Cost implications of early treatment among patients with alzheimer's disease - A medicaid perspective.


Authors: Geldmacher D, Kirson N, Birnbaum H, Eapen S, Cummings K, A, Joish V.


Authors: Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E.

Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective.


Authors: Demaerschalk B, Switzer J, Xie J, Fan L, Villa K, Wu E.

Atypical antipsychotics versus non-antipsychotics: Comparative treatment patterns, resource utilization, and costs in stimulant-treated adolescents with adhd who require subsequent pharmacotherapy.


Authors: Sikirica V, Pliszka SR, Betts K, Hodgkins P, Samuelson T, Xie J, Dammerman R.

Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.


Authors: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.
Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.


**Authors:** Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

PMH65 Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, 2012.

**Authors:** Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder M.

Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.


**Authors:** Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M.

Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.


**Authors:** Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Early retirement and income loss in patients with early and advanced Parkinson’s disease.


**Authors:** Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, Siderowf A.

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.

**Publication:** Am Health Drug Benefits 2011 03; 4(2): 78-87.

**Authors:** Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH.

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.


**Authors:** Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH.

Physicians’ decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan.


**Authors:** Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emani S, Sheehy M.

Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine.

**Publication:** Cephalalgia 2011 02; 31(3): 357-367. doi: 10.1177/0333102410379890.

**Authors:** Yang M, Rendas-Baum R, Varon SF, Kosinski M.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.


**Authors:** Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.


**Authors:** Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.
Characteristics and clinical and economic outcomes in medicaid patients receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.

Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Faught E.

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention deficit/ hyperactivity disorder: A retrospective study.

Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

Effect of treatment timing on risk of institutionalization among patients with Alzheimer’s disease.

Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Kantor E, Eapen S, Joish VN.

PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents.

Abstract: International Society for Pharmacoeconomics and Outcomes Research, Nov 5-8, 2011.
Authors: Sikirica V, Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu E.

Comparative efficacy of guanfacine extended-release and atomoxetine for the treatment of oppositional symptoms in children with attentiondeficit/ hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).

Authors: Signorovitch JE, Sikirica V, Lu M, Xie J, Wu EQ, Erder MH.

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of ADHD: A retrospective study.

Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

Treatment patterns, resource utilization, and costs associated with atypical antipsychotics vs. non-antipsychotics added to or switched from stimulants among children with attentiondeficit/ hyperactivity disorder (ADHD).

Authors: Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, Wu EQ.

Characteristics, clinical and economic outcomes in medicaid patients 17 years and younger receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.

Authors: Helmers SL, Duh MS, Guirin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in medicaid patients with drug-resistant epilepsy.

Authors: Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.
Assessment of parkinson's disease progression rates by stage of disease.

Authors: Johnson SJ, Kaltenboeck A, Diener M, Tarrants M, Birnbaum H.

Comparison of real-world health care costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder.

Authors: Swindle R, Ivanova JI, Birnbaum HG, Cummings AK, Kantor E, Schiller M, Clark T, Reed C.

The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents.

Authors: Erder M, Chen K, Wu EQ, Hodgkins P, Sikirica V.

Direct and indirect costs of privately-insured patients treated with oxymorphone extended-release or oxycodone controlled-release tablets.

Authors: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, KH S.

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in medicaid patients with drug-resistant epilepsy.

Authors: Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.

Abstract: 30th Annual Scientific Meeting of the American Pain Society Conference Austin, TX United States. May 19-21, 2011.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

Uncontrolled epilepsy in a medicaid population.

Authors: Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Mishagina N, Parisé H, Rovba L, Lefebvre P, Faught E.

Burden of uncontrolled epilepsy in a privately insured population.

Authors: Manjunath R, Faught E, Paradis PE, Parisé H, Lafeuille MH, Lefebvre P, Duh MS.

Relationship between adherence to disease-modifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis.

Authors: Philips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance.

Publication: American Journal of Managed Care 2011 08; 17(8): e314-323.
Authors: Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.
Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy.


Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients.

Authors: Marynchenko M YA, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM, Bose A.

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.

Authors: Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.

Publication: Current Medical Research and Opinion 2011 06; 27(6): 1089-1096.
Authors: Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Andrew PY, Wu EQ, Dworak H, Erder MH.

Switch to generic SSRIs may boost costs in MDD.

Authors: Wu E.

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.

Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD.


Authors: Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, Duh MS.

A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.

Authors: Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.

Authors: Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lefeuvre MH, Michna E, Greenberg PE.

Generic antiepileptic drugs and associated medical resource utilization in the United States.

Authors: Labiner DM, Paradis PE, Manjunath R, Duh MS, Lefeuvre MH, Latremouille-Viau D, Lefebvre P, Helmers SL.

Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.

Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.
Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications.


*Authors:* Michna E, Duh MS, Korves C, Dahl JL.

The risks and costs of multiple-generic substitution of topiramate (author reply).

*Publication:* Neurology 2010 02; 74(8): 701-702; author reply 701-702. doi: 10.1212/WNL.0b013e3181c7770b.

*Authors:* Sethi NK, Torgovnick J, Sethi PK, Arsura E, Emmanuel Paradis P, Duh MS, Durkin MB, Wan GJ.

Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.


*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux PY, Greenberg PE.

Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics.


*Authors:* Frois C, Guerin A, Saraogi A, Panish J, Dirani R.

Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative.


Real-world use of duloxetine for chronic low back pain: Treatment pattern and costs.


*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle R.

Compliance and persistence to single-tablet levodopa/carbidopa/entacapone compound versus levodopa/carbidopa in idiopathic parkinson’s disease.


*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

Cost of illness of post-traumatic stress disorder compared with major depressive disorder.


*Authors:* Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G.

Descriptive profile of Medicaid patients with post herpetic neuralgia treated and untreated with lidocaine patch 5%.


Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in medicaid patients with post herpetic neuralgia.

Authors: Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.

Authors: Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

Real-world use of duloxetine for low back pain and chronic low back pain: Treatment pattern, direct and indirect costs.

Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R.

Economic value of lidocaine patch 5% versus gabapentin or pregabalin in medicaid patients with post-herpetic neuralgia.

Abstract: 22nd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP Conference San Diego, CA United States. Apr 7-10, 2010.
Authors: Ivanova J, Puenpatom A, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.

Authors: Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D.

Impact of levodopa/carbidopa/entacapone compound versus levodopa/carbidopa on hospitalization rates in patients with idiopathic parkinson’s disease.

Authors: Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.

Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.

Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH.

Economic burden of epilepsy among the privately insured in the US.

Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.

Authors: Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M.
Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.
Authors: Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE.

Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.
Authors: Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A.

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
Authors: Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

Antidepressant treatment patterns and costs among US employees.
Authors: Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R.

Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.
Authors: Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G.

Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Authors: Faught RE, Weiner JR, Guerin A, Cunnington MC, Duh MS.

The risks and costs of multiple-generic substitution of topiramate.
Authors: Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.
Authors: Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.
Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
Authors: Birnbaum HG, Ivanova Ji, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D.

Economic consequence of switching to citalopram after its generic entry among major depressive disorder patients treated with escitalopram.
Authors: Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Erder H.
Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.

Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression.

Authors: Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, Wu EQ, Erder H.

The potential economic impact of generic substitution of topiramate on health care costs in the G4 European countries.

Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Evaluation of cardiovascular diseases (CVDs) risk in French patients receiving milnacipran (MLN) relative to patients receiving other antidepressants therapies.

Authors: Mease PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P, Zimetbaum PJ.

Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.

Authors: Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G.

Compliance, persistence, and outcomes in patients with Alzheimer’s disease treated with oral cholinesterase inhibitors.

Authors: Mody-Patel N, Vekeman F, Laliberte F, Kahler KH, Duh MS, Lefebvre P.

Clinical consequences of generic substitution of topiramate.

Authors: Paradis P, Dominick L, Patrick L, Marie-Helene L, Natalia M, Moore Y, Gaudig M, Duh M.

Economic impact of generic entry of topiramate in Germany.

Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy., 2009.
Authors: Paradis P, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh MS.

Impact of generic substitution of topiramate for patients with epilepsy.

Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy. Conference Publication: (var.pagings).
Authors: Paradis P, Latremouille-Viau D, Lefebvre P, Lafeuille M, Mishagina N, Moore Y, Gaudig M, Duh MS.

The impact of generic substitution of topiramate on healthcare costs: Conversion of the Canadian experience into the settings of Germany.

Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy., 2009.
Authors: Paradis P, Latremouille-Viau D, Lafeuille M, Lefebvre P, Gaudig M, Duh MS.
Antipsychotic drug use in patients with Alzheimer’s disease treated with rivastigmine versus donepezil: Evidence from health claims data.

Authors: Lefebvre P, Vekeman F, Kahler K, Mody-Patel N, Duh MS, Scharre DW.

Comparison of hospitalizations and health care costs of elderly major depressive disorder (MDD) patients treated with escitalopram, generic SSRIs, or SNRIs.

Authors: Wu EQ, Cahill KE, Bieri C, Ben-Hamadi R, Yu AP, Erder MH.

Compliance and persistence of oral cholinesterase inhibitors in patients with Alzheimer’s disease.

Authors: Vekeman F, Laliberte F, Kahler K, Mody-Patel N, Lefebvre P, Duh MS.

Direct costs in older patients with depression treated and untreated with antidepressant therapy.

Authors: Ivanova J, Birnbaum HG, Samuels S, Emani S, Sheehy M, Cattelin F.

Direct costs of patients with treatment resistant and non-treatment resistant major depressive disorder.

Authors: Ivanova J, Birnbaum HG, Kidolezi Y, Subramanian G, Stensland MD, Khan SA.

Economic assessment of second-line treatment: Switching from a generic ssri to escitalopram, an snri, or another generic ssri by patients with major depressive disorder (MDD).


Economic impact of generic entry of topiramate in the G4 European countries.

Authors: Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI.


Economic implication of dose escalation in depressed patients treated with escitalopram or venlafaxine XR.

Authors: Yu AP, Bensimon AG, Wu EQ, Ben-Hamadi R, Bourezak A, Erder MH.

The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.

Authors: Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

Physicians’ attitude to prescribing antidepressant therapy in older patients with depression.

Authors: Ivanova JI, Birnbaum HG, Connolly C, Emani S, Bienfait-Beuzon C.

Real-world use of duloxetine for low back pain.

Assessing the relationship between compliance with antidepressant therapy and costs among employees in the United States.

Authors: Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Cremieux P, Greenberg P.

Healthcare resource utilization and costs of mild, moderate, and severe depression in the workforce in the United States.

Authors: Birnbaum H, Kessler R, Joish V, Kelley D, Ben-Hamadi R, M. H, Greenberg P.

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors: Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.

Authors: Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

Impact of generic substitution of topiramate for patients with epilepsy.

Publication: European Journal of Neurology 2009 16 (S3): 140.
Authors: Paradis PE, Latremouille-Viau D, Lefebvre P, Lafeuille MH, Mishagina N, Moore Y, Gaudig M, Duh MS.


Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.

Publication: Current Medical Research and Opinion 2008 09; 24(9): 2587-2595. doi: 10.1185/03007990802303525.
Authors: Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.

Authors: Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.

Authors: Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC.

Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.

Authors: White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.

Authors: LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs.

Authors: Erder MH, Wu E, Ben-Hamadi R, Beaulieu N, Lu M.
Treatment compliance and health care costs of Medicaid depressed adult patients treated with escitalopram versus citalopram.


Authors: Erder MH, Wu E, Lu M, Ben-Hamadi R, Beaulieu N.

Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI.


Authors: Wu EQ, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.

Publication: Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.

Authors: Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Publication: Journal of Managed Care Pharmacy 2007 09; 13(7): 561-569.

Authors: Wu EQ, Birnbaum HG, Zhang HF, Ivanova Ji, Yang E, Mallet D.

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.

Publication: Archives of General Psychiatry 2007 05; 64(5): 543-552. doi: 10.1001/archpsyc.64.5.543.

Authors: Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC.

Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.


Authors: Andermann F, Duh MS, Gosselin A, Paradis PE.

Factors related to antipsychotic oversupply among Central Texas Veterans.


Authors: Yang M, Barner JC, Worchel J.

Considering the costs of bipolar depression.

Publication: Behav Healthc 2007 01; 27(1): 45-47.

Authors: Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg PE, Hirschfeld RM, Wang PS.

Foundations of opioid risk management.


Authors: Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzseo RW, Carr DB, Cicero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.


Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

Antidepressant Treatment Patterns and Related Costs among U.S. Employees.


Authors: Birnbaum H, Greenberg P, Tang J, Hsieh M, Wu EQ, Reygrobellet C, Ben-Hamadi R.
Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.

Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.

Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIs.

Authors: Wu EQ, Elaine Y, Greenberg P, Erder M.H., Yu A.

Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI).

Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Yu A, Buessing M.

MH2 Comparison of health care costs and hospitalization days of elderly major depressive disorder patients treated with escitalopram and other antidepressants.

Authors: Wu E, Yang E, Greenberg P, Erder M, Yu A, Buesing M.

Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram.

Authors: Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Health Economics Impact in the Treatment of Depression.

Authors: Navarro R, Wu EQ.

Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.


Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.

Authors: Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R.


Authors: Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.

Authors: Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA.
Prevalence of diabetic peripheral neuropathy and associated pain in French adults.
Abstract: JOURNAL OF NEUROLOGY.

Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies.
Authors: Wu EQ, Birnbaum H, Zhang HF, Radeva J, Yang E, Castor A.

MH4 Medical costs and hospitalization of adults diagnosed with attention-deficit/hyperactivity disorder who received alternative therapies.
Authors: Wu E, Birnbaum H, Zhang H, Radeva J, Yang E, Castor A.

Patterns of Antidepressant Treatment Response in an Employed Population.
Authors: Wu EQ, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E.

PMH7 Annual costs associated with patterns of antidepressant treatment response among employees.

Economic burden of illness for employees with painful conditions.
Authors: White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA.

The economic burden of schizophrenia in the United States in 2002.
Authors: Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).

The economic burden of depression in the US: societal and patient perspectives.
Authors: Greenberg PE, Birnbaum HG.

The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.
Authors: Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustun TB.

Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
Authors: Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

Costs of schizophrenia have shifted.
Authors: Wu E.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L.

Authors: Wu EQ, Birnbaum H, Kessler R, Shi L, Ball D.

PMH37 The economic burden of schizophrenia in the united states in 2002.
Authors: Wu E, Birnbaum H, Shi L, Ball D, Kessler R, Moulis M, Aggarwal J.

PMH49 Estimating annual us prevalence of schizophrenia in 2002.
Authors: Wu E, Birnbaum H, Aggarwal J, Moulis M.

Unemployment drives high cost of schizophrenia in the US.
Authors: Wu E.

Authors: Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients.
Authors: Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.

Money can't buy happiness.
Authors: Greenberg PE BH, Kessler RC.

Comorbidities and Cost Associated with Bipolar Disorder.
Abstract: American Public Health Association's (APHA).
Authors: Parece A, Wu EQ, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC.

Cost and Comorbidities Associated with Bipolar Disorder.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Parece A, Wu EQ, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC.

Drug Treatment Patterns of Bipolar Disorder and Associated Costs.
Abstract: National Institute of Mental Health's (NIMH) New Clinical Drug Evaluation Unit (NCDEU) meeting.

Economic implications of treatment-resistant depression among employees.
Authors: Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.

What's so different about anxiety disorders (such as phobias).
Publication: WPA series evidence and experience in psychiatry 2004 7.
Authors: Greenberg P, Birnbaum H, Sisitsky T.
Authors: Corey-Lisle PK, Birnbaum H, Greenberg P, Marynchenko M, Dube S.

Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis.
Authors: Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA.

The economics of women and depression: an employer's perspective.
Authors: Birnbaum HG, Leong SA, Greenberg PE.

Economic cost and epidemiological characteristics of patients with fibromyalgia claims.
Authors: Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ.

Attention-deficit/hyperactivity disorder: increased costs for patients and their families.
Authors: Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A.

The economic burden of depression in the United States: how did it change between 1990 and 2000?
Publication: Journal of Clinical Psychiatry 2003 12; 64(12): 1465-1475.
Authors: Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK.

The economic burden of depression with painful symptoms.
Publication: Journal of Clinical Psychiatry 2003 05; 64 Suppl 7: 17-23.
Authors: Greenberg PE, Leong SA, Birnbaum HG, Robinson RL.

PNP16: The comparison of different methods for determining the impact of migraine prophylaxis on costs.
Authors: Barlev A, Globe D, Wu E, Yu W, Johnson K.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
Authors: Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

Identification of a claims data "signature" and economic consequences for treatment-resistant depression.
Publication: Journal of Clinical Psychiatry 2002 08; 63(8): 717-726.
Authors: Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

The economic burden of anxiety and stress disorders.
Authors: Kessler RC, Greenberg PE.

Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.

Authors: Greenberg PE, Birnbaum SA.
Depression and work productivity: the comparative costs of treatment versus nontreatment.
Authors: Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC.

Assessing the economic impact of psychiatric disorders: where to begin?
Authors: Greenberg PE, Leong SA, Birnbaum HG.

Survival and Nursing Home Free Survival (NHFS) of Alzheimer’s Disease (AD) Patients.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Hay J.

The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Authors: Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.

The Economics of Anxiety Disorders.
Authors: Greenberg P, Sisitsky T.

The Impact of an Over-the-Counter Migraine Medication on Quality of Life.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Burk C, Nichol MB, Wu EQ, Gilderman A, Salas J.

Management of major depression in the workplace.
Authors: Birnbaum HG, Cremieux PY, Greenberg PE, Kessler RC.

The workplace burden of depression: underlying causes, recent empirical findings, and future directions.
Authors: Greenberg P, Birnbaum H.

Depression in the workplace: effects on short-term disability.
Authors: Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P.

The economic burden of anxiety disorders in the 1990s.
Authors: Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ.

Workplace burden of depression: a case study in social functioning using employer claims data.
Publication: Drug Benefits Trends 1999 11: 6BH-12BH.
Authors: Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T.

Workplace performance effects from chronic depression and its treatment.

Epidemiologic interpretation of artificial neural networks.
Authors: Duh MS, Walker AM, Ayanian JZ.
Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example.

*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K.

**Interpretation of the Weight Matrix in an Artificial Neural Network**

*Authors:* Duh MS, Walker AM, Ayanian JZ.

**Depression in the workplace: an economic perspective.**

*Authors:* Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER.

**Improvement in subjective work performance after treatment of chronic depression: some preliminary results.**

*Authors:* Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB.

**The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment.**

*Authors:* Duh MS, Shepard MJ, Wilberger JE, Bracken MB.

**The Economics of Clinical Depression.**

*Authors:* Greenberg P.

**Depression: a neglected major illness.**

*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

**The economic burden of depression in 1990.**

*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

**Oncology**

**Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.**

*Publication:* Medical Oncology 2017 05; 34(5): 88. e-pub ahead of print 2017/04/11; doi: 10.1007/s12307-017-0927-0.
*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E.

**A Risk Score for Fluconazole Failure among Patients with Candidemia.**

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Authors: Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.

Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
Authors: McKay R, Haider B, Duh MS, Valderrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen L, Kantoff P.

Authors: Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.

Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
Authors: Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.
Authors: Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
Authors: Rose DB, Nellesen D, Neary MP, Cai B.
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.


*Authors:* Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ.

Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.


*Authors:* Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, Chawla A.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.


*Authors:* Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.

Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC).


*Authors:* Li N, Du EX, Chu L, Peeples M, Xie J, Barghout VE, Tang DH.

Treatment Disruption of First-line Endocrine and Chemotherapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer (mBC).


*Authors:* Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.

Assessment of costs associated with adverse events in patients with cancer.

*Abstract:* the ISPOR 22nd Annual International Meeting Boston, MA May 22, 2017.


Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.

*Publication:* Urology Practice. 2017 04. doi: http://dx.doi.org/10.1016/j.urpr.2016.06.004.

*Authors:* Pilon D, Ellis LA, Behl AS, Gozalo L, Emond B, Lefebvre P, Calabrese R, Prime H, Gaylis F.

Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide.


*Authors:* Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA.

Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency.


*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.
Real-world economic outcomes during time on treatment among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.

**Abstract:** AMCP Managed Care & Specialty Pharmacy Annual Meeting, Denver, CO Mar 27-30, 2017.

**Authors:** Nicholas J. Vogelzang, Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Mark Meiselbach, Jose Ricardo Perez, Neeraj Agarwal.

---


**Authors:** Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ.

---

Real-world treatment patterns and costs in patients with newly diagnosed acute myeloid leukemia.

**Abstract:** AMCP Managed Care Specialty Pharmacy Annual Meeting, Denver, Colorado Mar 27-30, 2017.

**Authors:** Stein EM, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Bonifacio G, Joseph GJ.

---

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.

**Abstract:** ASCO Quality of Care Phoenix, AZ Feb 26-27, 2016.

**Authors:** Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

---

Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC).

**Abstract:** 41st European Society for Medical Oncology Congress, ESMO., Denmark Oct 7-11, 2016.

**Authors:** Yim YM, Gandhi M, Guerin A, Ionescu-Ittu R, Pivneva I, Shi S, Wu E.

---

Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer.


**Authors:** Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J.

---

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.


**Authors:** Bendaly E, Dalal A, Culver K, Galebach PJ, Bocharova I, Foster R, Struebbe G, Guerin A.

---

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.


**Authors:** Hurry M, Zhou ZY, Zhang J, Zhang C, Liangyi F, Rebeira M, Xie J.
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.


The economic burden of brain metastasis among lung cancer patients in the United States.


Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.

Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.

Authors: Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.

Economic burden of common adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).


Efficacy of front-line treatment combinations with ponatinib versus 1st- and 2nd-generation tyrosine kinase inhibitors for Ph+ acute lymphoblastic leukemia: A meta-analysis and meta-regression.

Authors: Jabbour E, DerSarkissian M, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, Duh MS.

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.


Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.

Authors: Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A.

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.


Economic burden of relapsed/refractory chronic lymphocytic leukemia.

Abstract: 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, NSW Australia Sep 6-9, 2015.
Authors: Guerin A, Ray S, Gauthier G, Hsu LI, Zhdanava M, Heroux J, Wu E.


*Authors:* Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.


Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.


*Authors:* Pilon D, Queener M, Lefebvre P, Ellis LA.

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.


Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.


*Authors:* Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.

Cost-analysis model of colonoscopy preparation using split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).


*Authors:* Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraze FA, Yenikomshian M.

Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2-mBC Patients With Multiple Metastatic Sites.


*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.


*Authors:* Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.


*Authors:* Kumar SK, Ma E, Engebritson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.


**Authors:** Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.

Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer.

**Abstract:** International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

**Authors:** Ganti AK, Hirsch F, Wynes MW, Ravelo A, Ramalingam S, Ionescu-Ittu R, Pivneva I, Borghaei H.

Ceritinib Dosing Patterns and Outcomes of Patients With ALK+ NSCLC in a Real-World Practice in the United States.

**Abstract:** Chicago Multidisciplinary Symposium in Thoracic Oncology (CMSTO), Chicago, IL Sep 22-24, 2016.

**Authors:** Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.


**Abstract:** IASLC 17th World Conference on Lung Cancer (IASLC WCLC 2016) Vienna, Austria Dec 4-7, 2016.

**Authors:** Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

Severe adverse events impact overall survival (OS) and costs in elderly patients with advanced NSCLC on second-line therapy.

**Abstract:** International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

**Authors:** Borghaei H, Yim YM, Guerin A, Gandhi M, Pivneva I, Shi S, Ionescu-Ittu R.

Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US.

**Abstract:** SABCS 2016 Annual Meeting, San Antonio, TX Dec 6-10, 2016.

**Authors:** Li N, Ohashi E, Koo V, Xie J, Hao Y, Tang DH.

Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.

**Abstract:** IASLC 17th World Conference on Lung Cancer (IASLC WCLC 2016) Vienna, Austria Dec 4-7, 2016.

**Authors:** Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.


**Abstract:** IKCS 2016 Annual Meeting, Miami, FL Nov 4-5, 2016.

**Authors:** Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miriam Zichlin, Emilie Duchesneau, Barinder Kang, Jose Ricardo Perez.


**Abstract:** IKCS 2016 Annual Meeting, Miami, FL Nov 4-5, 2016.

**Authors:** Nicholas J. Vogelzang, Sumanta K. Pal, Sameer Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Jose Ricardo Perez, Neeraj Agarwal.

Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.

**Abstract:** Annals of Oncology Conference: 41st European Society for Medical Oncology Congress, ESMO, Denmark Oct 7-11, 2016.

**Authors:** Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB.
**Patient characteristics and Overall Survival (OS) in the post-docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) community setting.**


*Authors:* Cheng WY, Miao R, Duh MS, Vekeman F, Sung J, Gauthier-Loiselle M, Fortier J, Dhawan R, Oh WK.

**Access to biomarker testing in patients with advanced nonsmall cell lung cancer.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 (Date of Publication: May 2016), United States Jun 3-7, 2016.


**Access to specialist care and treatment in patients with advanced non-small cell lung cancer.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 United States. (Date of Publication: May 2016), United States Jun 3-7, 2016.

*Authors:* Ganti AK, Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ionescu-Ittu R, Pivneva I, Ramalingam SS.

**Disparities in treatment patterns and outcomes between caucasian and African American patients with multiple myeloma (MM).**


**Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval.**


*Authors:* Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Macalalad AR, Shi S, Uhm JH.

**Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2016 United States. (Date of Publication: May 2016), United States Jun 3-7, 2016.

*Authors:* Bonnet P, Cloutier M, McKee MD, Loiselle MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL.

**Reduction in hospital visits in patients with chronic myeloid leukemia (CML) with better adherence to tyrosine kinase inhibitors (TKI) and increased molecular monitoring frequency.**

*Abstract:* Using Smart Source Parsing


*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

**Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis.**


*Authors:* Vogelzang NJ, Signorovitch JE, Swallow E, Peeples M, Koo V, Perez JR, Ghate S, Pal SK.

**Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.**

*Abstract:* International Association for the Study of Lung Cancer, Chicago, IL May 29 - Jun 2, 2015.


**Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy.**

Authors: Hao Y, Li N, Fang A, Koo V, Peeples M, Kageleiry A.

**Real-world treatment patterns of everolimus + exemestane in patients with hormone-receptor-positive, human epidermal growth factor receptor-negative advanced breast cancer by line of therapy: A global chart review.**


**Treatment sequences, patient characteristics, and overall survival of patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.**


Authors: Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Fortier J, Dhawan R.

**Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.**


Authors: Daniel Shao-Weng Tan, Geoffrey Liu, Dong-Wan Kim, Michael Thomas, Enriqueta Felip, James Signorovitch, Jie Zhang, Tomek Szczudlo, Alice Shaw, et al.

**The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.**


Authors: Jie Zhang, Yan Song, Zheng-Yi Zhou, Chenxue Zhang, James Signorovitch.

**Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naive metastatic castration-resistant prostate cancer.**


**Real-World Treatment Patterns and Brain Metastases Development in ALK-Positive Non-Small Cell Lung Cancer.**


Authors: Betts K, Song J, Guo J, Wong W, Ravelo A, M. S.

**Treatment patterns and healthcare costs in newly diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States: A retrospective claims database analysis.**


Authors: Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon-Sanschagrin P, Gagnon-Sanschagrin P, Chen L.

**Treatment patterns and key factors associated with high treatment costs among commercially insured patients with advanced basal cell carcinoma.**


Authors: Migden M, Wei J, Tang W, Herrera V, Xie J, Palmer J.

**Survival and Tumor Response Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Systematic Literature Review.**


Authors: Signorovitch J, Li N, Zhang C, Shaw J, Dastani H, Orsini L.
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US.

Publication: Current Medical Research and Opinion 2016 02; 32(2): 385-394.
Authors: Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.

Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.

Authors: McKay RR, Haider B, Duh MS, Valdarrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen LK, Kantoff PW.

Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.

Authors: Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T.

Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

Authors: Maziarz RT, Guérin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.


Patient outcomes following curative-intent lung resection among non-small cell lung cancer (NSCLC) patients in China.


Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.

Authors: Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.

Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2-Advanced Breast Cancer From a US Payer Perspective.

Authors: Xie J, Hao Y, Zhou ZY, Qi CZ, De G, Gluck S.

Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2-breast cancer with liver metastasis in the USA.

Authors: Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment.


**Authors:** Chen L, Wu EQ.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.


**Authors:** Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.

**Publication:** Current Medical Research and Opinion 2015 03; 31(3): 537-545. doi: 10.1185/03007995.2015.1021906.

**Authors:** Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.


Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.

**Publication:** Current Medical Research and Opinion 2015 06; 31(6): 1095-1103. doi: 10.1185/03007995.2015.1021906.

**Authors:** Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA.

Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.


**Authors:** Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

The epidemiology of herpes zoster and its complications in Medicare cancer patients.


**Authors:** Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).

**Publication:** Current Medical Research and Opinion 2015 02; 31(02): 263-273. doi: 10.1185/03007995.2014.980885.

**Authors:** Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C.

Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.


**Authors:** Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ.

Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.

**Publication:** Current Medical Research and Opinion 2015 08; 31(8): 1561-1572. doi: 10.1185/03007995.2015.1062356.

**Authors:** Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS.
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.


*Authors:* Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.


*Authors:* Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J.

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.


Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.


Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study.

*Abstract:* 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL Dec 5-8, 2015.

*Authors:* Leleu X, Mateos M-V, Delforge M, Lewis P, Schindler T, Gibson CJ, Yang M, Weisel K.

A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond.

*Abstract:* San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX December 8-12, 2015.

*Authors:* Gauthier G, Guerin A, Zhdanava M, Wu E.

Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites.


*Authors:* Xie J, Hao Y, Li N, Lin P, Ohashi E, Koo V, Wu E.

Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from us payers' perspective.


*Authors:* Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.
The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.

*Abstract:* 57th ASH Annual Meeting and Exposition, Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L-I, Zhdanava M, Wu E.

Nilotinib vs Dasatinib as Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) based on Real-World Data.

*Abstract:* ASH annual meeting, Orlando, FL December 5-8, 2015.

*Authors:* Li N, Yang C, Fan L, Totev T, Guerin A, Chen L.

Real-world effectiveness of everolimus subsequent to different first targeted therapies (TTs) for the treatment of advanced renal cell carcinoma (aRCC): Synthesis of three retrospective chart reviews.


*Authors:* Pal SK, Signorovitch JE, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2-metastatic breast cancer patients with liver metastasis or multiple metastatic sites.


*Authors:* Li N, Hao Y, Lin P, Koo V, Ohashi E, Wu E, Xie J.

Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US.


*Authors:* Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guerin A.

Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients.

*Abstract:* 57th ASH Annual Meeting and Exposition, 57th ASH Annual Meeting and Exposition Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu Ling-I, Zhdanava M, Wu EQ.

What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?

*Abstract:* San Antonio Breast Cancer Symposium (SABCs), San Antonio, TX December 8-12, 2015.

*Authors:* Cloutier M, Guerin A, Heroux J, Emond B, Wu E.

Comparative efficacy of treatments for previously treated advanced or metastatic non-small cell lung cancer (NSCLC): a network meta-analysis.

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhang J, Zhou Z, Cai X, J. S.

Cost-effectiveness of ceritinib in previously treated patients with crizotinib in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.


*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

Overall Survival (OS), Quality of Life (QoL), and Neurocognitive Function (NF) in Recurrent Glioblastoma Multiforme (GBM): A Systematic Literature Review.

Authors: Signorovitch J, Li N, Ohashi E, Dastani H, Shaw J, L. O.

Patient relevant outcomes in recurrent glioblastoma: a systematic literature review.
Authors: Signorovitch J, Li N, Kim S, Dastani H, Shaw J, Orsini L.

Real-world effectiveness, dosing, and drug costs of everolimus (EVE) and axitinib (AXI) as second targeted therapies (TTs) for advanced renal cell carcinoma (aRCC) in the US: A retrospective chart review.
Authors: Jonasch E, Pal SK, Signorovitch JE, Li N, Liu Z, Perez JR, Vogelzang NJ.


Access to cancer directed therapies and cancer specialists in patients with metastatic lung cancer.
Abstract: 16th World Conference on Lung Cancer (WCLC), Denver, CO  Sep 6-9, 2015.

Bone pain, skeletal-related events and opioid analgesic use in prostate cancer patients with bone metastases.
Authors: Valderrama A, Eapen S, Hennessey KA, Jones C, Wen L, Germino J, Duh MS.

Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study.
Authors: Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasame M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J.

Diverse characteristics of ALK+ NSCLC patients in the United States.

Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?

Physician decision-making on modifying or discontinuing crizotinib in ALK+ NSCLC: A survey of U.S. physicians.
Real-world characteristics and outcomes for ALK+ NSCLC in Korea.

Symptoms of bone and liver metastases in patients with ALK+ Non-Small Cell Lung Cancer (NSCLC).
Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ, Macalalad A.

Testing and treatment practice of oncologists managing ALK+ NSCLC: International physician survey across four regions.

Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC.
Authors: Geoffrey Liu, J Zhang, Zheng-Yi Zhou, Junlong Li, Xiaopeng Cai, James Signorovitch.

Treatment patterns and best response in a contemporary cohort of patients with relapsed / refractory chronic lymphocytic leukemia with 17p deletion.
Abstract: (Lamanna, Hurst, Latremouille-Viau, Ionescu-Ittu, Guerin, Yim, Reyes) Hematologic Malignancies Section/Herbert Irving Comprehensive Cancer Center, NY, USA; Genentech, Inc., South San Francisco, CA, USA; Analysis Group, Inc., Montreal, Canada, Sydney, NSW Australia Sep 6-9, 2015.
Authors: Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Ittu, Guerin A, Yim YM, Reyes C.

Treatment patterns and survival among ALK+ non-small cell lung cancer (NSCLC) patients: A chart review study.

What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses.

Bone Pain, Skeletal-Related Events and Opioid Analgesic Use in Prostate Cancer Patients With Bone Metastases.
Abstract: ISPE's 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA Aug 22-26, 2015.
Authors: Eapen S, Valderrama A, Hennessey K, Jones CP, Wen L, Germino J, Duh MS, Vekeman F.

Treatment patterns and characteristics of postmenopausal women with HR+/HER2- metastatic breast cancer receiving everolimus.
Abstract: ISPE's 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), Boston, MA Aug 22-26, 2015.
Authors: Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.
Median overall survival meta-analysis comparing brentuximab vedotin with other therapies in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant.


Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.

Authors: Ayyagari R, Cheng WY, Cai X, Jones C, Ma E, Bonthapally V, Zhu Y, Lefebvre P, Wei LJ, Duh MS.

Association between duration of treatment (DOT) and healthcare costs in multiple myeloma (MM) patients receiving initial therapy with bortezomib.

Authors: Xiao Y, Wong BJ, Lefebvre P, Fortier J, Ma E, Bonthapally V, Duh MS.

Bone pain, skeletal related events and opioid use in patients with prostate cancer and bone metastases.

Authors: Valderrama A, Eapen S, Hennessey KA, Jones C, Wen L, Germino J, Duh MS.

Budgetary impact analysis of abiraterone acetate plus prednisone (AA+P) versus enzalutamide (ENZ) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors: Ellis L, Pilon D, Lefebvre P.

Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: A comparison of retrospective chart reviews conducted in 2012 and 2014.

Authors: Perez JR, Pal SK, Signorovitch JE, Reichmann WM, Li N, Liu Z, Jonasch E, Vogelzang NJ.

Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.

Authors: Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R.

Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: A retrospective chart review.

Authors: Signorovitch JE, Pal SK, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ, Jonasch E.

Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.

Authors: Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.
Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.


*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ.

Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer.


*Authors:* Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naive anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.


Economic burden of relapsed/refractory chronic lymphocytic leukemia.

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL May 29-Jun 2, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L, Zhidanava M, Heroux J, Wu EQ.

The evolving treatment patterns in multiple myeloma (MM): Retrospective database analyses of U.S. community oncology electronic medical records and administrative claims.


*Authors:* MS D, Lefebvre P, Fortier J, Ma E, Bonthapally V, Wong BJ.

Overall survival in post-menopausal women with HR+/HER2-metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy.


*Authors:* Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille M, Duh MS.

Realworld treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with zivafibercept (Z) in community oncology practices in the United States (US).


Systematic literature review (SLR) of clinical and realworld observational studies of octreotide LAR for treatment of neuroendocrine tumors (NETs).


*Authors:* Sorg R, Neary M, Tang C, Song C, Xie J.

Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.


*Authors:* Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.
Treatment patterns of endocrine therapy and chemotherapy among post-menopausal women with HR+/HER2-Metastatic Breast Cancer.

Authors: Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR, Ohashi E, Zhou Z, Wu EQ.

Overall survival with first line endocrine therapy or chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review study in the US.

Authors: Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, Wu EQ.

Real-World Dosing and Drug Costs with Everolimus (EVE) and Axitinib (AXI) as 2nd Targeted Therapies (TTs) for Metastatic Renal Cell Carcinoma (mRCC): A Retrospective Chart Review.

Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: considerations for U.S. payors.

Authors: Ellis L, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

Current treatment characteristics in postmenopausal women with HR+/HER2- metastatic breast cancer.

Authors: Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille MN, Duh MS.

Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.


Treatment patterns of recently approved therapies for metastatic castration resistant prostate cancer (mCRPC): Real world evidence from three datasets.

Authors: Ellis L, Lafeuille MH, Gozalo L, P L, Malangone-Monaco E, Wilson K, McKenzie S.

Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.


Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer.

Authors: Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ.

Cost-effectiveness of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).

Authors: Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
Authors: Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.
Publication: Drugs Context 2015 03; 4. doi: 10.7573/dic.212274.
Authors: Girvan AC, Carter GC, Li L, Kaltenboeck A, Ivanova J, Koh M, Stevens J, Hayes-Larson E, Lahn MM.

Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.
Publication: Current Medical Research and Opinion 2015 01; (0): 1-38.
Authors: Fuldeore M, Yang H, Soliman AM, Winkel C.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Authors: Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Authors: Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

Authors: Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.

One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
Authors: Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ.

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.


Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.


*Authors:* Lafeuille MH, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, Kozma C.

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.


*Authors:* Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L.

Real-world treatment patterns among patients with advanced gastric cancer in Taiwan.


Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.


*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ.

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.


*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.


Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management.


*Authors:* Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekian J, Sheng M.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.


*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.


*Authors:* Guerin A, Sasane M, Gauthier G, Keir CH, Zhdvavana M, Wu EQ.
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Authors: Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.

Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.
Authors: Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.
Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Authors: Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J.

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer.
Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).

Authors: Signorovitch J, Wang J, Tan R, Thomason D, Kageleiry A, Swallow E.

Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).


Overall survival in patients with HER2+ early stage breast cancer patients treated with trastuzumab in the us department of defense practice setting.


Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.


Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States.

Authors: Xie J, Hao Y, Zhou J, Qi C, De G, S G.


Authors: Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Description of ALK+ NSCLC patient characteristics and ALK testing patterns.


Economic burden and treatments of progression to metastatic disease in ALK+ NSCLC patients.


Economic burden of brain metastases among lung cancer patients.

Authors: Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Guérin A.

Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review.

Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Liu Z, Perez JR, Vogelzang NJ.


Authors: Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.
Predictors of treatment (tx) response and progression in BRAF V600E metastatic melanoma (mM) patients (pts) with brain metastases (BM) receiving vemurafenib (vem) in a real-world setting.

**Abstract:** 2014 European Society for Medical Oncology Congress, Sep 26-30, 2014  
**Authors:** Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Yeun MY, Sarang A, Reyes C, Guerin A.

Treatment failure patterns in patients with mantle cell lymphoma: results of a large U.S. observational study.

**Abstract:** ESMO Congress, Madrid, Spain  
**Authors:** Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Incidence of hepatic resection among colorectal cancer patients with liver metastases.

**Abstract:** 16th World Congress on Gastrointestinal Cancer, ESMO 2014, Spain  
**Authors:** Betts K, Lu M, Zhuo D, Sharma H, Morlock R, Sommer N, Ogale S.

Treatments and clinical burden among hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature review.

**Abstract:** 19th Congress of the European Hematology Association, Milan Italy  
**Authors:** Bonthapally V, Ayyagari R, Yang H, Wu EQ, Shonukan O.

Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices.

**Authors:** Lin PL, Macalalad AR, Hao Y, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCd) compared to bortezomiblenalidomide-dexamethasone (VRd) for initial treatment of newly diagnosed multiple myeloma (MM).

**Abstract:** AVBCC 3rd Annual Conference, Hollywood, FL  
**Authors:** Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV.

Description of ALK+ NSCLC patient characteristics and ALK testing patterns.

**Authors:** Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach PJ, Jarvis J, Kageleiry AJ, Huang Q, Culver KW, Wu EQ, Guerin A.

Impact of underestimation of risk on treatment duration and recurrence in GIST patients.

**Authors:** Guerin A, Conley AP, Sasane M, Macalalad AR, Huang Q, Schwiep FA, Keir CH, Wu EQ.

One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.

**Abstract:** ASCO 50th Annual Meeting, Chicago, IL  
**Authors:** Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ.

Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice.

**Authors:** Hao Y, Lin PL, Macalalad AR, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.
Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States.


Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.

Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).
Authors: Bonthapally V, Lafeuille MH, Fortier J, Duh MS, Ng Y, Van De Velde H, Niculescu L, Ma E, Goy A.

Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.

Treatment and survival patterns among ALK+ NSCLC patients following crizotinib discontinuation.

Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Authors: Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guerin A.

Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices.

Brain Metastases in Patients with ALK+ Non-Small Cell Lung Cancer: Treatment Patterns and Economic Burden.
Authors: Macalalad AR, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Guérin A.
Duration of treatment by line of therapy among post-menopausal women with HR+/HER2- metastatic breast cancer.


Authors: Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin PL, Ohashi E, Zhou Z, Wu EQ.

Economic burden of bone and liver metastases in patients with ALK+ non-small cell lung cancer.


Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ.

Monitoring of multifunctional nanocomplex containing gold coated iron oxide particles in human prostate tumoral cells through MRI.


Authors: Oghabian MA, Montazerabadi A, Delavari HH, Irajirad R, Muhammadnejad S.

Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among post-menopausal women with recurrent HR+/HER2- metastatic breast cancer.


Authors: Song Y, Hao Y, Macalalad A, Lin PL, Signorovitch JE, Wu EQ.

Robust feature selection and gene committee predictor for breast cancer patient survival prediction.


Authors: Yang HH, Lee MP.

Symptoms of bone and liver metastases in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).


Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver KW, Macalalad AR, Wu EQ.

Treatment and Costs Post Crizotinib Monotherapy in Patients with ALK+ Non-Small Cell Lung Cancer: A Retrospective Claims Database Analysis.


Authors: Guérin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Macalalad AR.

Treatment patterns and predictors of everolimus use among post-menopausal women with HR+/HER2-metastatic breast cancer in the US.


Authors: Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors.


Authors: Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ.

Prostate cancer patients demonstrate adherence to medication use while on abiraterone acetate (AA) therapy.


Authors: Kozma C, Slaton TS, Ellis LA, McKenzie RS, Lafeuille M, Grittner AM, Lefebvre P.

Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.


Authors: Lafeuille M, Ellis LA, McKenzie RS, Grittner AM, Lefebvre P.
Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Authors: Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, Roman AS, Koh M, Lee HJ, Rajan N, Ballal S, Birnbaum H, Bang YJ.

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.
Authors: Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG.

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Authors: Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.

Authors: Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Yang H, Shi L.

Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.
Authors: Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L.

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Authors: Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.

Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy.
Authors: Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.
Authors: Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.
Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.
Authors: Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS.

Authors: Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernandez Pastor LJ, Bellmunt J.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
Authors: Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Impact of low-grade adverse events (AES) on health-related quality of life (HRQOL) in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (PH+ CML-CP) from the enesnd trial: 48-month follow-up.

Multi-center experience with CELLSEARCH circulating tumor cell kit on patients with metastatic breast cancer.
Authors: Montero AJ, Eapen S, Tran KN, Gorin B, Adler P.

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer.
Authors: Campone M, Yang H, Faust E, Kageleiry A, Signorovitch J, Zhang J, Gao H.

Efficacy of brentuximab vedotin and other treatments in patients with relapsed or refractory (RR) systemic anaplastic large-cell lymphoma (SALCL): A systematic review.
Authors: Bonthapally V, Yang H, Macalalad AR, Wu EQ, Lutes R, Shonukan O, Chi A, Huebner D.

Glioblastoma treatment patterns and outcomes and resource use in the United States.


Association between guideline-adherent imaging and overall survival following 2nd-line targeted therapy for metastatic renal cell carcinoma.
Authors: Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver K, Scott JA, Vogelzang NJ.
Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell Carcinoma: Analysis of two practice-based chart reviews.


Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Authors: Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL.

Overall survival and hospitalization rates in medicare patients diagnosed with advanced NSCLC treated with bevacizumab-paclitaxel-carboplatin vs paclitaxel-carboplatin: A retrospective cohort study.

Authors: Langer CJ, Ravelo A, Hazard S, Guerin A L-VD, Ionescu-Ittu R, Wu EQ, Ramalingam SS.

Survival advancements in advanced non-small cell lung cancer in the past 20 years: A story of hope.

Authors: Ravelo A, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Wu EQ.


Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+), HER2–, Que Fallaron a Los Inhibidores De Aromatasa No Esteroideos (IANES) En México.


Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis.

Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ.

Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma.

Authors: Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver KW, Scott JA, Vogelzang NJ.
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.


Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.

Authors: Brammer M, Lalla D, Gauthier G, Guerin A, Giguere-Duval P, Wu EQ, Santos E.

Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab.

Authors: Lalla D, Brammer M, Guerin A, Gauthier G, Giguere-Duval P, Wu EQ, Santos E.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).

Authors: Chen L, Guerin A, Wu EQ, Dea K, Goldberg SL.

The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.

Authors: Eapen S, Andrews R, Gorin B, Higano CS.

Health care resource utilization and cost of medicare patients with non-small cell lung cancer (NSCLC).

Authors: Yenikomshian M, Hackshaw M, Cai X, Trahey A, Arondekar B, Knoll S, Duh MS.

Incremental cost of brain metastases among patients with metastatic melanoma.

Authors: Vekeman F, Cloutier M, Yermakov S, Amonkar M, Arondekar B, Duh MS.

A meta-analysis of efficacy and safety of prescription opioids, including formulations with tamper-resistant technologies, in non-cancer pain management.


Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Observed abiraterone acetate utilization by prostate cancer (PC) patients in a large administrative claims database in the united states.

Authors: Lafeuille MH, Dean J, Lefebvre P, Ellis L, Senbeta M.
Prescribing decision drivers in patients with recurrent gastrointestinal stromal tumor (GIST) previously treated with adjuvant imatinib: A retrospective chart extract-based approach.

Authors: Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

A single-center experience with CELLSEARCH system circulating tumor cell test on patients with metastatic breast cancer.

Authors: Montero AJ, Eapen S, Andrews RM, Gorin B.

Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.

Abstract: Digestive Disease Week, Orlando, FL May 18-21, 2013.
Authors: Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.


Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract-based approach.

Authors: Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer.

Authors: Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E.

Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States.

Authors: Jonasch E, Signorovitch JE, Lin P, Liu Z, Culver KW, Pal SK, Scott JA, Vogelzang NJ.


Authors: Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver KW, Scott JA, Pal SK, Jonasch E.
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Authors: Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States (Re:).
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Authors: Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS.

Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.
Authors: Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B.

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.
Authors: Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guerin A.

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Authors: Guerin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A.

Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using medicare current beneficiary survey data.
Authors: Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW.

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.
Authors: Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.

Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
Authors: Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.
Authors: Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E.

Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.
Authors: Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS.


Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Authors: Xie J.

The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Authors: Montero AJ, Eapen S, Gorin B, Adler P.

Authors: Wu E, Chen L.

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Authors: Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Authors: Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
Authors: Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN.

Publication: Journal of Medical Economics 2012 12.
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.


*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model


Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12 month complete cytogenetic response failure: A chart review analysis.


*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Aberki C, Giguere-Duval P, Wu EQ.

Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States.


*Authors:* Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib: A retrospective analysis.


*Authors:* Gauthier G, Guerin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D.

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with firstand second-line chemotherapies.


*Authors:* Hurvitz SA, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.

*Abstract:* ASCO’s Quality Care Symposium 2012 San Diego, CA United States. Nov 30-Dec 1, 212.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

A systematic review of the heterogeneity of treatment effect in ovarian cancer (OC)-Are there implications for outcomes research?


*Authors:* Chawla A, Nellesen D, Yee K, Brown J, Boye ME.

Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review in community oncology practices.


*Authors:* Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Jonasch E.

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP).


*Authors:* Vander Velde NS, Chen L, Sharma H, Marynychko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.
Budget impact analysis of everolimus for ER+, HER2-metastatic breast cancer patients in the united states.
Authors: Xie J, Diener M, De G, Wu EQ, Namjoshi M.

Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.
Authors: Guerin A, Conley AP, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis.
Authors: Gauthier G, Guerin A, Styles A, Wu EQ, Brammer MG, Lalla D.

Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis.
Authors: Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.
Authors: Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky M, Wu EQ, Lalla D.

Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy.
Authors: Wagner M, Amodu L, Duh MS, Korves C, Solleza F, Mykletun A, Manson S, Diaz J, Neery MP, Demetri GD.

Economic burden of hepatocellular carcinoma in China.

Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI).
Authors: Bonthapally V, Guerin A, Wu EQ, Gauthier G, Cloutier M, Holen KD, Ray S.

Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.
Authors: Chen L, Guerin A, Aberki C, Wu EQ, Ericson S, Jabbour E.
Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.

Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.
Authors: Signorovitch JE, Swallow E, Kantor E, Wang X, Hass T, Klimovsky J, Metrakos P.

PCN42 Health Care Utilization and Costs Among Lung Cancer Patients in China.
Abstract: International Society for Pharmacoeconomics and Outcomes Research, Jun 2-6, 2012.

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase.
Authors: Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis.
Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.
Authors: Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M.

Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML).
Authors: Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ.

Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with colorectal cancer treated with an epidermal growth factor receptor inhibitor (EGFRI).
Authors: Bonthapally V, Guerin A, Wu EQ, Gauthier G, Holen KD, Ray S.

Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer.
Authors: Johnson SJ, Sorg RA, Borker RD, Duh MS.

Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.
Authors: Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB.
Re: Economic Evaluation of Denosumab Compared With Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients With Bone Metastases.

Authors: XIE J, NAMJOSHI M, WU E.

Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.

Authors: Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Publication: Journal of Managed Care Pharmacy 2011 10; 17(8): 621-643.
Authors: Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

Authors: Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.


Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.

Authors: Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.

Authors: Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting.

Authors: Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E.

The association between treatment (TX) modifications due to adverse events (AES) and overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with sunitinib and sorafenib: Results from a multi-country study in europe.

Authors: Oudard S, Porta C, Castellano D, McDermott R, Nathan P, McCaffrey J, Neary MP, Korves C, Dial Suthoff E, Duh M.
Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population.

Abstract: 10th International Conference on Cancer-Induced Bone Disease Conference, Sheffield United Kingdom. Sept 22-25, 2010.
Authors: Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N.

Complications associated with chemotherapy in patients with metastatic breast cancer.
Authors: Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S.

Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.
Authors: Yu AP, Diener M, Wu EQ, Namjoshi M.

Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.
Authors: Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.
Authors: Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjosi M.

A pan-european study of treatment (TRX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC).

Treatment (TX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in Spain.
Authors: Castellano D, Duh MS, Dial Suthoff E, Korves C, Vekeman F, Ramamurthy P, Mykletun A, Lyon-Caen S, Neary MP, Bellmunt J.

Sunitinib (SU) treatment (Trx) patterns and toxicity in patients (Pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).

Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting.
Authors: Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M.

Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.
Authors: Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA.
Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.


*Authors:* Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial.


Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML).


*Authors:* Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, Ericson S, Quintas-Cardama A.

Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France.


Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).


Treatment (trx) of metastatic renal cell carcinoma (mRCC) with angiogenesis inhibitors (AIs): Safety and treatment patterns observed in Taiwanese patients.


The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the united states.


*Authors:* Wang ST, Huang H, Ba-mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Van De Velde H, Duh MS.

Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.


*Authors:* Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.


*Authors:* Delea TE, Duh MS, Wei LJ, Robins J.
Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma (MRCC) in Ireland.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-25, 2011.

**Authors:** McDermott R, Donnellan P, McCaffery J, Keane F, Sarda SP, Korves C, Luka A, Wei R, Neary MP, Hanley R, Duh MS.

Real world clinical resource utilization of metastatic prostate cancer patients in the United States: Results from two large claims databases.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-25, 2011.

**Authors:** Senbetta M LM, Dean J, McKenzie RS, Lefebvre P.

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma (MRCC) in the United Kingdom: Preliminary results of an ongoing chart review study.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-25, 2011.


Transfusional iron overload (TIO) monitoring and treatment: Findings from an electronic medical records review study at the Moffitt Cancer Center and Research Institute.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-25, 2011.

**Authors:** Duh MS, Wetzstein G, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray L.

Treatment patterns and healthcare resource utilization of metastatic prostate cancer patients by physician specialty.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-25, 2011.

**Authors:** Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P.

Health care resource utilization and costs associated with bevacizumab versus cetuximab in second-line treatment of metastatic colorectal cancer patients.

**Abstract:** 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacy, AMCP 2011 Minneapolis, MN United States. Apr 27-29, 2011.

**Authors:** Yang H, Yu A, Yim Y, Yu E, Wu E.

Treatment (trx) patterns of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in Ireland.


**Authors:** McDermott RS, Donnellan PP, McCaffery J, Sarda SP, Korves C, Luka A, Wei R, Neary M, Hanley R, Duh MS.

Treatment patterns and health care resource utilization of metastatic colorectal cancer (mCRC) patients who received bevacizumab or cetuximab in second-line regimen.


**Authors:** Yang H, Yu AP, Yim Y, Yu E, Wu E.

5002 ORAL Complications Associated With Chemotherapy in Patients With Metastatic Breast Cancer.

**Publication:** European Journal of Cancer 2011 09; 47: S330.

**Authors:** Brammer M, Lalla D, Guerin A, Latremouille-Viaud D, Yu A, Wu E, Hurvitz S.
The economics of the hematopoietic growth factors.
Authors: Eldar-Lissai A, Lyman GH.

Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Authors: Yang H, Yu AP, Wu EQ, Yim YM, Yu E.

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Authors: Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.


Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Authors: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Authors: Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Authors: Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.

Healthcare costs of second-line (2l) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX).
Authors: Yim Y, Wu EQ, Yu AP, Yang HY, Yu E.

Monitoring and treatment among patients with transfusional iron overload: Preliminary findings from an electronic medical records review study at H. Lee moffitt cancer center and research institute.
Authors: Ray LA, Wetzstein GA, Korves C, Wang ST, Clinton B, Wei R, Corral M, Duh MS.

Costs of treatment with angiogenesis inhibitors (AIS) in patients with metastatic renal cell carcinoma (MRCC): Results from a medical chart review study.
Authors: Oh WK, McDermott DF, Duh MS, Antras L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK.
Costs to medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.


Authors: Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS.

Health care costs associated with angiogenesis inhibitors (AIS) and mtor inhibitors (MTORS) in patients with metastatic renal cell carcinoma (MRCC) treated at us community oncology clinics.


Authors: Chen K, SP S, Antras L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P.

Health care costs associated with multikinase inhibitors (MKIS) for treatment of metastatic renal cell carcinoma (MRCC) in a clinical practice setting in Italy.


Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).


Authors: Dial E, Duh MS, Antràs L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study.


Authors: wGuerin A, Bollu V, Williams D.

Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.


Authors: Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short-and long-term negative impacts on health care resource utilization and costs.


Authors: Guerin A, Bollu V, Guo A, Wu E, Yu A, Sirulnik L, Griffin J.

PCN47 Comparison of health care resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML).


Authors: Wu E, Bollu V, Guo A, Guerin A, Tsaneva M, Williams D, Griffin J.

Puk1 incidence and cost of adverse events (AES) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIS).


Authors: Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.
Tolerance, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Authors: Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Authors: Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Authors: Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Authors: Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
Authors: Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK.

Costs to medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.
Authors: Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh M.

Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs.
Authors: Wu EQ, Bolu VK, Guo A, Guerin A, Yu AP, Sirulnik A, Griffin JD.

Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): Evidence from US community oncology clinics.

Safety and treatment (trx) patterns of multikinase inhibitors (MKI) in patients (pts) with metastatic renal cell carcinoma (mRCC) in Italy.
Authors: Di Cesare P, Porta C, Lasagna A, Ferraris E, Imarisio I, Paglino C, Antras L, Chen K, Neary MP, Duh M.
Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.


**Authors:** Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Patients (Pts) with metastatic Renal Cell Carcinoma (mRCC) receiving Angiogenesis Inhibitor (AI) therapies: Treatment efficacy and safety in clinical practice.


Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.


**Authors:** Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

Treatment (Tx) and dosing patterns for Angiogenesis Inhibitor (AI) therapies in patients (Pts) with metastatic Renal Cell Carcinoma (mRCC).


**Authors:** Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Antras L, Chen K, Jayawant SS, Duh MS, Luka A, Neary M, Oh WK.

Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia.

**Abstract:** ASCO Annual meeting, Orlando, FL May 29 - Jun 2, 2009.

**Authors:** Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsnaeva M, Yu P, Wu EQ, Signorovitch J, Demetri GD.


**Authors:** Pike C, Birnbaum H, Kaufman R, Muehlenbein C, Pohl G, Natale R.

Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States May 16-20, 2009.

**Authors:** Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States May 16-20, 2009.

**Authors:** Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Direct health care and work loss burden of chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States May 16-20, 2009.

**Authors:** Pike C, Birnbaum HG, Kaufman R, Muehlenbein CE, Pohl G, Natale R.
Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Authors: Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E.

Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

Authors: Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib.

Abstract: ASCO Annual meeting, Orlando, FL May 29 - June 2, 2009.
Authors: Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD.

Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Publication: J Clin Oncol (Meeting Abstracts) 2009 05; 27(15S): 7092.
Authors: Wu E, Guo A, Williams D, Guérin A, Yu A, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin J, Bolu V.

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

Authors: Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT.


Abstract: International Association for the Study of Lung Cancer.
Authors: Chen L, Antras L, Duh MS, Neary M, O’Brien ME.

Patients (PTS) with metastatic renal cell carcinoma (MRCC) receiving angiogenesis inhibitor (AIS) therapies: Treatment efficacy and safety in clinical practice.


Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC).

Authors: Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Chen K, Duh MS, Neary MP, Oh WK.

Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.

Authors: Wu EQ, Mulani P, Farrell MH, Sleep D.

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.

Authors: Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.

Authors: Chen L, Antras L, Duh MS, Levy N, Neary M, O’Brien ME, von Pawel J.
The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.

Authors: Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA.

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

Authors: Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS.

Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients.

Authors: Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J.

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.

Publication: Current Medical Research and Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.
Authors: Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Dose conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.

Authors: Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M.
Lifetime Costs of Patients With Clinically Detected Uterine Fibroids: An Employer’s Perspective.


*Authors:* Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.


*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.


*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.


*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.


*Authors:* Duh MS, L Mark T.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis.


*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.


*Authors:* Baker L, Deal B.

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.


*Authors:* Gabrilove JL, Sarokhan B, Cremieux P.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.


*Authors:* Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Anemia-related costs for cancer patients.


*Authors:* Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

Cost Effectiveness of rHuEPO in Oncology.


*Authors:* Cremieux P, Dial E, Gustafson M, Sarakoh B, Slavin M.
The costs of cancer: cancer-related conditions can add dramatically to overall costs of care.
Authors: Cremieux P, Slavin M, Fendrick A, Hiriak T, Kosicki G.

The costs of cancer to a major employer in the United States: a case-control analysis.
Authors: Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M.

Cost of outpatient blood transfusion in cancer patients.
Authors: Cremieux PY, Barrett B, Anderson K, Slavin M.

Costs Associated with Anemia and Cancer.
Authors: Cremieux PY GM, Holland M, Slavin MB.

Understanding the Pharmacoeconomic profile of cancer.
Authors: Cremieux PY BH, Greenberg PE.

Publication: Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472.
Authors: Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

An alternative in terminal care: results of the National Hospice Study.
Authors: Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, H. B.

Overall Survival (Os) and Quality-of-Life (Qol) Outcomes in Recurrent Or Metastatic Squamous Cell Carcinoma of the Head And Neck (Scchn): A Systematic Literature Review.
Authors: Signorovitch J, Li N, Zhong Y, Shaw J, Dastani H, L. O.

Renal

Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.
Publication: Diabetes Therapy 2017 03. e-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.

Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.
Real-world economic outcomes during time on treatment among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.

**Abstract:** AMCP Managed Care & Specialty Pharmacy Annual Meeting, Denver, CO Mar 27-30, 2017.

**Authors:** Nicholas J. Vogelzang, Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Mark Meiselbach, Jose Ricardo Perez, Neeraj Agarwal.


**Authors:** Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.


**Authors:** Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.


**Authors:** DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

Resource utilization of adult patients with sporadic angiomyolipoma in the Netherlands.


**Authors:** Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.


**Authors:** Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.

**Abstract:** Annals of Oncology Conference: 41st European Society for Medical Oncology Congress, ESMO, Denmark Oct 7-11, 2016.

**Authors:** Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB.

Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

**Authors:** Zhou Z, Yang H, Fang A, Zhao J, Wu E, Chaudhari P, Seifeldin R.

The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.

**Abstract:** 52nd Annual Meeting of the European Association for the Study of Diabetes, EASD., Germany Sept 12-16, 2016.

**Authors:** Yang H, Zhou Z, Zhao J, Fang A, Wu E, Chaudhari P, Seifeldin R.

Natural history for adult patients with sporadic angiomyolipoma in the Netherlands.

**Abstract:** 53rd ERA-EDTA Congress, Vienna Austria. May 21-24, 2016.

**Authors:** Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.


**Authors:** Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ.

Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.


**Authors:** Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on antimuscarinic therapy for overactive bladder.


**Authors:** Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T.

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.


**Authors:** Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.

The healthcare cost impacts of switching antimuscarinic agents among patients with overactive bladder in a privately insured population.

**Abstract:** AUGS/IUGA Scientific Meeting, Washington, DC Jul 22-26, 2014.

**Authors:** Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H.

Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.

**Abstract:** ISPOR 19th Annual International Meeting, Montreal, QC Canada. May 31 - Jun 4, 2014.

**Authors:** Ivanova J, Hayes-Larson E, Sorg RA, Birnbaum HG, Fitzmartin J, Berner T.

Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.

**Abstract:** ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

**Authors:** Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner G.

Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.

**Abstract:** 51st ERA-EDTA Congress Amsterdam Netherlands. May 31-Jun 3, 2014.

**Authors:** Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies.


**Authors:** Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Wang X, Moonis M, Cattaneo A, Stergiopoulos S, Kollmannsberger C.

HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington’s Disease.

**Publication:** Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 223. doi: 10.7916/D8PN93NZ.

**Authors:** Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulsky D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Frank S.


*Authors:* Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernandez Pastor LJ, Bellmunt J.

Serum urate and incidence of kidney disease among veterans with gout.


*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.


*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Development and validation of a new chronic kidney disease risk equation: The role of pulse pressure.

*Abstract:* European Society of Cardiology, ESC Congress 2013 Amsterdam Netherlands Aug 31 - Sep 4, 2013.

*Authors:* Ayyagari R, Vekeman F, Faust E, Ong S, Trahey A, Lefebvre P, Machnicki G, Duh M.


*Authors:* Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J.

Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder.


Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.


*Authors:* Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.


*Authors:* Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.


*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN.

Cost-effectiveness analysis of mirabegron versus tolterodine extended release in the treatment of patients with overactive bladder in the United States.


*Authors:* Xie J, Zhou ZY, Bui CN, Yan Y, De G, Runken MC, Wu EQ.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.


*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Authors: Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.
Authors: Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

Treatment (trx) patterns and toxicity of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in United Kingdom (UK).

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Authors: Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.


Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Authors: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Authors: Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis.
Authors: Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P.

Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis.
Authors: Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P.
Seven year trends of pharmacy benefit erythropoiesisstimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis.

Authors: Vekeman F, Bailey RA, Laliberte F, Senbeta M, McKenzie RS, Lefebvre P.

Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.

Authors: Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Publication: Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.
Authors: Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

Authors: Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK.

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.

Authors: Parfrey PS, Lauve M, Latremouille-Vial D, Lefebvre P.

The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer’s perspective.

Authors: Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.

Authors: Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer’s perspective.

Authors: Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.

Publication: Current Medical Research and Opinion 2007 07; 23(7): 1571-1573; author reply 1573-1574. doi: 10.1185/030079907X199655.
Authors: Einarson T, Machado M, Walker J, Iskedjian M.

The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.

Authors: Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.

Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.
Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Authors: Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
Authors: Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis.
Authors: Wu EQ, Birnbaum H, Bookhart B, Mody SH.

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
Authors: Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
Authors: Cremieux PY, Van Audenrode M, Lefebvre P.

Comorbidity contributes to high treatment cost of interstitial cystitis.
Authors: Wu E.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Publication: Drugs and Aging 2006 12; 23(12): 969-976.
Authors: Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population.
Authors: Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H.

Employees with overactive bladder: work loss burden.
Authors: Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D.

Interstitial Cystitis Costs, Treatment and Comorbidities in an EMployed Population.
Authors: Wu EQ, Birnbaum H, Parece A, Kang Y, Mareva MN, Taitel H.

Cost of stress urinary incontinence: a claims data analysis.
Authors: Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.
Authors: Birnbaum H, Leong S, Kabra A.
Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.

**Publication:** Pharmacotherapy 2003 05; 23(5): 690-693; discussion 693-694.

**Authors:** Barnett AL, Cremieux PY.

---

**Respiratory**

**Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists.**


**Authors:** Bollu V, Guerin A, Gauthier G, Hiscock R, Wu EQ.

**Burden of systemic glucocorticoid-related complications in severe asthma.**


**Authors:** Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

---

**Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.**


**Authors:** Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr.

---

**Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.**


**Authors:** Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.

---

**Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.**


**Authors:** Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS, Merrigan JF, Schatz M.

---

**Characteristics and outcomes of patients with hospital-acquired pneumonia (HAP).**

**Abstract:** ISPOR 19th Annual European Congress., Austria Oct 29 - Nov 2, 2016.

**Authors:** Han S, Xie J, Song H, Zhang C, Wu EQ.

---

**Feasibility of matching-adjusted indirect comparison (MAIC) of omalizumab (OMA) vs. mepolizumab (MEPO) in moderate-to-severe asthma.**

**Abstract:** ISPOR 19th Annual European Congress., Austria Oct 29 - Nov 2, 2016.

**Authors:** Ayyagari R, Alvares L, Mu F, Hacking V, Martinez R, Signorovitch JE.

---

**Spectrum of idiopathic pulmonary fibrosis severity in clinical practice: implications for clinical trial feasibility and design.**


**Authors:** Macaulay D, Nathan SD, Terasawa E, Yu Y.
Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma.
Authors: Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P.

Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease.
Authors: Au DH, Macaulay DS, Jarvis JL, Desai US, Birnbaum HG.

CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.

Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Authors: Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
Authors: Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.
Authors: Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.
Authors: Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD.

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Authors: Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD.

Clinical and Economic Burden of Pulmonary Exacerbations In Patients With Cystic Fibrosis Who are Homozygous For The F508del Mutation.
Authors: O’Sullivan AK, Signorovitch JE, Fang A, Wagener J, Hodgkins P.

Inpatient Burden Among Patients With Cystic Fibrosis Who Are Homozygous for The F508del Mutation.
Authors: Hodgkins P, Ayagari R, Guo J, Wagener J, O’Sullivan AK.
Association of change in forced vital capacity with healthcare resource utilization in patients with newly diagnosed idiopathic pulmonary fibrosis.

Authors: Reichmann WM, Yu Y, Macaulay D, Nathan SD.

Change in forced vital capacity and clinical outcomes in newly diagnosed idiopathic pulmonary fibrosis patients.

Authors: Nathan SD, Reichmann WM, Macaulay D, Yu YF.

Cost and resource utilization in hospital-treated cap patients.

Authors: Tuttle EG, Llop CJ.

Economic and clinical burden of acute and chronic systemic corticosteroid-related complications in asthma patients Respiratory Disease.


Impact of suspected idiopathic pulmonary fibrosis acute exacerbations on clinical and healthcare resource utilization outcomes.

Authors: Nathan SD, Reichmann WM, Macaulay D, Yu YF.

Time to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA) combination therapy.

Authors: Patel J, Mapel DW, Roberts MH, Sama S, Gilmore J, Sundaresan D, Laliberte F, Pilon D, Lefebvre P, Duh M.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Authors: Knopf KB, Duh MS, Lafuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

A cost-analysis model for anticoagulant treatment in the hospital setting.

Authors: Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

Pulmonary medication adherence and health-care use in cystic fibrosis.

Authors: Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA.

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.

Authors: Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.
Cluster analysis of objectively measured physical activity in 1001 COPD patients.


Assessment of COPD exacerbation risk: Utilizing health claims data to develop and validate a risk equation.

Authors: Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan J, Duh M.

Risk assessment of first severe COPD exacerbation using predictive models based on health claims data.


Effects of care management and telehealth: a longitudinal analysis using medicare data.

Authors: Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG.

Burden of illness of patients with allergic asthma versus non-allergic asthma.

Authors: Lafeuille MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P.

Development and validation of a claims-based prediction model for COPD severity.

Authors: Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF.

A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.


Risk of Hospital Readmissions in Patients with Chronic Obstructive Pulmonary Disease Receiving Arformoterol Tartrate versus Nebulized Short-Acting Beta2-Agonists Following Hospital Discharge.

Authors: Bollu VK, Guérin A, Gauthier G, Hiscock R, Wu EQ.

Impact of integrated telehealth and care management program on resource utilization in medicare beneficiaries with chronic obstructive pulmonary disease.

Authors: Au DH, Jarvis J, Macaulay D, Birnbaum HG.
Re-hospitalization risk in patients with chronic obstructive pulmonary disease (COPD) initiating nebulized long-acting vs. Short-acting beta2-agonists.


Association between consistent omalizumab treatment and asthma control.

*Publication:* The Journal of Allergy and Clinical Immunology: In Practice 2013 1(1): 51-57.

*Authors:* Lafeuille M-H, Gravel J, Zhang J, Gorsch B, Figliomeni M, Lefebvre P.

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.


*Authors:* Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K.

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.


*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.


*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsch B, Lefebvre P.

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.


*Authors:* Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L.

Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.


*Authors:* Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S.

Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model.


Annual healthcare costs for patients with cystic fibrosis from a medicaid perspective.


*Authors:* Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E.

Lower adherence to chronic pulmonary medications is associated with increased health service utilization in patients with cystic fibrosis.


*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Riekert KA.

Pulmonary medication adherence among individuals with cystic fibrosis.


*Authors:* Riekert KA, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Quittner AL.
A validated claims-based prediction model for COPD severity.

Impact of omalizumab initiation on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids and long-acting beta2-agonists Respiratory Disease.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Association of allergic rhinitis with asthma exacerbations and health care costs in asthma patients Respiratory Disease.
Authors: Ivanova JI, Desai U, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

Development of a pulmonary exacerbation risk score among cf patients not receiving recommended therapies for pulmonary care.

Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China.

Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care.

Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.
Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.

Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.

Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.

Authors: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P.

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.

Authors: Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS.

Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.

Authors: Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J.

Development of a pulmonary exacerbation risk score among CF patients not receiving recommended therapies for pulmonary care.


Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis.


Cost-effectiveness analysis of roflumilast/tiotropium combination therapy vs. tiotropium monotherapy in patients with severe to very severe COPD.

Authors: Yu AP, Sun S, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu E.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.

Authors: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.

Authors: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.
PRS7 Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.
Authors: Signorovitch J, Sawicki G, Zhang J, Latremouille-Viau D, Wu E, von Wartburg M, Lizheng S.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.
Authors: Lafeuille M, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Swensen A, Stanley EL, Lefebvre P.

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Authors: Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ.

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Authors: Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.
Authors: Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J.

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
Authors: Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Authors: Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.

Association between private-to-medicaid change in health insurance & healthcare utilization & outcomes among children with cystic fibrosis.
Authors: Zhivan N, Campbell CR, Signorovitch J, Zhang J, Shi L.

Comparison of drug costs & clinical outcomes with tobramycin solution for inhalation & aztreonam lysine for inhalation in cystic fibrosis.
Authors: Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J.

Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.
Authors: Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.
Authors: Kirson NY, Bimbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.
Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.


*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.


*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.


*Authors:* Sawicki GS, Signorovitch J, Latremouille-Viau D, Von Wartburg M, Wu E, Zhang J, Shi L.

Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations Respiratory Disease.


*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Colice GL, Silverman R, McLaurin KK.

Economic burden of exacerbations in chronic obstructive pulmonary disease.


*Authors:* Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J.

Relationship between daily dosing frequency, compliance, health care resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD).


*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Piauschinat C, Swensen A, Duh MS.

Persistence and Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Multiple vs Single Long-Acting Inhalers.

*Publication:* CHEST Journal 2010 138(4_MeetingAbstracts): 482A-482A.

*Authors:* Yu AP, Guérin A, de Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format.


*Authors:* Kosinski M, Kite A, Yang M, Rosenzweig JC, Williams A.

Asthma severity categorization using a claims-based algorithm or pulmonary function testing.


*Authors:* Birnbaum HG, Ivanova JI, Yu AP, Hsieh M, Seal B, Emani S, Rosiello R, Colice GL.

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.


*Authors:* Frois C, Wu EQ, Ray S, Colice GL.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.


*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.
The direct economic impact of exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A review of the literature.

Authors: Toy EL, Gallagher KF, Stanley EL, Duh MS.

The risk of hospitalization or emergency care following outpatient treatment of community-acquired pneumonia (CAP) with levofloxacin versus moxifloxacin.

Authors: Signorovitch JE, Gu A, Sengupta A, Raut M, Mody SH, Grant R, Schein J, Fisher AC, Ng D, Duh MS.

The direct economic impact of exacerbations of chronic obstructive pulmonary disease (COPD): A review of the literature.

Authors: Toy EL, Gallagher KF, Stanley EL, Duh MS.

Costs and resource use of mild persistent asthma patients initiated on controller therapy.

Authors: Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C.

Adherence to inhaled corticosteroid use and local adverse events in persistent asthma.

Publication: American Journal of Managed Care 2008 12; 14(12): 801-809.
Authors: Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL.

Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature.

Authors: Weiner JR, Toy EL, Sacco P, Duh MS.

Hemodynamic changes induced by positive pressure capnothorax during thoracoscopic thymectomy.

Publication: Chirurgia 2007 05; 102(3): 263-270.
Authors: Tomescu D, Grigorescu B, Nitulescu R, Tomulescu V, Popescu I, Tulbure D.

Use of inhaled corticosteroids and healthcare costs in mild persistent asthma.

Authors: Colice G, Wu EQ, Birnbaum H, Daher M, Maryna BM.

Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.

Authors: Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

Development of a COPD severity score.

Authors: Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G.

Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population.

Authors: Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S.
Inpatient and Emergency Department Utilization of Persistent Asthma Patients.
Authors: Colice G, Crivera C, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST.

Development of a COPD Severity Score in Claims Database.
Authors: Wu EQ, Birnbaum H, Cifaldi M, Colice G, Kang Y.

Healthcare Costs of Patients with Persistent Asthma.
Abstract: Academy of Managed Care Pharmacy (AMCP).

PRS3 Acute exacerbation of chronic bronchitis (AECB) treatment effectiveness: Comparison of macrolides to fluoroquinolones.
Authors: Wu E, Birnbaum H, Cifaldi M, Kang Y, Colice G.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Publication: Critical Care Medicine 2004 03; 32(3): 666-674.
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH, Group CS.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH.

Treatment costs of community-acquired pneumonia in an employed population.
Publication: Chest 2004 06; 125(6): 2140-2145.
Authors: Colice GL, Morley MA, Asche C, Birnbaum HG.

Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Johnson KA, Nichol MB.

Lower respiratory tract infections: impact on the workplace.
Publication: Pharmacoeconomics 2003 06; 21(10): 749-759.
Authors: Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

PRP13: Assessing the cost implications of combined pharmacotherapy in the long term management of asthma.
Authors: Wu E, Johnson K, Nichol M.

Direct and indirect costs of asthma to an employer.
Publication: Journal of Allergy and Clinical Immunology 2002 02; 109(2): 264-270.
Authors: Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA.

Economic burden of respiratory infections in an employed population.
Publication: Chest 2002 08; 122(2): 603-611.
Authors: Birnbaum HG, Morley M, Greenberg PE, Colice GL.

Economic burden of pneumonia in an employed population.
Authors: Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL.
Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients.
*Authors:* Duh MS, Walker AM, Lindmark B, Laties AM.

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.
*Publication:* Clinical Therapeutics 2000 01; 22(1): 140-151.
*Authors:* LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O.

Lack of Intraocular Pressure Effect of Budesonide Inhalation Therapy in a Mixed Asthmatic Population.
*Authors:* Duh M, Walker A, Lindmark B, Laties A.

**Substance Abuse**

The economic burden of opioid abuse: Updated findings.
*Authors:* Kirson NY, Scarpati LM, Enloe CJ, Dincar AP, Birnbaum HG, Mayne TJ.

(263) A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.
*Authors:* White A, Yenikomshian M, Carson M, Masters ET, Roland C.

The costs and cost drivers of opioid misuse by diagnosis: Abuse, dependence, and overdose/poisoning.
*Authors:* Howard J, Kirson N, Scarpati L, Dincar A, Hanway J, Zichlin M, Birnbaum H.

The economic burden of opioid abuse and its drivers: Evidence from a payer perspective.
*Authors:* Howard J, Kirson N, Scarpati L, Dincar A, Hanway J, Zichlin M, Birnbaum H.

A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.
*Abstract:* Annual Scientific Meeting of the American Pain Society, Austin Convention Center, Austin, TX May 11-14, 2016.
*Authors:* White AG, Yenikomshian M, Carson M, Masters ET, Roland CL.

Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.

Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.
*Publication:* Journal of Managed Care & Specialty Pharmacy 2015 21(10): 902-9-.

Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
*Authors:* White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J.
The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.
Authors: Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Sources of prescription opioids among diagnosed opioid abusers.
Authors: Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Sources of prescription opioids among diagnosed opioid abusers.

Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
Authors: Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E.

The economic burden of diagnosed opioid abuse among commercially insured individuals.
Authors: Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R.

Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management.
Authors: Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekian J, Sheng M.

Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.
Authors: Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Authors: Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Authors: Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

A model to estimate the health system burden of prescription opioid abuse in Europe.
Authors: Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop W.

Authors: Shei A, Rice B, Kirson NY, Bodnar K, Cummings AKG, Birnbaum HG, Holly P, Ben-Joseph R.

Comparing the prevalence and healthcare costs of opioid abuse using two commercial claims databases.
Authors: Rice B, Kirson NY, Shei A, Enloe CJ, Cummings AK, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.
Methods to estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially-insured individuals.

Authors: Shei A, Rice B, Kirson NY, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

The burden of opioid abuse among commercially-insured patients.

Authors: Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R.

Differences between high-cost and low-cost patients diagnosed with opioid abuse.

Authors: Rice JB, Kirson NY, Bodnar K, Shei A, Birnbaum HG, Holly P, Ben-Joseph R.

Characteristics of high-cost patients diagnosed with opioid abuse.

Authors: Birnbaum H, Kirson N, Shei A.

Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database.

Authors: Birnbaum H, Kirson N, Shei A.

Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation.

Authors: Birnbaum H, Kirson N, Shei A.

The relationship between positive subjective measures in abuse liability studies and real-world non-medical use: potential impact of abuse deterrent opioids on rates of non-medical use and associated healthcare costs.

Authors: White AG, LeCates J, Cheng W, Roland CL, Schaaf D, Mardekian J.

Prescription opioid abuse: challenges and opportunities for payers.

Authors: Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.

Estimating the payer-specific excess medical costs of opioid abuse in the united states.

Authors: Michna E, Kirson NH, Shei A, White A, Birnbaum HG, Ben-Joseph R, Rossiter LF.

A Model to Identify Patients at Risk for Prescription Opioid Abuse, Dependence, and Misuse.

Authors: Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL.

Characteristics and use patterns of chronic hydrocodone users.

Authors: Rice J, Samuelson T, Birnbaum H, Katz N.

A systematic literature review of the efficacy and safety of abuse-deterrent formulation and non-abuse-deterrent formulation prescription opioids in non-cancer pain management.

Identifying predictors of chronic hydrocodone use.


**Authors:** Rice JB, Samuelson TM, Birnbaum HG, Katz N.

Economic impact of opioid abuse, dependence, and misuse.

**Publication:** American Journal of Pharmacy Benefits 2011 05; 3(3): e59-e70.

**Authors:** White AG, Birnbaum HG, Schiller M, Waldman T, Cleveland JM, Roland CL.

Societal costs of prescription opioid abuse, dependence, and misuse in the United States.


**Authors:** Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.


**Authors:** Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

Societal costs of opioid abuse, dependence, and misuse in the United States.


**Authors:** Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL.

Analytic models to identify patients at risk for prescription opioid abuse.

**Publication:** American Journal of Managed Care 2009 12; 15(12): 897-906.

**Authors:** White AG, Birnbaum HG, Schiller M, Tang J, Katz NP.

Health care and work loss burden of prescription opioid abuse, dependence, and misuse.


**Authors:** White AG, Birnbaum H, Schiller M, Waldman T, Cleveland JM, Setnik B, Roland CL.

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.


**Authors:** White AG, Birnbaum HG, Rothman DB, Katz N.

Estimated costs of prescription opioid analgesic abuse in the United States in 2001 - A societal perspective.


**Authors:** Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP.

Direct costs of opioid abuse in an insured population in the United States.

**Publication:** Journal of Managed Care Pharmacy 2005 07; 11(6): 469-479.

**Authors:** White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N.
Other Diseases & Conditions

Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome.
Authors: Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG.

Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Authors: Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.

Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.
Authors: Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.
Authors: Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, Ganguli A.

Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Authors: Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M.

Adherence and persistence with cyclosporine ophthalmic emulsion for treatment of dry eye disease in a large US healthcare System.
Authors: Schaumberg DA, Bradley J, Guerin A, Pivneva I, Evans A, Stillman IO, Dana R.

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.
Authors: Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD.

The direct and indirect costs associated with endometriosis: a systematic literature review.
Authors: Soliman AM, Yang H, Du EX, Kelley C, Winkel C.
Estimates of incidence and prevalence of dry eye disease across age groups in the US using data from a large healthcare system. 
**Abstract:** American Academy of Optometry 95th Annual Meeting, Anaheim, CA Nov 9-12, 2016
**Authors:** Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Dana R, Schaumberg DA.

Incidence and prevalence of dry eye disease in a large US healthcare system across a wide range of ages.
**Abstract:** American Academy of Ophthalmology AAO Chicago, IL Oct 15-18, 2016
**Authors:** Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Schaumberg DA.

Comparative hepatotoxicity of echinocandins in hospitalized patients (pts): A retrospective cohort study.
**Authors:** Vekeman F, Weiss LS, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak R, Tawadrous M, Duh MS.

Impact of the introduction of newer Long Acting Reversible Contraceptive (LARC) methods on LARC use in a commercially insured population.
**Authors:** Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

Development of a Risk Score for Fluconazole Failure among Patients with Invasive Candidiasis.
**Abstract:** ASM 2016 | ICAAC 2016, Boston, MA Jun 16-20, 2016.
**Authors:** Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N HY, Xie J, Lin PL, Ohashi E, Koo V, Wu EQ, Zhao J, Koo V, Wu E.

Comorbidities and symptoms among endometriosis patients: A systematic literature review.
**Abstract:** ISPOR 21st Annual International Meeting Research, Washington, DC May 21-25, 2016.
**Authors:** Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

Impact of the introduction of newer long acting reversible contraceptive (LARC) methods on LARC use in a commercially insured population.
**Abstract:** ISPOR 21st Annual International Meeting Research Washington, DC May 21-25, 2016.
**Authors:** Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

Income growth trajectory for parents of children with down syndrome in the United States.
**Abstract:** ISPOR 21st Annual International Meeting Research Washington, DC United States May 21-25, 2016.
**Authors:** Samuelson D, Kageleiry A, Duh MS, Lefebvre P, Campbell JY, DerSarkissian M, Haider BA, Skotko BG.

Measuring opportunities to improve health outcomes via individualized treatment assignment.
**Authors:** Patterson-Lomba O, Signorovitch J.

Rates of subsequent endometriosis-related surgeries following an initial laparoscopy or hysterectomy: A longitudinal analysis of commercially insured endometriosis patient in the united states.
**Authors:** Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

A systematic literature review of comorbidities and symptoms among uterine fibroids patients between 2000 and 2013.
**Authors:** Soliman AM, Yang H, Du EX, Kelkar S, Winkel C.
Predictors of CD4 count recovery in the CIPRA HT-001 trial of early ART.
Authors: Collins SE, Calnan M, Juste MAJ, Severe P, Secours R, Bernard D, Batavia A, Fitzgerald DW, Koenig SP, Pape JW.

Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
Authors: Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J.

Incremental direct and indirect costs of untreated vasomotor symptoms.
Authors: Sarrel P, Portman D, Lefebvre P, Lefeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM.

Simulations Show Diagnostic Testing For Malaria In Young African Children Can Be Cost-Saving Or Cost-Effective.
Authors: Phillips V, Njau J, Li S, Kachur P.

Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Authors: Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C.

The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.
Authors: Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C.

The Clinical Burden Associated with Zygomycosis-Related Hospitalizations in the U.S.
San Diego, CA Oct 7-11, 2015.

The Economic Burden Associated with Zygomycosis-Related Hospitalizations in the U.S.
Abstract: IDSA IDWeek annual meeting, San Diego, CA Oct 7-11, 2015.

Cellular rejuvenation and ageing-proteome by Ginsenoside 20(S)-Rg3.
Authors: Kim YR, Baek SJ, Kang YM, Oh KS, Kwon J, Choi JS.

Out-of-pocket medical costs for parents with children with down syndrome in the united states.
Authors: Kageleiry A, Samuelson D, Duh MS, Lefebvre P, DerSarkissian M, Campbell JY, Skotko BG.

Treatment patterns of women diagnosed with uterine fibroids 5 years pre and post diagnosis: A longitudinal retrospective claims analysis of a commercially insured population in the US.
Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.
Comparison of Annual Treatment Costs for Patients Treated with Infusion / versus Injectable Biologics.
Authors: Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.
Publication: Current Medical Research and Opinion 2015 01; (0): 1-38.
Authors: Fuldeore M, Yang H, Soliman AM, Winkel C.

Monitoring testing patterns among patients with tuberous sclerosis complex-related angiomyolipomas.

The randomized blind start trial: Evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations.
Authors: Signorovitch J, Ayyagari R, Kakkis E.

Budget impact model of ORALAIR® for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in adults and children.

Clinical and economic burden of vasomotor symptoms among untreated menopausal women.
Authors: Sarrel P, Lefebvre P, Lafaille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).
Authors: Sarrel P, Lefebvre P, Lafaille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

A longitudinal retrospective claims analysis of healthcare costs incurred by uterine fibroids patients.
Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Treatment patterns among us women diagnosed with endometriosis: A retrospective claims analyses pre- and post-diagnosis.
Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Diagnosis and treatment patterns among patients with tuberous sclerosis complex-related angiomyolipomas.

Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis.
Authors: Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel CA.
### Direct and indirect resource use and costs associated with non-infectious non-anterior uveitis.

**Abstract:** Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL May 4-8, 2014.

**Authors:** Thone J, Tundia N, Skup M, Macaulay D, Revol C, Chao J, Mulani P, Dick A.

### Risk of leaving the workforce in non-infectious uveitis.

**Abstract:** Association for Research in Vision and Ophthalmology (ARVO), May 4-8, 2014 May 4-8, 2014.

**Authors:** Tundia N, Skup M, Sorg R, Macaulay D, Chao J, Mulani P, Thorne JE.

### Risk of ocular complications in non-infectious uveitis.

**Abstract:** Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL May 4-8, 2014.

**Authors:** Skup M, Tundia N, Sorg R, Chao J, Mulani P, Dick A.

### Clinical and economic burden of vasomotor symptoms among untreated menopausal women.

**Abstract:** AMCP 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

**Authors:** Sarrel P, Lefebvre P, Lafeuille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

### Medicaid spending on contraceptive coverage and pregnancy-related care.


**Authors:** Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P.

### Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

**Publication:** Journal of ophthalmic inflammation and infection 2013 11; 3(1): 64.

**Authors:** Chu DS, Johnson SJ, Malley UG, Davis MR, Sorg RA, Duh MS.

### Systematic literature review of the costs of pregnancy in the US.


**Authors:** Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS.

### Direct and indirect costs for women with vasomotor symptoms (VMS) receiving lower-versus higher-dose paroxetine.


**Authors:** Portman D, Lafeuille MH, Lefebvre P, Gravel J, Duh MS, Aupperle PM, Sarrel P.

### Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).


**Authors:** Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

### Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.


**Authors:** Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

### Actuarial analysis of Medicaid spending for contraception and pregnancy care.

**Abstract:** 1st Global Conference on Contraception, Reproductive and Sexual Health 2013 Conference Copenhagen Denmark. May 22-25, 2013.

**Authors:** Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.
Medicaid spending for users of contraceptives and pregnancy-related care.
Authors: Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

Actuarial analysis of medicaid spending for contraception and pregnancy care.
Authors: Laliberte F, Lefebvre P, Law A, Duh MS, Lynen R, Darney P.

Medical resource use and costs associated with chylomicronemia.
Authors: Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB.

Cost burden and treatment patterns associated with management of heavy menstrual bleeding.
Authors: Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, Duh MS.

Economic burden and quality of life of vulvodynia in the United States.
Authors: Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C.

Effects of quinestrol and levonorgestrel on populations of plateau pikas, Ochotona curzoniae, in the Qinghai-Tibetan Plateau.

Comparisons of patient characteristics and health care costs by quartile among patients with allergic rhinitis.
Authors: Desai U, Ivanova Jl, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

Health care costs and utilization for privately insured patients treated for non-infectious uveitis in the United States.
Authors: Johnson S, Duh MS, Mallya U, Diener M, Sorg R, Chu D.

Direct and indirect costs associated with Dupuytren’s contracture.
Authors: Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.
Authors: Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US.
Authors: Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.
Analysis of genetic diversity of gemyplasm of Pinellia ternata based on SRAP.


**Authors:** Yang M, Chen K.

Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.


**Authors:** Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

Direct and indirect costs associated with dupuytren’s contracture.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-25, 2011.

**Authors:** Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

Health care resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer’s perspective.

**Abstract:** 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2011 Baltimore, MD United States. May 21-24, 2011.

**Authors:** Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, MS. D.

A qualitative study on feasibility of a web-based Women’s Health Portal and Information System.


**Authors:** Yang M, Kosinski M, Boulanger R.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.


**Authors:** Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.

**Publication:** Appl Health Econ Health Policy 2010 02; 8(2): 129-140. doi: 10.2165/11532210-000000000-00000.

**Authors:** Rendas-Baum R, Yang M, Gricar J, Wallenstein GV.

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.


**Authors:** Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.

**Publication:** Current Medical Research and Opinion 2009 10; 25(10): 2487-2494. doi: 10.1185/03007990903167415.

**Authors:** Yang M, Morin CM, Schaefer K, Wallenstein GV.

The costs of non-vertebral osteoporotic fractures in the United States.

**Abstract:** ISPOR 14th Annual International Meeting Orlando, FL United States. May 16-20, 2009.

**Authors:** Birnbaum HG, Pike C, Schiller M, Sharma H, Gu A, Burge RT, Edgell ET.

Burden of premenstrual dysphoric disorder on health-related quality of life.

**Publication:** J Womens Health (Larchmt) 2008 01; 17(1): 113-121. doi: 10.1089/jwh.2007.0417.

**Authors:** Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S.


*Authors:* Yu A, Wu EQ, Perrson B, Chang J, Costales C, Gricar J.

WH3 Clinical and economic outcomes among women using levonorgestrel-releasing intrauterine system (LNG-IUS).

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research, May 3-7, 2008.


The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.


*Authors:* Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA.

Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.


*Authors:* Meadows ES, Rousculp M, Sasser AC, Birnbaum HG, Moynier E, Mallet D, Johnston JA.

Annual costs associated with diagnosis of uterine leiomyomata.


*Authors:* Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P.

Annual Costs Associated with Diagnosis of Uterine Fibroids.

*Abstract:* The American College of Obstetricians and Gynecologists (ACOG).

*Authors:* Hartmann KE, Birnbaum H, Wu EQ, Ben-Hamadi R, Farrell MH, Spalding J, Stang P.

Lifetime Costs of Patients With Clinically Detected Uterine Fibroids: An Employer’s Perspective.


*Authors:* Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective.

*Abstract:* The American College of Obstetricians and Gynecologists (ACOG).

*Authors:* Wu EQ, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE.

Assessing the economic impact of chronic conditions in postmenopausal women.


*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

POS1 Using a budget impact model to predict first-year use of a new osteoporosis therapy.

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research, 2005.

*Authors:* Sasser A, Rousculp M, Birnbaum H, Moynier E, Wu E, Marcus R.

Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy.

*Abstract:* Academy of Managed Care Pharmacy (AMCP).

*Authors:* Rousculp MD, Sasser AC, Birnbaum HG, Moynier E, Wu EQ, Mallet D, Marcus R.

PMD3: Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ate).


*Authors:* Wu E, Johnson K, Nichol M.
PMD4: Performance of two conditional expectation methods under unobserved selection bias.
Authors: Wu E, Nichol M, Johnson K.

Other (Health Policy, Market Access, and other topics)

Insurer And Provider Market Share.
Authors: Dyckman Z.

Practical Uses For Machine Learning In Health Care Cases.
Publication: Law360 2016 09.
Authors: Yenikomshian M, Pinheiro LB, Royer J, Greenberg PE.

Updated trends in US brand-name and generic drug competition.
Authors: Grabowski H, Long G, Mortimer R, Boyo A.

The Myth Of ‘Price Disconnects' In US Pharma Markets
Publication: Law360 2016 05.
Authors: Fink S, Lewis M.

Correlation Or Cause: Brand-Name Drug Prescription Rates
Publication: Law360 2016 03.
Authors: Greenbert P, Sisitsky T, R M.

Stock Prices Aren't Enough For 'Rule Of Reason' Analysis.
Publication: Law360 2016 07.
Authors: Cremieux P, Davis T, Lewis M, Greenberg P.

Care pathways in US healthcare settings: current successes and limitations, and future challenges.
Authors: Chawla A, Westrich K, Matter S, Kaltenboeck A, Dubois R.

Reliable Analysis Is Key To Addressing Ascertaintability.
Publication: Law360 2016 12.
Authors: Cacciola S, Fink S.

Can The Life Sciences Industry Bank On Biosimilars?
Publication: Law360 2016 04.
Authors: Greenberg P, Sisitsky T, Mortimer R.

Updated trends in US brand-name and generic drug competition.
Authors: Grabowski H, Long G, Mortimer R, Boyo A.

Retention of clinically stable art patients in a rapid model of care in Haiti.
Authors: Moise CG, Bellot C, Hennessey KA, Rivera VR, Severe P, Aubin D, Homeus F, Saint-Vil A, Koenig SP, Pape JW.
Publication: Law360 2016 06.
Authors: Pinheiro L, Royer J, Dadson N, Greenberg P.

Viewing Recent Opioid Regulations In Context.
Publication: Law360 2016 04.
Authors: Pike C, Weinstein K, Darling P, Greenberg P.

Publication: AHLA Connections 2015 09.
Authors: Chipty T, Sendonaris A.

Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
Authors: Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P.

The roles of patents and research and development incentives in biopharmaceutical innovation.
Authors: Grabowski HG, DiMasi JA, Long G.

The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
Authors: Cockburn I, Long G.

Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in the U.S. and EU-5: Payer and manufacturer experience and outlook.
Authors: Ko J, Nazareth T, Carpenter S, Demean S, Wu E, Sasane R, Navarro R.

Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: Payer and manufacturer experience and outlook.
Authors: Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, Sasane R, Navarro R.

Statistical identification of potential selection bias in retrospective chart reviews.
Authors: Signorovitch JE, Reichmann WM, Li N, Liu Z, Hao Y, Perez JR.

Comparison of Annual Treatment Costs for Patients Treated with Infusion Versus Injectable Biologics.
Authors: Macaulay D, Wei J, Terasawa E.

Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: considerations for U.S. payors.
Authors: Ellis L, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.
Economic consequences of cytomegalovirus disease among stem cell transplant recipients.
Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snydman DR.

Comparison of Annual Treatment Costs for Patients Treated with Infusion /versus Injectable Biologics.
Authors: Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

Advanced Diagnostics: Innovation, Reimbursement, and Coverage Challenges.
Publication: In Vivo 2014 10.
Authors: Gorin B, Tuttle E.

Random Selection Is Best For MDL Bellwether Trials.
Authors: Brown L, Holian M, Rothman D.

Cost-effectiveness of health research study participant recruitment strategies: a systematic review.
Authors: Huynh L, Johns B, Liu SH, Vedula SS, Li T, Puhan MA.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.
Authors: Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Recent trends in brand-name and generic drug competition.
Authors: Grabowski H, Long G, Mortimer R.

The role of health economics and outcomes research in health care reform in China.
Authors: Liang W, Xie J, Fu H, Wu EQ.

What Attorneys Should Know about FDA’s MedWatch Data.
Publication: Law360 2014 01.
Authors: Duh MS CP, Greenberg P, Ellman B.

Quality measure attainment in patients with type 2 diabetes mellitus.
Publication: American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15.
Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P.

Cost of illness: an ongoing battle worth fighting.
Authors: Greenberg PE.

Evolving provider payment models and patient access to innovative medical technology.
Authors: Long G, Mortimer R, Sanzenbacher G.

Big Data Can Yield Big Insights on Promotional Practices.
Publication: Law360 2014 08.
Authors: Greenberg P, Sisitsky T.
Evaluation of the value of webdata for detecting drug adverse events.

Identifying high-value treatment populations in clinical trials and real-world data.
Authors: Signorovitch J, Shaw J, Betts K, Wu EQ.

Outcomes-based contracting for pharmaceutical products in the United States: payer and manufacturer experience and outlook.
Authors: Frois C, Carpenter S, Demean S, Wu E, Navarro R.

Biosimilars.
Authors: Grabowski H, Long G, Mortimer R.

The impact of Brazil’s Bolsa Familia conditional cash transfer program on children’s health care utilization and health outcomes.
Authors: Shei A, Costa F, Reis MG, Ko Al.

Effects of care management and telehealth: a longitudinal analysis using medicare data.
Authors: Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG.

Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.
Authors: Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L.

On-Market Pricing Strategies.
Publication: Pharmaceutical Executive 2013 06.
Authors: Works J, Parece A.

Brazil’s conditional cash transfer program associated with declines in infant mortality rates.
Authors: Shei A.

Innovation in the Biopharmaceutical Pipeline: A Multidimensional View.
Authors: Long G, Works J.

Cost utility of hub-and-spoke telestroke networks from societal perspective.
Publication: American Journal of Managed Care 2013 12; 19(12): 976-985.
Authors: Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, Wu EQ.
*Publication*: Today’s General Council 2013 08; 10(4).
*Authors*: John L, Leckerman J, Greenberg P.

Estimating chronic disease prevalence from claims data: Reducing bias by accounting for diseased individuals who do not generate claims.
*Authors*: Signorovitch J, De G, Drabo E, Ayyagari R, Wu E.

Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio.
*Authors*: Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ.

Investigator-initiated approach to address an optimization problem in designing cost-efficient studies.
*Authors*: Huynh L, Clark M, Frick KD.

*Authors*: Signorovitch J, Ayyagari R, Cheng D, Wu E.

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication.
*Publication*: JHEOR 2013: 54-61.
*Authors*: C CF, Tl OC, Pesa J, Fastenau J, Doshi D.

Recent Average Price Trends for Implantable Medical Devices, 2007-2011.
*Authors*: Long G, Mortimer R, Sanzenbalcher G.

Prioritizing Safety Versus Budget: FDA and CMS Adopt Different Stances.
*Publication*: FDLI Update 2012 05.
*Authors*: Sisitsky T, Greenberg P.

Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment.
*Authors*: Long G, Mulhern C.

How to use Clinical-Trial Data in Court.
*Publication*: Law360 2012 07.
*Authors*: Cremieux P GA, Pinheiro L.

Confounding factors in off-label drug use.
*Authors*: Greenberg PE, Pike C, Sisitsky T.

Review of national institute for health and clinical excellence (NICE) recommendations for anti-cancer agents across multiple drug-indication combinations.
Authors: Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ.

Impact of medicare part D coverage gap on beneficiaries’ adherence to prescription medications.
Authors: Desai U, Carroll NV.

Modeling the progression of chronic diseases in a dynamic market: Implications for budget impact analysis.
Authors: Eldar-Lissai A, Banerjee R, McBride S, Leaf-Herrmann W.

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Authors: Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings.
Authors: Baker LC, Johnson SJ, Macaulay D, Birnbaum H.

Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
Authors: Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.

Interprofessional education about decision support for patients across cultures.
Authors: Hagoel L, Volz S, Palileo LM, Eldar-Lissai A, Kamath CC, Cox ED.

Publication: CPI Antitrust Chronicle 2011 05.
Authors: Chipty T.

President Reignites Biologics Exclusivity Battle With Proposal for Seven Years.
Publication: Specialty Pharmacy News 2011 03.
Interviewed: Long G.

Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.

Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.
Authors: Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW.

Data exclusivity for biologics.
Authors: Grabowski H, Long G, Mortimer R.
Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market.
Publication: Specialty Pharmacy News 2011 02; 8(2).
Interviewed: Long G.

Budget Proposals on Biosimilars, "Pay for Delay" Spark Controversy.
Publication: AIS's Health Reform Week 2011 02; 2(6).
Interviewed: Long G.

The role of public-sector research in the discovery of drugs and vaccines.
Authors: Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML.

Authors: Danzon PM, Johnson SJ, Long G, Furukawa MF.

Comparative effectiveness research using matching-adjusted indirect comparison – A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data.
Abstract: 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Maryland Jun 6-7, 2011.
Authors: Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, Erder MH.

Utilizing rich data sources to identify patients' subgroups that can benefit most from a treatment.
Abstract: The 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Maryland Jun 6-7, 2011.
Authors: Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, Erder MH.

Improved indirect treatment comparisons for comparative effectiveness research.
Authors: Signorovitch J, Navarro R, Betts K, Wu EQ.

An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are Low.
Publication: FDLI Update 2011 01; Jan/Feb.
Authors: Wei E, Claggett B, Greenberg P, Wei LJ.

Implementation of the biosimilar pathway: economic and policy issues.
Authors: Grabowski H, Long G, Mortimer R.

Introducing perspectives on comparative effectiveness research.
Authors: Birnbaum HG, Greenberg PE.

CER The Fruits of Comparative Effectiveness Sometimes it’s necessary to compare apples to oranges, as well as to other apples. New tools and a commitment to managing the impact of comparative effectiveness research grants payers the evidence they need to control drug costs.
Publication: Pharmaceutical Executive 2010 11: 78.
Authors: Tuttle E, Chawla A, Nellesen D, Works J.

Methodological issues in a meta-analysis.
Authors: Cremieux P.
Selecting the optimal target population for formulary coverage.

Authors: Wu EQ, Yu D, Xie J, Gu.

Comparative Effectiveness Research for Personalized Medicine.

Authors: Signorovitch J, Wu EQ, We LJ.

Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy.

Authors: Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T.

The role of compliance in telehealth adoption.

Authors: Newell D, Johnson S, Rutherford P, Welte I.

ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership-Measurement Model of Disease Management.

Authors: Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T.

Perspectives on comparative effectiveness research: views from diverse constituencies.

Authors: Nellesen D, Birnbaum HG, Greenberg PE.

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.

Authors: Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.

Publication: Current Medical Research and Opinion 2009 07; 25(7); 1793-1805. doi: 10.1185/0300799090344374.
Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Economic Analysis in Off-Label Promotion Cases.

Publication: Law360 2009 02.
Authors: Greenberg P, Sisitsky T.

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.

Authors: Tian L, Cai T, Pfeffer MA, Plankov N, Cremieux PY, Wei LJ.

Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.

Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.
Comparative Effectiveness without Head-To-Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data.
Authors: Wu EQ, Signorovitch J, Yu A.

Economic impact of generic entry of topiramate in the G4 European countries.
Authors: Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.
Authors: Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

Personalized medicine: trends in clinical studies based on national registry data.
Authors: Nellesen D, Person A, Yee K, Chawla A.

A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees.
Authors: Rice JB, Kasper JD, Pezzin LE.

Authors: Greenberg P, Sisitsky T.

Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
Authors: Kalb PE, Greenberg PE.

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy
Authors: LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.

Does generic substitution always make sense?
Authors: Greenberg PE.

Publication: FDLI Update 2008 05; (3).
Authors: Duh MS, Greenberg P, Antras L.

The Role of Epidemiology in Drug Safety Litigations.
Authors: Duh MS, Greenburg PE, Weiner JR.

Authorized generic drugs, price competition, and consumers' welfare.
Authors: Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E.
The value of antihypertensive drugs: a perspective on medical innovation.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA.
Authors: Long G, Cutler DM, Berndt ER.

Authors: Wu EQ, Greenberg P, Erder MH.

Competition between Generic and Branded Drugs.
Authors: Grabowski H.

Do drugs reduce utilization of other healthcare resources?
Authors: Cremieux PY, Ouellette P, Petit P.

The Drug Delivery Delimma.
Authors: Gorin B, Tuttle E.

The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions.
Publication: white paper 2007 08.
Authors: Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S.

Pharmaceutical spending and health outcomes.
Authors: Cremieux P-Y, Jarvinen D, Long G, Merrigan P.

Retrospective economic and outcomes analyses using non-US databases: a review.
Authors: Shi L, Wu EQ, Hodges M, Yu A, Birnbaum H.

The market for follow-on biologics: how will it evolve?
Authors: Grabowski H, Cockburn I, Long G.

A Roundtable Discussion: The Importance of Causation Analysis in Mass Tort Cases.
Publication: Food and Drug Law Institute Update 2006 11.
Authors: Greenberg PE, Lykos G, Gourley S, Davies C.
Generic competition in the US pharmaceutical industry.
Authors: Saha A, Grabowski H, Birnbaum H, Greenberg P, Bizan O.

Retirement patterns from career employment.
Publication: Gerontologist 2006 08; 46(4): 514-523.
Authors: Cahill KE, Giandrea MD, Quinn JF.

A Regulatory Perspective on Productivity Claims: Implications for Future Productivity Research.
Publication: Health and Work Productivity: Emerging Issues in Research and Policy. 2006 04; (Spring).
Authors: Greenberg PE, Birnbaum HG.

Publication: Analysis Group Forum 2006 11.
Authors: Greenberg P, Sisitsky T.

Hospital cost flexibility in the presence of many outputs: a public-private comparison.
Authors: Cremieux PY, Ouellette P, Rimbaud F, Vigeant S.

Public and private pharmaceutical spending as determinants of health outcomes in Canada.
Authors: Cremieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K.

Systematic Differences in Subjective vs. Societal Preferences.
Abstract: International Society for Quality of Life Research (ISOQOL).
Authors: Sullivan PW, Ghushchyan V, Wu EQ.

Treatment and Comorbidities in an Employed Population.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Parece A, Kang Y, Mareva MN, Taitel H.

Your patent is about to expire: what now.
Authors: Parece A, Tuttle E, Hector A.

Authors: Cremieux P, Greenberg PE.

Administrative Claims Data: A Valuable Tool in Pharmaceutical Litigation.
Publication: FDLI Update 2004 01.
Authors: Birnbaum HG, Greenberg PE.

Measuring hospital efficiency in the presence of quasi-fixed inputs: An analysis of Quebec hospitals.
Authors: Bilodeau D, Cremieux PY, Jaumard B, Ouellette P, Vvor T.

Measuring hospital performance in the presence of quasi-fixed inputs: an analysis of Québec hospitals.
Authors: Bilodeau D, Crémieux P-Y, Jaumard B, Ouellette P, Vvor T.
The relationship between technology availability and health care spending.
Publication: Health Affairs 2003 07; Suppl Web Exclusives: W3-537-551.
Authors: Baker L, Birnbaum H, Geppert J, Mishol D, Moynier E.

Provision of pharmacy services in community health centers and migrant health centers.
Authors: Barner JC, Brown CM, Shepherd MD, Chou JY, Yang M.

Switching costs, price sensitivity and health plan choice.
Authors: Strombom BA, Buchmueller TC, Feldstein PJ.

Hospital technology in a nonmarket health care system.
Authors: Bilodeau D, Cremieux P-Y, Ouellette P.

Actual and perceived impacts of tobacco regulation on restaurants and firms.
Authors: Cremieux PY, Ouellette P.

The effects of chronic medical conditions on work loss and work cutback.
Authors: Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS.

Omitted variable bias and hospital costs.
Authors: Cremieux PY, Ouellette P.

Impact of illness and its treatment on workplace costs: regulatory and measurement issues.
Authors: Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P.

Évaluation de l’efficience budgétaire des CLSC au Québec à partir de la méthode DEA.
Authors: Crémieux P-Y, Gadbois D, Jaumard B, Ouellette P, Vovor T.

Modeling for health care and other policy decisions: uses, roles, and validity.
Authors: Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK.

Pharmaceutical spending and health outcomes in the United States.
Publication: RESEARCH IN HUMAN CAPITAL AND DEVELOPMENT 2001: 59-76.
Authors: Cremieux P-Y, Ouellette P, Meilleur M-C, Leong S, Greenberg P, Birnbaum H.

Comparative Econometric Models of Medical Costs.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Hay JW.

Diagnosing the illness.
Authors: Cremieux P-Y, Ouellette P.
Hospital cost function in a non-market health care system.
Authors: Bilodeau D, Cremieux P-Y, Ouellette P.

Health care spending as determinants of health outcomes.
Authors: Cremieux PY, Ouellette P, Pilon C.

Pharmacoconomics and health policy. Current applications and prospects for the future.
Publication: Pharmacoeconomics 1999 11; 16(5 Pt 1): 425-432.
Authors: Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, LeLorier J, Ouellette P, Slavin MB.

Tackling costs one disease at a time.
Publication: Business and Health 1999 05; 17(5): 31-32, 37.
Authors: Greenberg P.

Using healthcare claims data for outcomes research and pharmacoeconomic analyses.
Authors: Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L.

The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data.
Publication: Medical Care 1998 05; 36(5): 757-765.
Authors: Birnbaum HG, Tang M.

Calculating Return on Investment from Reducing Workplace Costs of Illness.
Publication: Drug Benefit Trends 1998 03.
Authors: Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J.

Une analyse de la performance des CLSC au Québec.
Authors: Crémieux P-Y, Gadbois D, Ouellette P.

The Next Phase of Managed Care: Targeting Investments in Employee Health.
Publication: On Managed Care 1997 09.
Authors: Greenberg PE, Berndt E, Finkelstein S.

Une analyse du contexte budgétaire de l’activité médicale au Québec (An analysis of the budgetary context of medical activity in Quebec).
Publication: Le Medicin du Quebec 1997 08.
Authors: Cremieux PY OP.

Etude d’impact du projet de loi sur le tabac (IMpact report on the proposed tobacco law).
Publication: Ministry of Health and Social Services 1997.
Authors: Cremieux PY FP, Lavoie F, Ouellette P, St Pierre Y.

Hospital Consolidation: Optimal Strategy for a Two-Hospital Town.
Publication: Ambulatory Health Care 1996.
Authors: Deal B, Tiscornia JF.

Price Growth of prescription pharmaceutical preparations: an update and extension.
Publication: Competitive Strategies in the Pharmaceutical Industry 1996.
Authors: Berndt E, Greenberg P.
Economic consequences of illness in the workplace.
Authors: Greenberg PE, Finkelstein SN, Berndt ER.

Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an Industry.
Authors: Danzon P, Stamm L, Greenberg P.

Calculating the workplace cost of chronic disease.
Authors: Greenberg PE, Finkelstein SN, Berndt ER.

Consolidation and restructuring: the next step in managed care.
Authors: Danzon PM, Boothman LG, Greenberg PE.

The Health Care System in Canada.
Authors: Mulhern C, Rozek R.

Navigating the Changing Tides of Managed Care and Health Reform.
Authors: R S.

When can a Medicare Insured Group (MIG) Succeed?
Authors: Birnbaum HG CN, Lang K.

Savings estimate for a Medicare insured group.
Authors: Birnbaum H, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP.

An alternative in terminal care: results of the National Hospice Study.
Authors: Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, H. B.

Impacts of the New York long-term home health care program.
Publication: Medical Care 1986 24(7).
Authors: Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellingon-Otto K.

An Alternative in Terminal Care: Results of the National Advice on Hospice Care for Benefits Design.
Publication: Business and Health 1985.
Authors: Birnbaum H.

What does hospice cost?
Authors: Birnbaum HG, Kidder D.

Publication: Gerontologist 1984 08; 24(4): 380-386.
Authors: Birnbaum H, Burke R, Swearingen C, Dunlop B.
Implementing community based long-term care: Experience of the long-term home health care program.
*Authors:* Birnbaum HG, Burke R, Swearingen C, Dunlop B.

Managing programs for the elderly: design of a social information systems.
*Authors:* Birnbaum H, Burke R, Pratte F.

The determinants of nursing home operating costs in New York State.
*Authors:* Lee AJ, Birnbaum H.

Medicare legislation for hospice care: implications of national hospice study data.
*Publication:* Health Affairs 1983 08; 2(2): 80-90.
*Authors:* Mor V, Birnbaum H.

Home care in hospices.
*Publication:* Caring 1983 06; 2(6): 40-44.
*Authors:* Birnbaum H, Mor V, Greer DS.

How does the nursing home sector behave: A multi-equation model of nursing home behavior.
*Publication:* Social Science and Medicine 1983 17(23): 1897-1906.
*Authors:* Birnbaum HG, Lee AJ, Bishop C.

How nursing homes behave: a multi-equation model of nursing home behavior.
*Publication:* Social Science and Medicine 1983 01; 17(23): 1897-1906.
*Authors:* Lee AJ, Birnbaum H, Bishop C.

National hospice study analysis plan.
*Authors:* Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum H.

Why do nursing home costs vary? The determinants of nursing home costs.
*Authors:* Birnbaum H, Bishop C, Lee AJ, Jensen G.
About Analysis Group’s HEOR Practice

Founded in 1981, Analysis Group is one of the largest private economics consulting firms, with more than 700 professionals across 11 offices. Analysis Group’s health care experts apply analytical expertise to health economics and outcomes research, clinical research, market access and commercial strategy, and health care policy engagements, as well as drug-safety related engagements in epidemiology. Analysis Group’s internal experts, together with its network of affiliated experts from academia, industry, and government, provide our clients with exceptional depth of expertise and end-to-end consulting services globally.

www.analysisgroup.com